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ABSTRACT
The murine myeloid leukaemias employed in this study were induced 
in male C B A /H  mice following irradiation with sublethal doses of X-ray.
The responses of these leukaemic cell lines and normal (murine) bone 
marrow cells to cytosine arabinoside and mitoxantrone treatment in  
v itro  were m onitored. Both clonogenic, and nonclonogenic 
chemotherapeutic assays such as radioactive precursor uptake, dye- 
exclusion assay and autoradiography were employed to determine drug- 
induced cell lethality. In addition, the in vitro proliferative responses of 
the leukaemic cell lines and normal bone marrow cells to growth factors 
were determined using a [3H]thymidine uptake assay.
Both cytarabine and mitoxantrone were as toxic to normal bone 
marrow cells as to leukaemic cells from most of the cell lines. 
Mitoxantrone appears to be more potent than cytarabine against 
leukaemic cells in vitro. However, it was also more toxic to normal 
bone marrow cells. Generally, combinations of cytarabine and 
mitoxantrone resulted in an additive cytotoxic effect.
Mitoxantrone appears to have a narrow therapeutic margin when 
administered to leukaemia bearing mice in vivo. The response of the 
(SA7) myeloid leukaemic cell line to mitoxantrone was distinctly 
different from those reported for murine lymphoid leukaemias (P388 
and L1210). Doubling the mitoxantrone dose w ithin the therapeutic 
range was not accompanied by an increase in the number of long-term 
survivors (cures). Bone marrow cells of cured mice or normal(CBA/H) 
mice administered low doses of mitoxantrone became less sensitive to 
subsequent treatm ent w ith  mitoxantrone in vitro  . Doses of 
mitoxantrone that resulted in loss of protective effect by bone marrow 
cells of normal mice were toxic to leukaemia bearing mice. |i
IV 1
Primary and low cell dose transplant myeloid leukaemias were less 
responsive to growth factors as compared to the high cell dose passages. 
The SA2  leukaemic cell line grew in vitro without requirement for 
growth factors. However, no growth was observed in serum-free 
medium which suggests that serum was providing the stimulus for in  
vitro proliferation.
Leukaemic bone marrow cells from the SA7 high cell dose passage 
cell line, were normally responsive to growth factors in vitro. However, 
at relapse following in vivo treatment w ith mitoxantrone, the 
leukaemic cells became significantly (P=0.04) growth factor insensitive. 
Bone marrow cells of normal mice retained growth factor sensitivity 
following in vivo treatment w ith mitoxantrone. Furthermore, bone 
marrow cells of mice cured of leukaemia by mitoxantrone treatment in  
vivo were responsive to growth factors.
Recovery of growth factor responsiveness occurred when the 
recurrent leukaemic cells were passaged in normal mice. However, no 
recovery of growth factor sensitivity was observed when recurrent 
leukaemic cells were passaged in mice that received a single dose of 
mitoxantrone (0.75mg/Kg) two days previously.
Even after passage in normal mice, the recurrent leukaemic cells 
were in some cases, significantly (P=0.012) resistant to mitoxantrone 
treatment in vitro. The degree of resistance appears to depend on the 
dose of mitoxantrone employed in the treatment of the leukaemia. 
However, passaging the recurrent leukaemia in mitoxantrone pretreated 
mice did not increase the level of resistance developed by the leukaemic 
cells.
These results suggest that these myeloid leukaemic cell lines may be 
useful models for preclinical evaluation of chemotherapeutic agents.
1. INTRODUCTION
sa
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CHAPTER ONE
INTRODUCTION
Haemopoiesis is the process whereby all types of blood cells are formed. 
In normal humans, the process is tightly regulated so that as old cells are 
destroyed new ones are formed to replace them and no excess cells of any 
lineage are produced. However, in some neoplastic diseases of 
haematopoietic system, this normal control of proliferation is lost, thus 
leading to abnormal proliferation of a particular cell lineage . 
Leukaemias are one of the commonest neoplastic diseases of the 
haematopoietic system.
1.1 LEUKAEMIA
Leukaemia literally means white blood and the leukaemias are a group 
of diseases characterized by progressive proliferation of white blood cells. 
(Thompson, 1977). They can be subdivided into two major types 
depending on the line of white blood cells affected : lymphocytic and 
myeloid forms. Both acute and chronic forms of both lymphocytic and 
myeloid leukaemias occur in humans. Only the acute myeloid type w ill 
be discussed as it is the subject of the study being reported.
Acute Myeloid Leukaemia (AML): In acute myeloid leukaemia (AML) 
there is excessive proliferation and abnormal differentiation of 
immature myeloid cells in the bone marrow and blood which result in 
disruption of normal haemopoiesis (Griffin and Vellenga, 1987). It is 
believed to be as a result of malignant transformation of haematopoietic 
stem or progenitor cells accompanied by clonal proliferation and 
accumulation of the transformed cells. Although the pathogenesis of
leukaemic transformation is poorly understood, it is believed to be a 
multi-step process (Champlin and Gale, 1987). An apparent maturation 
block occurs early in the myeloid pathway, although some circulating 
granulocytes and other mature cells may be derived from the malignant 
clone.
By the time leukaemic symptoms are manifested as a result of disturbed
I haemopoiesis, the leukaemic burden could be as high as 1 0  ^ to 1 0 ^ 2  cells 
and there is considerable heterogeneity among patients in cellular 
phenotype, degree of cytogenetic abnormality and response to 
chemotherapy. Generally, however, there are excess number of 
leukaemic blasts in the bone marrow and some enter the blood and 
infiltrate other tissues. In a majority of cases, the bone marrow is 
hypercellular, although in 5-10% of cases it may be hypercellular. In up 
to 25% of patients, AM L was preceded by a myelodysplastic preleukaemic 
syndrome (Koeffler and Golde, 1980), In these patients, normal 
haemopoiesis is suppressed by ill-defined mechanisms. In most patients, 
normal progenitors persist in the bone marrow that can restore 
haemopoiesis following effective antileukaemic therapy. In rare cases, 
in patients in complete remission, there may be evidence of clonal 
haemopoiesis suggesting either maturation of the leukaemic clone or 
restoration of a preleukaemic state (Champlin and Gale, 1987).
Etiology : Although the exact cause of acute myeloid leukaemia is not 
known, a number of factors have been implicated which acting singly or 
in combination may be responsible for causing the disease. These 
include:
R adiation: Radiation exposure has been known to result in acute
leukaemia. The most conclusive evidence was obtained from data *
concerning the role of irradiation in the production of leukaemia among 
survivors of the atomic bomb blasts in Hiroshima and Nagasaki. There 
was a sharp rise in both chronic myeloid leukaemia (CML) and AM L  
which continued for nearly 2 0  years after exposure. Although there 
appears to be no threshold value of radiation dose and evidence of 
leukaemia, no leukaemogenic effects were seen at radiation doses below 
50 rads (Ellison, 1982).
Exposure to Chemicals: A ll drugs implicated as being leukaemogenic 
were known to cause bone marrow depression and or aplasia. The only 
chemical w ith unequivocal relationship to AM L is benzene (Aksoy,
Eredem and Discol, 1974). Even seemingly trivial exposure has been 
followed by development of AM L with or without development of 
clinically recognised steps of aplastic anaemia, other cytopenias, 
myelofibrosis or myeloid metaplasia. Other suspected leukaemogens 
include Chloramphenicol, phenylbutazone and arsenicals. AM L was 
also preceded by the use of alkylating agents for treating conditions such 
as ovarian cancer, gastric cancer and Hodgkins disease (Ellison, 1982).
Genetic Factors: Chromosomal abnormalities alone may not be
sufficient to induce AM L except with the aid of some external factors 
such as drugs, virus or physical agents. Diseases that predispose the 4
patients to subsequent development of AM L include Down's Syndrome 
and Bloom's Syndrome (Ellison, 1982).
V iruses: Both RNA and D N A  viruses have been known to cause
neoplastic disease in animals. Some viral particles have been 
demonstrated by electron microscopy in samples from patients with  
leukaemia. In  addition, reverse transcriptase characteristic of type C 
RNA oncogenic virus and portions of nucleotide sequences similar to
those in human oncogenic viruses have been isolated from human 
leukaemia cells. It  has not yet been determined whether this represents 
a cause-effect relationship or simply an evidence of endogenous type C 
virus which are ordinary occult but are activated incidentally within the 
leukaemic cells and which share many attributes w ith oncogenic viruses 
(Ellison, 1982).
C lin ical M anifestation: These are related to suppression of
haemopoiesis and the functional consequences of tissue and organ 
infiltration and include anaemia, neutropenia, haemorrhage, infection 
and or fever.
Classification: Classification of acute myeloid leukaemia is made on the 
basis of morphology of bone marrow and peripheral blood cells in 
Romanovsky-stained films and supplemented by certain cytochemical 
reactions such as test for peroxidases, which myeloid blasts stain 
positively. Also sudan- black and tests for non-specific esterases are used. 
The clinical classification is based on guide-lines proposed by the French- 
American-British (FAB) study group (Bennet et aL1976). Using this 
guide-line, presence of granules in cytoplasm and auer rods indicate 
myeloid origin of the leukaemia as they do not occur in lymphoid 
leukaemias. The myeloid leukaemias are subdivided into six main types 
( M l ,  M 2 , M 3 , M 4 , Ms and M 6 ) according to (a) the direction of 
differentiation along one or more cell lines (b) the degree of maturation 
of the cells. Thus M i, M 2  and M 3  show predominantly granulocytic 
differentiation and differ from each other only in the degree and extent 
of granulocytic maturation; M 4  shows both granulocytic and monocytic 
differentiation, M 5  predominantly monocytic differentiation and M^ 
predominantly erythroblastic differentiation (Bennet, et al, 1976).
sOncogenes: Proto-oncogenes are the normal cellular counterparts of 
retroviral transforming genes (Griffin and Vellenga, 1987). It is thought 
that the products of these genes in normal cells regulate cellular 
proliferation and differentiation. Whereas the exact functions of 
oncogenes are unknown, some appear to produce either growth factors 
or growth factor receptors. For example, C-fms gene product is 
homologous with the CSF-1 receptor (Sherr et aL 1983), It has been 
speculated that activation of some proto-oncogenes alters cell growth by 
causing inappropriate growth factor production, activation of receptor in 
the absence of a ligand or abnormal receptor - coupled signal 
transduction. It may be that activation of one or more oncogenes initiate |
human tumour formation and evolution of progressively more 
malignant subclone takes place through activation of yet other 
oncogenes. Although the exact mechanism governing the activation of f
proto-oncogenes is not yet known, one mechanism that is likely to be 
important in AM L is chromosomal translocations or deletions (Croce,
1986).
t
1.2 Growth of Leukaemic cells In Vitro
Substantial data on the biology of leukaemia are derived from ç
observations of leukaemic growth in vitro. Experimental evidence 
suggests that leukaemia occurs as a result of imbalance between self 
renewal, proliferation and differentiation. Leukaemia is therefore seen 
as clonal proliferation of tumour cells able to escape normal controls of 
proliferation and differentiation.
i
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Primary AM L exhibit heterogeneity when grown in culture. Only a 
small fraction of cells are actually capable of proliferating - usually less 
than 1% (Moore, W illiam  and Metcalf, 1973). W hile few AM L cases 
appear to have the capacity to proliferate autonomously in culture, many 
cases appear to have the ability to augment their own proliferation by 
either producing colony stimulating factors (CSF) or secreting factors 
such interleukin -I (IL -I) which induce normal accessory cells to supply 
CSF (Griffin and Vellenga, 1987).
Leukaemic colony forming cells (AML-CFU) are identified by their ability 
to form colony of leukaemic blasts in semi solid media (Buick, T ill and 
McCulloch, 1987). It is likely that AML-CFU may function as stem cells 
in vivo. Firstly, they are actively synthesizing DN A  as demonstrated by 
thymidine suicide studies (Minden, T ill and McCulloch, 1978). Secondly, 
replating experiments have shown that AML-CFU have lim ited self­
renewal capacity. However, tertiary replating was low and more than 4- 
generations of colonies have not been observed. Although in a few cases 
AM L cells can proliferate in vitro without the need for exogenously 
added growth factors, many leukaemias require the presence of growth 
factors in order to survive and proliferate in vitro (Young, Wagner and 
Griffin, 1987).
1.2.1 Colony Stimulating Factors
These are glycoproteins that stimulate the proliferation of both normal 
and leukaemic cells in vitro. Four major types have been described and 
include:
Interleukin-3 (IL-3, M ulti- CSF): This factor stimulates the growth and 
differentiation of m ultipotential stem cells and of progenitor cells 
committed to all the non-lymphoid lineages. Thus, it stimulates the 
formation (from normal marrow) of granulocytes, macrophages, mixed 
granulocyte and macrophage colonies, erythroid, eosinophillic and 
megarkaryocytic colonies.
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF): This 
factor stimulates the formation of granulocytes, macrophages and 
precursors of mixed granulocyte and macrophages in normal bone 
marrow cells (Walker et al 1985). Most cases of acute myeloid leukaemia 
(AML) respond to the addition of IL-3 and GM-CSF by an increase in 
proliferation and growth factor induced proliferative response is at least 
in part dependant on the recruitment of blast cells from the resting phase 
to the proliferative compartment. Autonomous proliferation of AM L  
cells is believed to involve, in some cases, activation of GM-CSF gene, 
and probably one reason why leukaemic cells take over normal bone 
marrow cells is through increased growth advantage as a result of 
autonomous proliferation.
Granulocyte Colony Stimulating Factor (G-CSF): This factor not only 
stimulates the production of granulocytic colonies in normal bone 
marrow cells, but it has also been reported to stimulate the formation of 
mixed granulocyte-macrophage colonies (progeny of bipotential 
progenitors) and pure macrophage colonies at high concentrations. 
Macrophage Colony Stimulating Factor (M-CSF): This polypeptide is 
only active as a dimer. When it is dissociated by urea-mercaptoethanol 
or acidic acetonitrite, the isomer was found to be no longer active. It  
stimulates almost exclusively the formation of macrophage colonies.
8M any of these colony stimulating factors are present in various 
conditioned media such as placenta conditioned medium and 
conditioned medium from various tumour cell lines (Lowenberg , Swart 
and Hagemeiejer, 1980).
The ability of colony stimulating factors to exert their biological effect is 
linked to the expression of receptors specific for that factor on the surface 
of target cells. It  has been established through receptor binding studies 
that each of the four colony stimulating factors bind to a unique receptor 4
(Walker et aL 1985). In addition, the receptors show complete specificity |
in that they do not bind other growth factors.
One of the obstacles of treating leukaemia by chemotherapy is that 4
leukaemic stem cells are not normally in cycle and are therefore difficult 
to kill by cycle-active drugs (Butturini and Gale, 1989). There is evidence I
that at least some leukaemic stem cells respond to growth and regulatory 
factors . It is possible therefore, to use these factors prior to initiating 
chemotherapy in order to increase the efficiency of many drugs such as 
cytosine arabinoside which are more effective against proliferating cells.
However, there is the potential drawback that normal myeloid or 
lymphoid stem cells may also be stimulated and w ill therefore be killed.
However, it may be an acceptable risk if treatment w ill result in cure 
(Butturini and Gale, 1989). In order for in vitro observations on the |
behaviour of leukaemic cells to be relevant, they must be shown to occur 
in vivo as well. Experimental murine tumours are usually employed in 
studying the in vivo biology of tumours. These may be more relevant to 
the clinical situation as compared to in vitro models such as continuous 
murine cell lines.
1.3 Acute Myeloid Leukaemia Models
Experimental myeloid leukaemia models are useful in the study of (a) 
leukaemogenesis (b) failure of normal haemopoiesis in leukaemias and 
(c) therapeutic procedures etc.
Leukaemia and lymphoma models have been used for screening new 
antitumour agents and the results in some cases have correlated well 
with the human disease. The vast majority of conventional cytotoxic |
agents have had their activity discovered against mouse leukaemia and 1
lymphomas before being introduced into clinical trials and all 
compounds that are active against human leukaemia and lymphoma are 
effective against some strains of rodent lymphoma and leukaemia 
(Birchenal, 1982).
There has been a lot of controversy over the relevance of transplanted 
leukaemia as models of the disease in humans. According to Schofield 
(1982), they do not provide good models of human leukaemias, because 
the latter occur spontaneously. Differences between long transplanted 
syngeneic leukaemias; the spontaneously occurring leukaemias in AKR 
mice and the human disease were highlighted using a comparable 
chemotherapeutic study (Birchenal, 1982). Approximately 99% of the 
cells in L I 210 transplantable leukaemia are in cycle (with cell a cycle time 
of 12 hours). When cytosine arabinoside which is a cell cycle specific 
agent was administered in a schedule that maintains a lethal 
concentration of the drug constantly in contact with the cells over two 
cell cycles followed by a 3-day interval to allow normal cells to recover, a 
net 5-6 log cell k ill was achieved and a high percentage of mice were 
cured. On the other hand, when the same schedule was applied to AKR 
spontaneous leukaemia in which the cell cycle time was at least 24 hours 
and only 1 % of the cells are in cycle, with a leukaemic burden of 1 0  ^ cells.
no cures were seen. S im ilarly, in human acute lymphoblastic 
leukaemia, the cells may have a doubling time of 2-4 days in the early 
stages of the disease, but in the latter stages of the disease, doubling time 
as high as 27 days have been reported (Clarkson and Fried, 1971). This 
indicates that in late stage of the disease, very small number of cells are 
in cycle and therefore cycle-specific agents alone w ill be of little use. 
Despite these drawbacks however, studies of combination therapy in 
mouse leukaemia have led to such active combinations as cytarabine 
and cyclophosphamide; cytarabine and thioguanine; vincristine and 
asparaginase etc (Gale and Cline, 1977). The treatment principles of 
intensive chemotherapy, schedule dependence, chemotherapeutic 
sanctuaries were all derived from mice models. These principles when 
applied in the clinic have resulted in an ever increasing percentage of 5- 
year survivors.
There are relatively few myeloid leukaemia models available and a 
survey of the literature reveals the following models:
W E H I-3 : This is a myelomonocytic leukaemia that was induced in 
BALB/C  mice follow ing mineral oil (paraffin) injections. It  is 
characterised by a mixed picture of early monocytic and myelocytic cells 
in contrast to pure granulocytic or pure monocytic forms of the disease. 
The supporting evidence for the cytological classification of W EHI-3 as a 
myelomonocytic leukaemia was the finding of high serum, urine and 
cellular levels of muramidase. This cell line also produce colony 
stimulating factors in vitro (Metcalf, Moore and Warner, 1969).
L5222: is an acute rat leukaemia which was induced as a result of 
adm inistration of nitrosourea. On cytochemical and electron 
microscopical grounds it was classified as a myelomonocytic leukaemia.
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After injection, the leukaemic cells proliferated mainly in the bone 
marrow and spleen and later they are detectable in the blood and also 
infiltrate other organs, A  direct relationship was found between thé 
number of cells injected and the time course of leukaemia development.
When 10^ leukaemic cells were injected the animals died within 12-13 
days (Hoelzer, 1973).
BNML: This leukaemia was induced in Brown Norway (BN) rats using
49,10-dimethyl 1,2-benzanthracene. A reproducible growth pattern was ^
observed upon transplantation. The model resembles very closely 
human A M L (Hagenbeek and Martens, 1973). Cytological and 
biochemical studies have revealed that the leukaemia is promyelocytic 
with a slow growth rate (1 0  ^ leukaemic cells k ill after 28 days) and 
severe depression of normal haemopoiesis during leukaemia growth 
due to decreasing number of normal haematopoietic stem cells 
(Bekkum et aL 1976),
Sutton August Leukaemia (SAL): Although spontaneously occurring 
leukaemias in rats are uncommon, the SAL leukaem ia arose 
spontaneously in normal female august rat and was maintained by serial 
transplantation through syngeneic rats. Rats died 8-10 days following 
implantation w ith 10^ SAL leukaemic cells. The cause of death was 
anaemia and infection occurring one day before death. Bone marrow 
was taken over by grossly abnormal leukaemic blasts. The leukaemia 
was classified as myeloid on the basis of the following evidence:
- the leukaemic cells primarily colonise bone marrow and any lymphoid 
organ involvement was apparently of secondary nature.
11
- in the spleen, the leukaemic cells proliferated mainly in the red pulp 
and not in the malpighian corpuscles.
- lymph nodes were not extensively infiltrated and lymphoid follicles 
remained intact.
- despite a high percentage of blasts in the blood, very few were detected 
in the thoracic duct lymph.
- the leukaemic cells were not lysed by antithymocyte serum which is 
lytic for rat thymocytes (Wrathmel, 1976).
Shay Chloroleukaemia: Shay Chloroleukaemia was induced in rats 
follow ing gastric instillation of 2 0 -methylcholanthrene and was 
classified as acute myeloid leukaemia on the basis of morphological and 
cytochemical characteristics. There are three distinct forms:
When transplanted subcutaneously (SC), a local tumour developed; 
when transplanted intraperitoneally (I-P), both ascites tumour and a 
generalised leukaemia resulted; when the cells were injected 
intravenously (IV ), a generalised disease was manifested. The main 
symptoms in terminally leukaemic mice were skin pallor, weakness and 
ruffled fur. When 2x10 ^ chloroleukaemic cells were injected, the mice 
died w ithin 8  days and w ith each 10-fold reduction of Inoculum, 
survival was increased by about 2.5 days (Foa, 1981).
Radiation-Induced Myeloid Leukaemias: No spontaneously developing 
leukaemias were found in C B A /H  mice (Major and Mole, 1978). This 
makes radiation-induced myeloid leukaemia a good model for the study
12
of the leukaemogenic process. In  addition, the leukaemia does not 
appear to be immunogenic (Hepburn et ah 1987). The incidence of 
leukaemia in irradiated mice was about 20% at the optimum X-ray dose 
of 150-300 rads (Major and Mole 1978). If  600 rads were administered, 1,4  
or 32 weeks following 300 rads, myeloid leukaemia frequency was 
markedly reduced. The dose response was curvilinear w ith leukaemia 
incidence decreasing within the dose range of 400-600 rads.
Recently, other radiation induced myeloid leukaemia models were 
reported (Hepburn et aL 1987). The leukaemias were induced following 
3 Gy whole-body X- irradiation in C B A /H  mice. In  terminally leukaemic 
mice, there was noticeable pallor of the feet, ruffled fur, weakness and 
loss of weight. The blood showed increased white cell counts 
accompanied by decreased haematocrit and haemoglobin counts. The 
spleen was massively enlarged and the bone marrow was replaced by 
leukaemic cells and the liver was often infiltrated as well. No lymph 
node involvement has been reported. It was possible to serially passage 
the leukaemic cells in syngeneic recipient. A ll mice receiving 10^, 10  ^or 
10^ primary leukaemic cells died of leukaemia w ithin 25-35 days. 
However, 40% of mice receiving 10  ^ cells remained leukaemia free for 
an observation period of 1 2 0  days. After the leukaemia was passaged 17 
times, it was possible to transfer the disease with as little as 1 0  cells 
(Hepburn et al 1987). Depending on the cell dose that was used to 
routinely passage the primary leukaemia, two distinct cell lines with 
different transplantation characteristics were obtained. A ll experiments 
reported in this study were performed using these models.
One of the most important uses of murine models is in the design of 
more effective treatment schedules for eradicating leukaemic disease in 
humans.
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1.4 Treatment of Leukaemia in Humans: The general principles
underlying treatment in humans is discussed (section 1.4.1) followed by 
the mechanism of myelosuppression (section 1.4.2) since this is the dose 
limiting toxicity. Next, is a discussion of the pharmacology of Ara-C and 
mitoxantrone (Section 1.4.3) the two drugs used in this study, followed 
by the principle behind drug scheduling (Section 1.4.4).
1.4.1 Principles of Treatment: Evidence from chemotherapy of acute 
leukaemia in both humans and animals indicate the presence of a dose- 
response relationship: that is higher doses produce more cures 
(Butturini and Gale, 1989). If  this is true then why has increasingly 
intensive chemotherapy not cured more people with leukaemia? There 
are many reasons that have been suggested as responsible for the failure. 
These include the possibility that chemotherapy was not sufficiently 
intensive, or that inferior drugs or schedules are used. Another 
possibility is that treatment fails not only because of resistant leukaemia 
but because it is too toxic to normal bone marrow cells needed to restore 
haemopoiesis.
Several models have been proposed to explain the current results of 
intensive chemotherapy of leukaemia (Butturini and Gale, 1989). First, 
in a homogeneous population with chemotherapy resistant leukaemia, 
there would be no dose response relationship and no cures. In practice, 
this has never been obtained, since some people w ith leukaemia are 
cured and therefore the first model cannot be correct. In  the second 
model, a homogeneous population is considered in which leukaemia in 
that population is responsive to chemotherapy. In  this case, increasing 
the dose w ill result in increasing cure until all members of this 
population are cured. In the third model the population of people with 
leukaemia consists of two sub populations one in which (a) the
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leukaemia is responsive to chemotherapy and (b) the leukaemia is 
resistant to chemotherapy. The population in (a) would show a dose- 
response relationship to chemotherapy, increasing doses w ill result in 
increasing cures until all cases in this subpopulation are cured. The 
non-responsive population (b) would not show any dose-response 
relationship and more intensive chemotherapy w ill not be accompanied 
w ith increasing cures. Thus, in the third model, more intensive 
chemotherapy produces more cures until a plateau is reached after 
which higher doses do not achieve more cures, and may even result in 
decreased outcome due to toxicity. It has been suggested that this model 
best explains current results of intensive chemotherapy of leukaemia 
although the real situation may even be more complex. (Butturini and 
Gale, 1989).
The aim of chemotherapy in leukaemia is to eradicate the malignant 
clone. Treatment is usually subdivided into several phases. In the first 
phase, termed remission induction, the aim is to reduce the number of 
leukaemic cells to below the level of detection and restore normal 
haemopoiesis. By definition, no leukaemic cells should be detected in 
complete remission; however in practice, in most patients, substantial 
numbers of malignant cells probably persist (Lowenberg and Hagenbeek,
1984). This ultim ately leads to leukaemia relapse if effective post 
remission therapy is not administered. The goal of post-remission 
therapy is to eradicate m inim al residual disease. Unfortunately, 
resistance to treatment commonly develops and most patients 
eventually relapse despite continued therapy.
The combination of cytarabine and an anthracycline has been the 
cornerstone of remission induction chemotherapy. The best results 
utilised Ara-C 100-200mg/m^/d by constant or intermittent I.V. infusion 
for seven days in combination with daunorubicin 30-70m g/m ^/d by I.V.
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bolus on the first and last 3 days (Gale, 1984). If  remission is not induced 
following one or two courses of this regime, the patients have poor 
prognosis. Even if remission is ultimately achieved, it is typically brief 
(Champlin et aL 1984). In 50% of the treatment failures, the leukaemia 
may be drug resistant while in the other 50% the patients might have 
suffered from chemotherapy related toxicity such as infections, bleeding 
(Estey et aL 1982). Combinations of cytarabine with either amsacrine or 
mitoxantrone appears as effective as w ith daunorubicin (Shenkenberg 
and Von Hoff, 1986). Patients with therapy induced AM L (as a result of 
treatment of other neoplastic conditions) have only a 20-40% likelihood 
of achieving remission with standard induction chemotherapy.
There is no convincing data that Ara-C administered in low doses is as 
effective as at conventional doses for induction chemotherapy in high- 
risk patients and its use is not recommended if the aim is to induce 
remission (Butturini and Gale, 1989),
The value of consolidation or early intensification, late intensification or 
maintenance chemotherapy in prolonging remission duration and in 
preventing relapse is controversial (Lewis, 1985).
In children, intensive chemotherapy results in about 35-50% 5-year 
leukaemia free survival (Grier et aL 1987). Results in adults with AM L 
are less satisfactory w ith almost 25-35% long term leukaemia free 
survival (Gale and Foon, 1987).
Doses of antileukaemic drugs can be substantially increased if treatment 
is followed by bone marrow transplantation (BMT). BMT has been used 
as a form of consolidation treatment in order to induce remission in 
relapsed or resistant leukaemia . An advantage of bone marrow  
transplantation is that in many situations the relapse rate following 
allogeneic (HLA-identical) BMT is lower than following intensive 
antileukaemic therapy or even than follow ing tw in transplants
16
(Butturini and Gale, 1989). This is because several potential 
antileukaemic mechanisms may be operating. An example is the 
immune related anti- leukaemia effect mediated by lymphoid or other 
cells in the graft. There is also the added anti-leukaemia effect of 
conditioning regimen. Transplant-related immune mechanisms can be 
divided into three: (a) graft-versus host disease (GVHD) (b) graft-versus- 
leukaemia effect (GVL) and (c) an independent effect produced by T-cells 
independent of (a) and (b). It  has been reported that these transplant- 
related immune mediated antileukaemic effect could be as effective as 
high-dose chemotherapy and radiation in eradicating leukaemia and 
offer a potential therapeutic option (Butturini and Gale, 1989).
Most tumour populations are inherently heterogeneous and they can 
undergo rapid phenotypic change and this represents two of the most 
formidable obstacles to effective antineoplastic therapies. More over, it 
has been reported that the treatments themselves can modify tumour 
cell phenotype and the rate at which variant cell subpopulations are 
generated. This is because most antineoplastic agents are mutagenic as 
well, but other non-mutagenic changes such as gene amplification are 
also implicated. The net result would be that cells that survive 
treatment and cause relapse may also possess an unstable phenotype 
(Lotan and Nicolson, 1988). Evidence suggests that random and 
spontaneous genetic changes not only result in development of drug 
resistant tumour types but could result in the acquisition of increased 
metastatic potential (Schimke, et aL 1986). As tumours progress and 
undergo phenotypic diversification they become less likely to succumb to 
therapy. In addition, treatment with chemotherapeutic agents have been 
shown to induce the metastatic phenotype (M cMillan, Rao and Hart, 
1986).
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1.4.2 Myelosuppression: This is the principal dose-limiting toxicity of 
many cytotoxic agents. The latter can be broadly classified into three 
groups depending on the extent of myelosuppression they produce 
clinically. The first group typified by vincristine or L-asparaginase are 
rarely associated with bone marrow toxicity. In the second group are 
found drugs such as methotrexate, vinblastine and cisplatin, which cause 
m ild to moderate myelosuppression. The third group of drugs are 
associated w ith predictable and potentially severe dose-lim iting 
haematopoietic toxicity. Examples of this group include mitoxantrone 
and other anthraquinones; anthracyclines, cytarabine and other 
pyrimidine analogues, nitrosoureas and other alkylating agents (Gale,
1985).
W hile haematopoietic toxicity is produced rapidly by drugs such as 
hydroxyurea (within 2-3 days), with the pyrimidine analogues it takes 1-3 
weeks. The severity of myelosuppression is dependent on the nature of 
the drug, its mechanism of action, the dose (total dose administered as 
w ell as dose per treatment), schedule of administration, route of 
adm inistration, prior chemotherapy or radiation therapy and 
combination chemotherapy with other drugs (Gale, 1985). It is apparent 
therefore that both antineoplastic effect and myelosuppressive toxicity 
are dose-dependant. There is generally a narrow therapeutic margin 
and sometimes no margin in selective toxicity is seen between tumour 
cells and normal bone marrow cells.
Antineoplastic drugs produce myelosuppression through either direct or 
indirect effects. Direct effect refers to interactions of the drug or 
metabolite(s) w ith myeloid cells or their progenitors. The mechanism 
involved may include a direct toxic effect which may result in a 
proliferative defect or by causing an imbalance between self renewal and 
cell differentiation or maturation (Gale, 1985). The indirect effect of
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antineoplastic agents is produced via interaction with the bone marrow 
micro- environment or by affecting haematopoietic growth or other 
regulatory factors. Examples of these mechanisms are provided by 
busulphan and cisplatin. W hile busulphan is directly toxic to bone 
marrow stem cells, cisplatin may cause anaemia by interfering with the 
renal release of erythropoietin. Similarly, the coagulation cascade may 
be activated following treatment of acute promyelocytic leukaemia with 
antineoplastic agents. This is as a result of the release of proagulant 
activity from the leukaemic promyelocytes and it could lead to 
disseminated intravascular coagulation (DIG).
Antineoplastic agents cause either intermediate, early, delayed or latent 
bone marrow suppression depending on their type. Drugs such as 
hydroxyurea and prednisone cause rapid reduction in blood cells 
detectable within 12-48 hours. Agents that cause reduction only after 1-3 
weeks following drug administration may do so due to an effect on 
immature haematopoietic cells that only becomes apparent after mature 
cells die and need to be replaced. Granulocytes have the shortest life 
span (24-48 hours) and therefore, granulocytopoienia may be the first 
detectable effect of antineoplastic drugs. The next cell lineage to be 
affected are platelets (life-span 1 0  days) followed by red blood cells (life­
span 1 2 0  days) and lymphocytes (life-span of many months).
It is uncommon for drugs like nitrosoureas and mitomycin C to cause 
delayed myelosuppression occurring 4-8 weeks after drug  
administration. The delayed type of myelosuppression is thought to 
selectively affect haematopoietic stem cells and requires several weeks to 
become evident. This latent effect has been studied prim arily in mice 
treated with busulphan. Under appropriate experimental conditions, 
such mice have normal circulating blood cells but have markedly 
decreased number of myeloid stem cells. It is believed that the
19
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pathophysiology of this effect is complicated but may relate to busulphan 
induced damage to stem cells, the bone marrow microenvironment and 
probably to lymphoid cells too (Gale, 1985). That the microenvironment 
is affected could be seen from the fact that transplantation fails to restore 
normal haemopoiesis in busulphan treated mice.
Although the exact mechanisms through which antineoplastic drugs 
affect haemopoiesis are subject to investigation, they may be unrelated to 
the mechanism of tumour k ill produced by these drugs. This is 
demonstrated by the observation that cyclophosphamide which is a 
potent alkylating agent, is thought to have a selective effect on mature 
progenitors while sparing multipotent stem cells.
A number of strategies have been devised to minimise the impact of 
myelosuppression. The suggested methods include rescue using 
cryopreserved autologous bone marrow cells, enclosing drugs in 
liposomes as w ell as using antibody-directed drugs and regional 
chemotherapy (Gale, 1985).
1.4.3 Cytosine Arabinoside (Cytarabine, Ara-C): Ara-C is the principal 
drug of choice in the treatment of acute myeloid leukaemia (Ellison et al,
1968) and when used singly produces about 25% incidence of complete |
remission (Heidelberger, 1982).
Ara-C is an analogue of deoxycytidine and its mechanism of action is 
believed to involve inhibition of D N A  polymerase and it is also 
incorporated into D N A  and RNA. The degree of sensitivity of 
leukaemic cells to Ara-C is dependent on the relative activity of 
deoxycytidine kinase which converts the drug to the active nucleotide 
Ara-CTP. The latter is a potent inhibitor of D N A  synthesis (Wist,
Krokan and Pyrdz, 1976). Almost complete inhibition of D N A  
synthesis (79%) is required for Ara-C to be toxic (Bhuyan et aL 1973). The
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Ara-C moiety are incorporated onto the ends of growing strands of DNA. 
Addition of the next deoxynucleotide is then inhibited and thus DN A  
replication is blocked (Kufe et aL 1980). An unusual finding was that 
following drug removal after temporarily blocking D N A  replication 
forks with Ara-C, DNA replication is reinitiated in some segments of the 
chromosomal D N A  that had already been replicated (Woodcock and 
Cooper, 1979; Woodcock, 1987). The consequence of this is that D NA  
segments are replicated more than once in a single cell cycle. This has 
been implicated as a probable mechanism of drug-induced gene 
amplification (Schimke, 1984). Ara-C is rapidly deaminated in many 
tissues to ara-uracil (ara-U) which is biologically inert. Since Ara-C is 
effective only in S-phase and is rapidly deaminated, in order to be 
maximally effective, it should be administered in frequent 12-hour 
pulses or continuous intravenous (I.V) infusion.
When Ara-C is given as a single agent by continuous I.V  or 12-hourly 
injection, remission is achieved in about 20-30% of cases. The 
combination of one-day daunorubicin plus 3-5 days of cytarabine 
produces remission in up to 50% of patients. The prognosis for AM L  
resistant to anthracyclines and Ara-C is poor.
The side effects encountered include nausea, vomiting, bone marrow 
suppression with very marked megaloblastic change. Less frequent side 
effects are fever, rashes and arthralgia.
M itoxantrone (M itozantrone, Novantronei&): Mitoxantrone is an 
anthracenedione which was synthesized in the 1970’s (Murdock et al, 
1979). It is structurally related to doxorubicin (Adriamycin) although it 
lacks an amino sugar moiety (Johnson et aL 1979). It inhibits both RNA  
and D N A  synthesis and is reportedly 6-7 times more potent than 
doxorubicin in inhibiting [3H]-thymidine incorporation into D N A  and
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[3H]-uridine incorporation into RNA. Just like doxorubicin, it binds 
D N A  by intercalation (Traganos et al, 1980). Cells in culture treated with 
mitoxantrone show nuclear morphological changes of chromosomal 
scattering and micronuclei formation (M urray and Wallace, 1980). 
Cytotoxicity was correlated with the extent of DNA strand breaks induced 
by mitoxantrone. It not only induces non-protein associated breaks in 
single stranded D N A , but it is also reported to act through non- 
intercalative electrostatic interactions. Mitoxantrone blocks cells in G2 
phase (Traganos et ah 1980) and may be more effective in late-S-phase. 
However, cell killing induced by mitoxantrone is not cell cycle specific 
(Evenson et aL 1979). Furthermore, mitoxantrone is lethal to both 
proliferating and non-proliferating cells in vitro, which suggests 
potential activity in slow growing tumours. (Wallace et aL 1979). For 
example, in concentrations of 0.5ug/m l more than 90% of colon 
carcinoma cells incubated with mitoxantrone were killed regardless of 
whether they were dividing or not (Wallace et aL 1979). Mitoxantrone 
has considerable activity against various experimental mouse tumours. 
When administered I.P to mice bearing P388 leukaemia, it was more 
effective than doxorubicin in almost every treatment schedule. There 
was significant increase in life-span and high frequency of "cures" (60- 
day survivors).
Mitoxantrone is rapidly taken up by tissues and stored in several body 
compartments and gradually released. This is supported by its high 
volume of distribution (Savaray, et aL 1982). It  is indicated in the 
treatment of acute leukaemia and relapsed cases seem to respond better 
than refractory cases (Masaoka, et aL 1985). When used alone, up to 20% 
of patients achieve complete remission (Champlin and Gale 1987). 
Response rate data in leukaemic patients previously treated and now in 
relapse or refractory with doxorubicin or daunorubicin support the idea
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of incomplete cross-resistance between anthracyclines and mitoxantrone 
in acute leukaemia (Poirier, 1986).
Mitoxantrone is less cardiotoxic as compared to doxorubicin. Other 
toxicities in animals receiving mitoxantrone include effects on 
gastrointestinal tract, lymphoid system and bone marrow (Murray and 
Wallace, 1980). Cytogenetic analysis of bone marrow from rats treated 
w ith mitoxantrone showed increased chromosomal aberrations similar 
to those caused by other antineoplastic agents (Dulak et al, 1982). 
Mitoxantrone can also inhibit lipid peroxidation, a mechanism thought 
to be responsible for anthracycline induced cardiomyopathy. It also 
inhibits prostaglandin synthesis. Myelosuppression, predominantly 
granulocytopenia is the dose-limiting toxicity (Von H off et aL 1980). 
Myelosuppression is related not only to the amount of prior therapy but 
also to the extent of bone marrow involvement with tumour (Posner 
^  1985). Some deaths have occurred in granulocytopoienic patients 
secondary to infections and thus peripheral blood counts need to be 
closely monitored during therapy. Erythrocytes are not acutely affected 
although m ild anaemia develops in most patients w ith successive 
courses of treatment. Thrombocytopoienia is less frequent. Other 
reported side effects include nausea and vomiting and diarrhoea (Poirier, 
1986).
1.4.4 Scheduling of Drug Com binations: When two cancer
chemotherapeutic agents are combined, a variety of drug-drug 
interactions ranging from antagonism to synergism can occur. For 
example, the use of Ara-C and asparaginase in combination 
chemotherapy of acute leukaemia is a logical choice since both agents are 
individually effective and have different mechanisms of action and host 
toxicities (Capizzi and Handschumacher, 1982). In  practice, it was
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observed that the combination of Ara-C and asparaginase was more 
effective than either drug alone in the treatment of human and murine 
leukaemia (Ekert, Colebatch and Mathews, 1972). Similarly, in the 
treatment of L5178Y leukaemia, whereas 3 doses of Ara-C administered 
on days 1, 4 and 7 after tumour implantation cured none of the mice, 3 
doses of asparaginase alone cured 3 of 15 mice. In contrast, simultaneous 
administration of both drugs on each of the three days cured 36 of 43 
mice (Schwart, Morgens tern and Capizzi, 1982).
Thus, the schedule in which cytotoxic drugs are administered could 
determine therapeutic outcome in both experimental and clinical 
settings. W hile some of the effects may be explained in terms of 
alteration of cell cycle kinetics, the mechanism underlying many of the 
interactions are yet to be elucidated.
1.5 In  Vitro Chemotherapeutic Assays
For ethical reasons drug testing cannot be done in humans, and 
therefore, there is a need to devise appropriate preclinical models that 
would accurately predict response in humans. Unfortunately, no non­
human assay predicts for efficacy in humans perfectly.
There are many factors that could influence the accuracy of an in vitro 
drug assay such as differences in cell kinetics in vitro and in vivo, altered 
chemosensitivity as a result of cells being removed from their normal 
environment and the in vitro culture method may select different 
subpopulation of cells. Also the lack of cell-cell contact as a result of 
preparation of a single-cell suspension, the in vitro drug concentrations 
and exposure times employed are important (Weisenthal,1981).
As mentioned, the choice of in vitro drug concentration is important. 
When doses are expressed in m g/m ^, there is a qualitative similarity 
between the dose of drug that w ill be lethal to 10% of mice (LD io) and
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the maximum tolerated dose in humans. As a result of this, most phase 
one trials in humans start at 10% of the LD io  in mice (m g/m ^). 
Traditionally, the concentration of a drug that has been used in in vitro 
assays has been 10% of peak plasma level. However, the actual 
concentration on the tumour bed (in -v ivo) may be much lower or 
higher (Lock and H ill, 1988). In  addition, peak plasma levels may not be 
satisfactory guides for those drugs that require extracellular or 
intracellular activation (Colins, 1988). Another parameter commonly 
used is the concentration x time (CXT) values. Results from in vitro cell 
culture experiments and some mouse tumour models system suggest 
that antitumour drug CXT is directly related to the degree of its cellular 
lethal effects (Alberts and Wetters, 1976). Thus, a range of clinically 
achievable drug concentrations should be used when selecting 
appropriate concentrations for sensitivity testing in vitro. In some 
experiments, an incubation time of one hour was chosen because |
pharmacokinetic data for intravenously administered drugs suggest that 
significant exposure to most drugs is greatest during the first hour after 
drug administration (Alberts et aL 1981). It has been suggested (Metcalfe,
1983) that concentrations lower than those clinically achievable should 
be used, since (solid) tumour drug levels may be less than that in the |
plasma due to poor perfusion w ithin the tumour leading to loss of 
accumulation of the drug. Conversely, some drugs may be retained in 
tumours resulting in accumulation within the tumours for long periods.
Drug resistant tumours arising from pretreatment in the patients, may 
need higher drug concentrations for testing in vitro.
Another problem with in vitro drug assays is that they do not take into 
account differences in host conversion and detoxification reactions and 
also tissue specific drug accumulation. It is also difficult to achieve the |
same total exposure to active drug metabolite in vitro as is produced in
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vivo. In vitro end points of cell death may not accurately reflect in vivo 
k ill and solid tumours present a particularly difficult problem of 
assessment (Weisenthal and Lippman, 1985). Drug induced cell lethality 
may be as a result of either metabolic death or reproductive death. 
Metabolic death is an event that can be measured by a variety of simple 
techniques that reflect immediate metabolic dysfunction, in contrast to 
reproductive death which is due to loss of proliferative capacity and is 
usually a delayed process (Roper and Drewinko, 1976). In proliferating 
cell populations, the inability to reproduce may be a more relevant 
assessment of cell kill. On the other hand, cells rendered incapable of 
sustained proliferation may still possess intact metabolic apparatus and 
may complete several cell divisions before the progeny perishes from the 
inherited damage. This means that assays of metabolic death may 
grossly over-estimate or under-estimate cell viability. In  addition, some 
chemotherapeutic agents such as bleomycin may induce progression 
delay (Tobey, 1972). This results in a temporary lag in the multiplication 
rate and increases the doubling time of the treated cell population in 
comparison to that of control population. This may mimic the effect 
produced as a result of cell kill.
Wherever possible, a battery of tests rather than any single assay type 
should be employed. This is because no methodology exists which does 
not have its shortcomings. In addition, patients with the same histologic 
type of cancer do not respond uniformly to antineoplastic agents. And it 
has been suggested that empiric drug screening may be more fruitful if 
carried out in fresh specimens of human tumour rather than in 
established cell lines or non-human tumour systems. And in drug 
development, appropriate in vitro models could be used to test different 
treatment modalities in the laboratory thus improving efficacy of new 
drugs. An ideal in vitro test should be simple, statistically acceptable.
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easily standardized, cheap, rapid, flexible and capable of taking account of 
different methods of drug action and should offer reasonable 
correlations with in vivo effects (Hamburger, 1981). The majority of in 
vitro chemosensitivity assays can be sub-divided into those assessing 
cellular damage such as loss of membrane integrity (dye-exclusion); 
measurement of inhibition of cellular metabolism; inhibition of 
radioactive precursor incorporation and lastly, measurement of 
clonogenic cells in a tumour cell population.
1.5.1 Dye-Exclusion or Differential Staining Cvtotoxicity (DiSC) Assay:
This assay measures the uptake of dye by cells as they lose membrane 
functions following drug treatment, and are regarded dead by this 
criteria. While no direct proof was obtained that the dye (fast green) 
specifically stain dead cells only, the estimates of cell viability obtained 
w ith traditional trypan blue wet preparations and with fast green wet 
preparations were similar (Weisenthal et ah 1983a). As compared to 
cloning assays, the dye-exclusion assay requires 1/lO th the number of 
cells. In addition, the assay is capable of detecting cell-kill in the non­
dividing cell fraction and may therefore have unique advantages in new 
drug screening particularly for agents capable of killing cells in Gq. It may
also be valuable for testing neoplasms which proliferate poorly in £
culture. Many cytotoxic drugs are not only effective against dividing 
cells but also alter essential cellular function in the resting phase of the 
cell cycle (Weisenthal and Lippman, 1985). Clonogenic assays do not 
measure such damage. Furthermore, clinical correlations have been 
obtained with dye-exclusion assays (Weisenthal and Lippman, 1985; Bird 
et al .1986: Durkin, Ghanta and Miromoto, 1983).
Some of the shortcomings of the dye-exclusion assay include the fact that 
it is not an automated technique and is therefore relatively tedious and
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subject to observer error. In  addition, sufficient time must elapse 
following drug treatment for lethally damaged cells to lose their 
membrane integrity. The cells that survive drug treatment may 
proliferate during the time required for the lethally damaged cells to lose 
membrane integrity. A  way must be found to account for lethally 
damaged cells that disintegrate before they are stained with the dye. The 
problems of proliferation in culture and disintegration of lethally 
damaged cells were solved by incorporating an internal standard of duck 
red cells in the assay; such that viability is assessed by determining the 
ratio of live tumour cells in drug treated samples in relation to control 
while relating both to the number of duck red cells (Weisenthal, 1983b; 
Bird et aL 1986). However, it may be difficult to differentiate tumour 
from non-tumour cells. In  a study comparing in vitro effects of 
adriamycin, BCNU, vinblastine and cisplatinum on seven human 
tumours using a dye-exclusion assay a close correlation was found with 
in vivo results of drug therapy in all patients (Durkin, Ghanta and 
Hiramoto, 1983).
1.5.2 Tétrazolium (MTT) Assay: Tétrazolium identifies living cells by 
means of changing colour as a result of metabolic activity within the 
cells. The assay is a semi-automated colorimetric technique based on the 
principle that mitochondria of living cells reduce the tétrazolium salt 
(MTT) to formazan, a blue dye which can be read spectrophotometrically 
(Alley and Leber, 1984). As with the dye-exclusion assay, the M TT assay 
was found to be simple, rapid, inexpensive and reproducible. The assay 
has been used to determine the sensitivity of cytotoxic drugs in patients 
with acute myeloid leukaemia (AML) (Sargent and Taylor, 1989). Blast 
cells were exposed to single and combinations of drugs and their 
survival measured using the assay. A linear relationship was found
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between the number of leukaemic cells and the optical density of the 
formazan produced. The assay was not only reproducible but was 
sensitive enough to detect variation in drug sensitivity between patients. 
No significant difference in sensitivity was observed between blast in the 
bone marrow and those circulating in the blood. Preliminary results 
show correlation between in vitro and in vivo data which suggests that 
the assay can be used to monitor changes in tumour sensitivity which 
could yield useful information that w ill assist in the management of 
acute myeloid leukaemia.
A  drawback of the assay is that activated cells produced more formazan 
than resting cells (Mosman, 1973). Some cells do not produce sufficient 
amounts of formazan resulting in an insignificant difference in optical 
density between control and experimental groups. Furthermore, bacteria 
cleave tétrazolium salts to formazan. Therefore, false negative results 
may occur if visually undetected bacteria were present.
1.5.3 Assays of Inhibition of Cellular Metabolism: Direct measurement 
of respiration and glycolysis and measurements of cellular 
dehydrogenase activity shortly following in vitro drug exposure have 
been correlated with clinical response (Dipaolo, 1971). A  potential 
problem is that this technique may not differentiate cells that are capable 
of repairing non-lethal damage from those that are reproductively dead. 
Additionally, the assay may not distinguish between tumour cells and 
stromal cells present in the preparation. Also, the test is incapable of 
differentiating damage to clonogenic cells and those cells that are non­
dividing which make up the bulk of the tumour. However, an 
advantage of such assays is that they do not require successful growth of 
the tumour in culture to be interpreted. They are also fast, simple and 
may not require disaggregation into single cell suspensions (Weisenthal
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and Lippman, 1985). Assays of resistance loci (Weisenthal and Lippman, 
1985) also fall into this category. Resistance loci are factors responsible 
for resistance of tumour to damage produced by antitumour drugs. 
These include assays of the levels of uridine kinase and phosphoribosyl 
transferase (Ardalan et al 1981) which activates 5-fluorouracil as well as 
deoxycytidine kinase which activates cytosine arabinoside (Harris and 
Grahame-Smith, 1982); assays of cytidine deaminase which inactivates 
cytarabine (Smyth, Robins and Leese, 1976) and assays of methotrexate 
uptake into cells (Bender et aL 1976). Except for an encouraging 
correlation with 5-FU activation in patients with breast cancer, many of 
these assays have proved disappointing in clinical trials.
Unless the mechanism underlying drug resistance is known for most 
drugs, it is difficult for the resistant loci approach to gain wide 
acceptance. In addition, the test is not easily adaptable to generalised 
screening of drugs, since it would require a different type of test for each 
drug being screened. As knowledge of resistance mechanism expands, 
assays of resistance loci may find clinical applications (Weisenthal and 
Lippman, 1985).
1.5.4 Inhibition of Radioactive Precursor Incorporation: This assay 
measures the incorporation of radioactive precursors ( [3H]-thymidine or 
[3H]-uridine) by proliferating cells in culture. In  a typical assay (Raich,
1978), leukaemic cells were incubated in vitro with concentrations of 
Ara-C well below that clinically achievable (Alberts and Chen, 1980). 
After 36 hours incubation, [3H]-thymidine was added and the cells were 
labelled for 8 hours. Uptakes were measured in drug treated sample and 
related to control values. It was possible to correlate in vitro results with 
clinical response in patients with acute lymphocytic leukaemia, acute 
myeloid leukaemia, acute myelomonocytic leukaemia, acute monocytic
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leukaemia and blast crisis of chronic myelocytic leukaemia (BC-CML). 
For many drugs, plots of [3H]-uridine incorporation resembled the 
respective plots of [3H]-thymidine incorporation. The standard deviation 
around the mean values for each concentration of a drug indicated a 
broad variability of in vitro response among individual tumours of the 
same type (Silvestrini, Sanfilippo and Daidone, 1983). It  was suggested 
that it is best to delay labelling for several generation times after drug 
exposure in order to reduce problems of artifactual alterations in 
nucleoside intracellular pool sizes (Nakata and Bader, 1969) and salvage 
versus de novo dTMP synthesis pathway (Wolberg, 1972).
Unlike clonogenic assays, radioactive precursor uptake assays measure 
the drug effect on the whole cell population. There is evidence that very 
early disappearance of the entire leukaemic blast population correlates 
w ell w ith eventual sustained remission (Hidem ann et aL 1982). 
Similarly, a study of response of human tumour xenograft to radiation 
and chemotherapy indicate that it is the effect on the whole tumour cell 
population that correlated w ith response (Weisenthal and Lippman, 
1985). The radioactive precursor assay was able to detect drug resistant 
cells when such cells constituted only 10% of the total cell population 
(Bech-Hansen et a l, 1977).
1.5.5 Clonogenic Assays: Whereas the dye-exclusion assay measures cell 
k ill in the whole tumour population, clonogenic assays measure the 
degree of cell k ill in dividing cells. These dividing cells constitute only a 
small proportion of the tumour population but are considered to be 
important because they are capable of repopulating the tumour. Single 
cell suspensions of tumour cells are plated into tissue culture plates or in 
semi-solid media in order to observe the number of colonies formed. 
The semi-solid conditions of the media most commonly employed are
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agar or methylcellulose and they allow the progeny to remain localized 
and the number of colonies formed provides a minimum estimate of 
progenitor frequency (Hamburger and Salmon, 1977). In  general, cells 
are plated at relatively low density (Rosenblaum et al , 1981) and are 
allowed to grow for 4-6 doubling times until colonies of greater than 50 
cells are formed. The difference between drug treated and control 
cultures are presumed to relate directly to the fractional k ill of 
clonogenic cells. The stem cell model of tumour growth is based on the 
principle that human tumours consist of a mixture of dividing and non­
dividing cells (Tannock, 1978). In most cases, the bulk of the tumour 
cells turns over slowly. Of the non-dividing cells, some are irreversibly 
non-dividing (or permanent Gq) while others are reversibly non­
dividing (temporary Gq) (Steel, 1977). Of the dividing cells, some are 
thought to have only a limited proliferative potential, while others are 
believed to have unlimited proliferative potential. The latter have been 
termed "tumour stem cells" (Steel, 1977). The end cells (those that have 
lost the capacity to divide) are lost either by lim ited differentiation, 
exfoliation or death. This model assumes that nonclonogenic in vitro 
assays may be measuring effect of drugs on cells that w ill probably not 
divide in vivo. The model assumes that only assays that measure effects 
of drugs on that small proportion of cells that maintain the growth of 
the tumour are relevant. Weisenthal and Lippman (1985) have 
proposed that to accept the validity of clonogenic assays, it is necessary to 
assume that (a) clonogenic cells in vitro are representative of stem cells 
in vivo, and (b) the stem cell population is the only relevant tumour cell 
target for chemotherapy. There are some reports in the literature 
suggesting the validity of the first assumption. For example, Mattox and 
Von Hoff (1980), have stated that colony formation is the only reliable 
indicator of cell viability following exposure to antineoplastic drugs.
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Similarly, Chang (1983), has suggested that the colony forming assay 
should be the standard by which other short-term assays are to be 
compared, while Selby, Buick and Tannock (1983), have stated that 
clonogenic assays are the only assays which predict tumour cure rather 
than merely predicting partial response. In addition, there is evidence 
from work on animal and human tumours which seem to suggest that 
cells that are clonogenic under test conditions in vitro may bè the same 
cells that are stem cells in vivo (Weisenthal and Lippman, 1985). 
Furthermore, using the clonogenic assay, in vitro resistance correlated 
with clinical resistance in 85% of patients whereas in vitro  sensitivity 
correlated with in vivo sensitivity in 60% of the patients ( Von Hoff et aL 
1983B).
Other possible uses of clonogenic assays include tailoring of individual 
chemotherapy regimen for each patient as w ell as identification of 
patterns of chemosensitivity for patients w ith unknown prim ary 
carcinomas (H ill, 1984). The assay could prove useful both in screening 
of new antineoplastic agents and in in vitro phase I I  studies of those 
agents. And the assay could not only be used to monitor development of 
resistance, but it could also be of assistance in establishing patterns of 
cross-resistance and sensitivity in relapsing patients. Lastly, the assay 
could provide information regarding the relationship, if any, between 
clonogenicity and prognosis in patients (H ill, 1984).
1.5.6 Assessment of Cell Number: Holmes and Little (1974) described a 
microtitration test in which cells were treated for 72 hours with drugs 
before being tryptinized and counted with a coulter counter. A  40% 
reduction in cell numbers compared to control cultures was considered a 
significant in vitro response. In  11 out of 12 patients response was 
accurately predicted.
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1.6 In Vivo Chemotherapeutic Assays
There is apparently less variety in the number of in vivo assays as 
compared to in vitro assays. A  survey of the literature reveals the 
following:
Assessment of Increase in Life Span: Increase in life-span of tumour- 
bearing hosts is one of the commonest parameters for determining the 
effects of potential chemotherapeutic agents in vivo. Ideally, it should 
only be employed in studying effect of cytotoxic agents on the 
leukaemias (Valeriote, 1979) as solid tumours can have extremely wide 
distributions of time to death. However, even in leukaemias the assay is 
of lim ited sensitivity (Wilcox et aL 1966) in that such measurements 
assess clonogenic cells indirectly, i.e. after they have m ultiplied  
sufficiently to kill the host. Furthermore, in treated animals the assay 
may be misleading in the sense that it is unable to give adequate 
information on leukaemia sanctuaries such as the central nervous 
system and in immunogenic tumours there w ill be the added 
complication of tumour immunity which may lead to difficulties in data 
interpretation (Grindley, 1972).
1.6.2. Human Tumour Xenograft: In the human tumour xenograft
model, the primary parameter of response is the extent of tumour 
growth inhibition as compared to controls. The treatment is started only 
after the tumours are well established and palpable at the site of 
implantation. Because of the relatively slow growth of the human 
tumour xenograft at the subcutaneous site of inoculation, tests may take 
as long as 60-90 days to complete. This assay utilizes heterotransplants of 
human tumours in the congenitally athymic "nude" (nu/nu) mouse. In  
a typical experiment, each mouse is inoculated subcutaneously (S.C) with 
up to 2 X 10  ^ cells. When palpable tumours appear, control mice were
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given sterile saline intraperitoneally (I.P) while test mice were 
administered L D io  of test drug (I.P). A ll mice were weighed and 
tumour sizes measured by caliper at weekly intervals. Tumour volumes 
were approximated as the product of the two longest perpendicular 
diameters. Every time the tumours were measured, control tumour 
volumes were compared w ith treated tumour volumes (Bellet et aL
1979).
1.6.3 Sub-renal Capsule Assay (SRCA): This assay involves insertion of 
small fragments (approximately Im m ^) of human tumour xenograft 
under the renal capsule of mice where there is a rich vascular bed 
ensuring both adequate nutrients for tumour growth and ready drug 
delivery. One of two types of assessment is used, in the first method, a I
stereoscopic microscope in which a micrometer disc is inserted into one 
eye piece is used. It  is reportedly possible to measure in situ the size of 
the initial graft and the ultimate size achieved at the termination of the 
experiment. An assay time period of eleven days was selected since it 
was long enough to permit measurement of extent of growth and of 
drug-induced inhibition of the human tumour xenografts. In the second Imethod, on days 1, 2 and 3 following tumour implantation, the mice |
were treated either with a placebo (control) or with various anticancer '
agents. Between days four and six, mice were sacrificed and the mean 
tumour diameter measured. The tumour bearing kidney is then fixed in 
bouins solution and processed for histological analysis after staining 
with haematoxylin-eosin. Seven histological parameters were blindly |
rated in a semi quantitative fashion using values between -3 to +11.
The criteria for drug activity against human tumour xenograft 
implanted subcutaneously and under the renal capsule are usually those 
set by the division of cancer treatment. National Cancer Institute, USA
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(Goldin et aL 1981). These are 58% inhibition relative to controls for the
S.C model and 80% inhibition for the subrenal capsule model. In
addition, it is possible to use tumour weight as an endpoint. Tumour
weight (W) in mg is estimated from caliper measurement according to
the formula : W  = x b 
2
where a is the width and b is the length in mm.
In  an effort to standardize the variability in tumour size among test 
groups at the initiation of treatment, Goldin et al (1981), calculated 
relative weight (RW) using the formula RW = W i/W o  where Wq is the 
mean tumour weight of a group at the beginning of treatment and W i is 
the mean tumour weight at any subsequent time. A  significant response 
to treatment is indicated when a test group shows an RW < 42% of that 
of the control at any time during a specified range of days after the last 
treatment. The tumour xenograft models (both s-c and subrenal) may be 
more valuable than the L I210 and P388 leukaemia models as screening 
assays for new chemotherapeutic agents. There were fewer false 
positive results obtained using this assay as compared to murine L I 210 
or P388 models which make them potentially good secondary screens 
(Goldin et al. 1981).
1.7 Aims and Objectives of this Study:
Most of the common murine tumour models employed in the 
preclinical screening of antitumour drugs are lymphoid in origin (e.g 
L I210 and P388 leukaemias). While these models may be adequate for 
predicting response of human lymphoid leukaemias, they may not be 
the logical screens for drugs effective against myeloid leukaemias. One 
aim of the present study was to evaluate the responses of two
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antileukaemic drugs (Ara-C and mitoxantrone) using murine myeloid 
leukaemias. The latter were induced in C B A /H  mice following whole- 
body x-irradiation. Although both drugs are already in clinical use, their 
re-evaluation in the laboratory would provide information regarding 
the suitability of these murine myeloid leukaemias as preclinical 
screening models. Cytarabine is an established drug of choice for treating 
acute myeloid leukaemia and has been in clinical use for over twenty 
years. In  contrast, mitoxantrone was recently introduced in the 
treatment of relapsed adult acute myeloid leukaemia. It would therefore 
be interesting to determine the similarities and differences between the 
two drugs bearing in mind that they belong to two distinct chemical 
classes. A  variety of techniques such as dye-exclusion assay, 
[3H]thym idine uptake assay, autoradiography and granulocyte- 
macrophage colony forming cell (GM-CFC) assay would be employed to 
determine drug-induced cell lethality.
Myelosuppression is the dose-limiting toxicity of many antileukaemic 
drugs including cytarabine and mitoxantrone. The effects of both drugs 
on normal (murine) bone marrow cells would be monitored and 
compared to their effects on myeloid leukaemic cells. This w ill give an 
indication of any selective toxicity to leukaemic cells as compared to 
normal bone marrow cells.
Finally, an attempt would be made to study the in vivo activity of 
mitoxantrone against leukaemia bearing mice.
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2. MATERIALS AND METHODS
CHAPTER TWO
2. MATERIALS AND METHODS
2.1.1 Mice and Housing: In all experiments, C B A /H  mice inbred in the 
departmental animal house and exposed to 12-hour cycle (each) of light 
and darkness were used. They were fed on animal house feed R M l(C) 
3 /8  and were allowed chlorinated water ad libitum . Not more than 6 
mice were housed per cage.
2.1.2 Leukaemias: The leukaemia models employed were passaged cell 
lines derived from transplantation of primary (1°) leukaemia induced 
following 3 Gy whole body X-irradiation in male mice aged 100 ± 10 days 
(Hepburn et aL 1987). The cell lines were given the code 81287 (1-10), 
SA2 (30-50), SA7 (100-180) and SA8 (90-150). The numbers in bracket 
indicate the range of passage number within which all experiments in 
that particular cell line were performed. For example, experiments using 
the 81287 cell line were performed between the 1st and 10th passage etc. 
Two pseudoprimary cell lines (given the code 10.12 and 10.13) were also 
used. The pseudoprimary leukaemias were derived as a result of 
transplanting bone marrow cells from mice irradiated with 3 Gy into 
mice that were irradiated with 4.5 Gy x-irradiation.
2.1.3 Autopsy Procedure: Overtly leukaemic mice which showed
characteristic signs of pale feet (due to anaemia), ruffled fur and weight 
loss were killed by ether anaesthesia. In all the cell lines, there was 
leukaemic in filtration of spleen and therefore, the presence of 
splenomegaly together w ith examination of blood smears confirms
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diagnosis of leukaemia. The femora were dissected free of muscle and 
fat and the marrow cells aspirated into RPMI medium supplemented 
with penicillin (50 I.U /m l), streptomycin sulphate (50ug/m l), 10% foetal 
calf serum (PCS) and 2mM glutamine using a No. 23 gauge needle using 
sterile technique. A  single cell suspension was prepared by gentle 
syringing through No. 23 followed by No. 25 gauge needles. Spleen 
cells were similarly treated except that they were in itially aspirated 
through a 1ml syringe without a needle. The upper portion of medium 
and cells were removed and a single cell suspension prepared as for the 
bone marrow.
2.1.4 Transplantation Procedure: To passage the leukaemias, spleen 
single cell suspensions in Fischers medium supplemented w ith  
glutamine and antibiotics were prepared as described above. Two 
morphologically distinct cell lines were derived depending on the 
number of cells routinely passaged (Hepburn et aL 1987). When 1 x 10  ^
cells were routinely injected intraperitoneally (I.P), the mice became 
overtly leukaemic 7 days later. This is termed "high cell dose 
passage"(HD). In contrast, when 1 x 10  ^ cells were routinely injected 
intravenously (I.V ), the recipient mice became moribund w ith  
leukaemia 30 days after tumour inoculation. This is called "low cell dose 
passage"(LD).
2.1.5 Drugs: Cytosine arabinoside (1,8-D-Arabinofuranosyl cytosine; 
cytarabine; Ara-C) was purchased from Sigma Chemical Company, 
St Louis, (USA) as the free base and was dissolved in RPMI or Dulbeccos 
medium depending on the type of experiment.
Mitoxantrone hydrochloride (Mitozantrone, Novantrone(^), M itox) 
2m g/m l, was a generous gift from Lederle Laboratories, Hampshire,
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England. Serial dilutions of the drugs were made in appropriate media 
(or saline) just before setting up the experiments.
2.2  CELL CULTURE ASSAYS
2.2.1 Differential Staining Cytotoxicity (DiSC) Assay: This assay is based 
on differential staining of live and dead cells so that they are easily 
distinguishable from each other.
2.2.1.1 Stains: Fastgreen (FCF No F252) and nigrosin (N-4754) were 
purchased from Sigma Chemical Company, St Louis, (U S A). Harris 
haematoxylin was prepared as follows:
Haematoxylin : Ig  
Absolute alcohol : 10ml 
Ammonium or potassium alum : 2g 
Mercuric oxide : 0.5g 
The haematoxylin was dissolved in alcohol and alum (previously 
dissolved in hot water) added. The mixture was quickly boiled and 
mercuric oxide added when the solution turn purple. It was then rapidly 
cooled under tap water and filtered before use. Acetic acid (8 ml) was 
added to sharpen nuclear staining.
2.2.1.2 Internal Standard of Pigeon Red Cells: Blood (10ml) was obtained I
from a pigeon in a bottle containing an anticoagulant. The pigeon red 
cells (PRC) were washed three times with 0.15M NaCl. They were then 
resuspended in 2% acetaldehyde in phosphate buffered saline by 
dropwise addition of packed red cells into the acetaldehyde with  
continuous stirring on a magnetic stirring plate. Cells were left in this I
buffer for ten days and were then sterilized by soaking in 99% ethanol 
overnight followed by extensive washing with sterile 0.15M NaCl. The 
cells were finally suspended in 0.15M NaCl containing streptomycin (100
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u g /m l) and penicillin (100 i.u /m l). The cells were adjusted to 
haematocrit of 2.5% (volume of PRC over total volume of PRC plus 
suspending medium). This working suspension was stored at 4°C and 
was of sufficient quantity for many assays. Prior to use in the assay, the 
working suspension was diluted 1:40 to approximately 7 x 10  ^ PRC/m l. 
One half of this suspension was added to 20ml fastgreen-nigrosin. The 
pigeon red cells were easily identifiable as nucleated microelliptocytes 
(Weisenthal et aL 1983 b).
2.2.1.3 Preparation of Slides: lOOpl of cells (7 x 10  ^ cells/m l in RPMI 
medium supplemented w ith PCS and antibiotics) were plated in a 
microtitre plate (Nunclon). lOOul W EHi conditioned medium was 
added to give a final concentration of 10%. This is the optimal 
concentration for cell proliferation stimulation. 100 ul each of Ara-C, 
mitoxantrone or combination of the two, or medium (control) was 
added per well and left in culture for the entire period of the assay. After 
4 days incubation at 37°C in a humidified atmosphere containing 5% 
CO2  in air, six wells were pooled and mixed 1:1 (V /V ) with dye solution
containing fast-green nigrosin to which permanently fixed pigeon red 
cells were added. The mixture was briefly mixed and after 10 minutes at 
room temperature it was cytocentrifuged onto ethanol washed slides and 
air dried.
2.2.1.4 Haematoxylin-Eosin Staining: Eosin was prepared as follows:
1% Eosin - 100ml 
1% Phloxin - 10ml 
95% ethanol - 780ml 
Glacial acetic acid: 4ml 
Slides fresh from cytocentrifuge were stained (without prefixing) in  
Harris formula haematoxylin. After 90 seconds, the staining rack was
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removed and transferred to a solution of 7.5% ethanol for two quick dips 
lasting less than five seconds (sec). Following this, the rack was quickly 
dipped twice in additional changes of 7.5% ethanol to remove excess 
haematoxylin before eosin staining. Following the ethanol washes, the 
slides were placed in the eosin solution for 30 sec during which time 
fixation also took place. The slides were then briefly dehydrated by 2 
successive quick dips in 95% ethanol, 100% ethanol and xylene. The 
slides were then allowed to dry and mounted. Living cells were stained 
pink with haematoxylin-eosin and dead cells were stained dark-green 
with fast green-nigrosin. Alternatively slides were counterstained with 
Diff-Quik (Merz and Dade, AG, Switzerland) or Jenner- Giemsa which 
not only gives comparable results but was also less tedious (Bird, 
Bosanquet and Gilby, 1985).
2.2.1. 5 D iff- Ouik^  Staining : Cytospin slides were prepared and
allowed to dry in the air. They were stained in the following manner:
1. Slides were dipped 6 times in fixative solution ( fastgreen in methanol 
(0.002g/L) ) with each dip lasting not more than 5 seconds. The excess 
fixative was allowed to drain after each dip.
2. The slides were dipped 6 times in solution 1 (eosin G in phosphate 
buffer at pH  6.6) with each dip lasting not more than 5 seconds.
3. The slides were dipped 6 times in solution 2 (thiazine dye in 
phosphate buffer at p H  6.6) w ith each dip lasting not more than 5 
seconds.
4. The slides were rinsed with water and allowed to dry. They were 
then mounted in euparol.
2.2.1.6 Tenner - Giemsa Staining: Cytospins were prepared and dried in 
air and were then fixed by immersing them in a jar of methanol for 10 -
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20 minutes. They were then transferred to a staining jar containing 
Jenner stain freshly diluted w ith an equal volume of water. After 
staining for 5 minutes the slides were immersed (without washing ) in 
Giemsa stain (freshly diluted w ith nine volumes of water). After 
staining for 10 minutes the slides were transferred in to a jar containing 
tap water and allowed to stand for 2 - 5 minutes. The slides were stood 
upright to dry. They were mounted in euparol.
2.2.1.7 Assay Interpretation: For the determinations of drug-induced |
cytotoxicity the ratio of live tumour cells over simultaneously counted 
pigeon red cells was determined for each slide and the ratio in drug- |
treated samples expressed as percentage of that in the control. This |
expression was termed "tumour cell viability" (TGV). The addition of 
PRC overcomes the problems of cell lysis and proliferation in culture 
thus allowing direct comparison of the number of surviving cells 
present in control and drug treated samples (Bird et aL 1986).
2.2.2 rSHl-Thymidine Uptake Assay: The tritiated thymidine ([3H]TdR) 
uptake assay measures the ability of proliferating cells to take up [3H]- 
thymidine for incorporation into DNA during D N A  synthesis (S-Phase).
The degree of D N A  synthesis Inhibition in drug treated samples 
compared to the untreated control gives a measure of cytotoxicity 
produced by a drug.
Leukaemic or normal bone marrow single cell suspensions were 
prepared as described previously (section 2.1.3). lOOfil cells (7 x 10^ 
cells/m l) in RPMI medium supplemented with foetal calf serum (10%), 
penicillin 100 i.u /m l), streptomycin (50gg/m l) and glutamine (2mM) 
were plated in microtitre plates (Nunclon) together w ith lOOpl W EHi 
conditioned medium (to give a final concentration of 10%) and then
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100|il drug or medium (control) was added. In  the continuous 
incubation method, the drugs were left in culture for the duration of the 
experiment. For the 1 hour pulse method, cells were incubated with one 
drug or medium (control) for one hour, washed twice and resuspended 
in RPMI medium and plated out after which the second drug was added 
either immediately or 24, 48, or 72 hours later. After four days 
incubation in hum idified atmosphere containing 5% CO2  , 7.5KBq
[3H]TdR (Specific activity 777MBq/mg) (Amersham International Pic, 
Buckinghamshire, England) was added per well and the plate further 
incubated for eight hours. The cells were harvested onto a glass fibre 
filter paper (Titertek, Flow Laboratories, Irvine, Scotland) using a cell 
harvester (Titertek, Skatron, Norway). After at least 12 hours drying in 
an oven, individual filter discs were placed in scintillation vials and 2ml 
of scintillant (Optiphase 'Safe', FSA Laboratory, Loughborough, England) 
added and radioactivity deposited on the discs determined using a liquid 
scintillation counter (LKB 1214 Rackbeta). Dose-response curves were 
obtained by plotting counts per minute in drug treated samples as a 
percentage of untreated control uptakes as a function of the drug 
concentration.
Definations of Additivity. Synergy and Antagonism: An additive effect 
is manifested when the combined effect of two drugs acting either by the 
same mechanism ( Levine, 1983 ) or via different mechanisms ( Grundy, 
1985 ) is equal to that expected by simple addition. When the joint effect 
of two drugs is greater than the algebraic sum of their individual effects 
a synergistic effect is said to be manifested ( Levine, 1983). An 
antagonistic effect is manifested when the effect produced by a 
combination of two drugs is less than the sum of the effects produced by 
the single drugs ( Levine, 1983).
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2.2.3 Cell Counting using Coulter Counter: Microtitre plates were set up 
as described under Section 2.2.2. On day 4, following drug incubation, six 
wells were pooled (each) from control and drug treated wells into coulter 
vial containing isoton (20ml). Three drops of Zaponin (Coulter 
Electronics, England) were added and the counts determined using a 
coulter counter (model Zm, Coulter Electronics, England) using the 
following settings:
current - 130 
full-scale -10  
lower threshold - 30 
Attenuation - 1
2.2.4 Autoradiography: This technique is usually employed to
determine the number of cells that are actively proliferating in a cell 
population. The sample is labelled w ith radioactive D N A  precursor 
which is usually [3H]- thymidine. A thin layer of photographic 
emulsion is placed on sections of the sample to be studied and left in the 
dark for a period of days. When the photographic emulsion is 
developed, those cells which contained radioactively labelled D N A  in 
their nuclei w ill have black silver grains deposited in the emulsion 
above them. The grains are caused by radioactive emission. Because B- 
particles emitted by tritium have less energy and therefore shorter range, I
the silver grains are clustered neatly over the labelled nuclei (Aherne, 
Cample-John and Wright, 1977).
2.2.4.1 Preparation of Slides: Plates were set up as for microtitre assay 
described previously (section 2.2.2). On day 4 following incubation in  
humidified atmosphere containing 5% CO2  in air, 7.5KBq 3HTdR was
added per well and the plates further incubated for one hour. At least six
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wells were pooled, washed twice and cells resuspended in RPM I 
medium (supplemented with serum to ensure good cytology). Cytospins 
were prepared onto ethanol washed slides using a Shandon 2-cytospin at 
800 rpm for ten minutes.
2.2.4.2 Autoradiographic Process: Each slide was dipped in K2  liquid 
emulsion in gel form (Illford nuclear research emulsion) which has been 
diluted (1:1) with 1% glycerol solution. After drying, slides were boxed 
and kept in the dark at 4°C for four days. They were then developed. 
This involved dipping the slides in D19 high contrast developer (Kodak 
5027065) for 3.5 minutes followed by rinsing for 30 seconds in distilled 
water and fixing for 5 minutes in Kodak acid fixer after which they were 
rinsed in running water for 5 minutes. After drying, the slides were 
stained with Jenner - Giemsa, the Jenner being previously filtered to 
remove any precipitation. The slides were allowed to dry and mounted 
in euparol.
2.2.4.3 Labelling Index: A ll slides were scored in a blind fashion under 
oil immersion (x40). A t least 400 cells were counted per slide unless 
cellularity was adversely reduced by drug treatment. The background 
grain count was determined from acellular field on the slide and the 
appropriate threshold value for a cell to be classified as labelled decided 
from this. The labelling index was taken as the fraction of labelled cells 
expressed as a percentage of the whole cell population.
2.2.5 Granulocyte-Macrophage Colony Forming Cell Assay: The 
cytotoxic effects of drugs on normal myeloid progenitor cells were 
determined using granulocyte-macrophage colony forming cell (GM- 
CFC) assay. Cells were either pulsed with drugs for one hour, washed
46
twice and then plated in agar or else the drugs were dissolved in the 
same medium in which the cells were suspended (i,e continuous 
exposure).
To 8ml of Dulbecco's medium supplemented with horse serum (20%), 
glutamine and antibiotics, was added 1ml of agar (3%) and 1ml of cell 
suspension (5x10^ cells/m l). The mixture was briefly shaken and 1ml 
aliquoted into 30mm petridish containing 0.1ml W EHi conditioned 
medium as a source of colony stimulating activity. The plates were 
incubated in a humidified atmosphere containing 5% CO2  in air at 37°C.
2.2.5.1. Assay Interpretation: Colonies ( > 50 cells) were scored using an 
inverted microscope on day 7. Dose-response curves were obtained by 
plotting the number of colonies in drug treated samples as a percentage 
of control colony numbers against the concentrations of the drugs used. 
A t least 40 colonies must be present in control plates for an experiment 
to be considered evaluable.
2.3.1 In Vivo Chemotherapeutic Study
Female C B A /H  mice weighing 20-25g and 17 weeks old were inoculated 
with leukaemic cells. On days 1 and 5 following tumour inoculation, 
mitoxantrone (freshly diluted in normal saline) was administered. 
Control mice received only leukaemic cells and saline. The mice were 
observed daily and if they showed any or a combination of these 
symptoms, they were autopsied in order to determine the cause of death: 
weight loss, pale feet, conjunctivitis, ruffled fur, etc.
An increase in life-span of drug treated mice relative to controls was 
used as an end point for assessing drug activity. The survival of treated 
mice counted from day of tumour inoculation was determined and
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compared to untreated control and the ratio of the two expressed as per 
cent increase in life- span (% ILS). The following formula was used to 
calculate (%)ILS (Fujimoto and Ogawa, 1982):
(T-1) X 100 
C
where:
T = mean number of days survived by treated mice 
C = mean number of days survived by control (untreated) mice
2.3.2 Normal Mice: Normal mice of similar weight and sex as leukaemic 
mice received similar schedule of mitoxantrone. The mice were 
sacrificed and spleen weight, femur cellularity, haemoglobin count (Hb) 
and haematocrit (packed cell volume, PCV) determined as follows:
Femur Cellularity: Bone marrow cells were flushed from a femoral bone 
using 3mls of RPMI medium supplemented w ith serum (10% foetal 
calf); glutamine and antibiotics. A  single cell suspension was then 
prepared ( Section 2.1.3). The cell suspension( lOOpl) was added to isoton 
(20ml) in a vial and 3 drops of Zaponin (to lyse red cells) added. The 
number of nucleated cells per m illilitre (ml) was then determined from  
the coulter counts. And the femur cellularity was obtained by 
multiplying this by 3.
Spleen W eight: Spleen was dissected free from fat and muscle and 
weighed.
Haemoglobin Count: Blood was collected following cardiac puncture in 
an anaesthetized mice and stored in heparinized tubes. The tubes were 
gently shaken in order to ensure proper m ixing of blood and 
anticoagulant to prevent clotting. A  haemoglobin photometer was
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calibrated using standard microcuvettes. The blood sample in a 
microcuvette chamber was then inserted into the photometer and the 
haemoglobin count (g /L ) read off.
Packed Cell Volume (PCV): Blood was drawn into a capillary tube one 
end of which was sealed with crystaseal. The tubes were cytocentrifuged 
using a microhaematocrit centrifuge. The packed cell volume was then 
read off using standard methods.
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CHAPTER THREE
3. RESULTS
3. In vitro Chemotherapeutic Assays
This chapter contains the results from a series of experiments where the 
responses of myeloid leukaemic cells were investigated following 
treatment with cytotoxic drugs used singly or in combination. The 
responses were monitored using the following assays
cell viability assay using fast green containing fixed pigeon red cells
- the D isc assay (section 3.1);
Assessment of cell number using coulter counter (section 3.1.3); 
[3H]-thymidine uptake assay following growth factor stimulation of cell 
proliferation (section 3.2);
Autoradiography following labeling the cells with [3H]-thymidine 
[[3H]TdR] (section 3.3.);
Granulocyte-macrophage colony forming cell (GM-CFC) assay following 
treatment of normal bone marrow cells with drugs and plating the cells 
in agar (section 3.4).
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3.1 Differential Staining Cytotoxicity (DiSC) Assay
Under this heading two assays were employed: pigeon red cell (Section
3.1.2) and assessment of cell number using coulter counter (Section
3.1.3).
Prior to setting up the pigeon red cell (DiSC) assay the methodology was 
evaluated by determining the ratio of live and dead cells in a mixed 
population (Section 3.1.1). The responses of the following leukaemic cell 
lines to Ara-C, mitoxantrone either singly or in combination were 
determined using both the DiSC assay and assessment of cell number 
using coulter counter: SA2, high cell dose (HD) transplant of SA7 
(SA7HD) and SA8  high cell dose passage (SA8 HD).
3.1.1 Evaluation of Pigeon Red Cell (DiSC) Method: Leukaemic bone 
marrow single cell suspension was prepared from femora of mice 
bearing the SA7HD leukaemia as described under section 2.1.3. Some of 
the cells were killed by heating at 60 °C for one hour and mixed with live 
cells to give 0, 25,50, 60, 80 and 100% live cells. Viability was determined 
after staining with fastgreen-nigrosin and counterstaining with Jenner- 
Giemsa.
Results: There was a good correlation between expected and observed 
values (Figure 1) and this indicated that the procedure does preserve 
and differentiate live and dead cells in a mixed population. Live cells 
assumed normal Jenner-Giemsa counterstain (pink) while dead cells 
were stained dark-green by fastgreen-nigrosin(Plate 1).
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3.1.2 Pigeon Red Cell (DiSC) Method: A single cell suspension was 
prepared from the following leukaemic cell lines (SA2, SA7HD, SA8 HD) 
and plated at 7 x 1 0 ^ cells per well in a microtitre plate. W EHi 
conditioned medium was added (except cells from SA2 cell line) to give a 
final concentration of 10% per well. lOOpl each of mitoxantrone, Ara-C 
or combinations of the two was added to give final concentrations in the 
range 0.12-120ng/ml. In combination experiments, the concentration of 
one drug was varied (0 .1 2 -1 2 0 ng /m l) while maintaining the final 
concentration of the second drug at 1.2ng/m l. After four days 
incubation, six wells were pooled and the cells were stained with  
fastgreen-nigrosin to which permanently fixed pigeon red cells were 
added. They were then cytocentrifuged onto ethanol-washed slides. 
After Jenner-Giemsa counter staining, the ratio of live cells over 
simultaneously counted pigeon red cells was determined (blindly) for 
each slide and the ratio in drug-treated samples expressed as a percentage 
of that in control. This expression called tumour cell viability (TCV) was 
plotted against drug concentrations to yield dose-response curves.
3.1.3 Assessment of Cell Number: Experiments were set up as described 
under section 3.1.2. On day 4 following drug incubations, six wells were 
pooled (each) from drug treated and control samples and counted using a 
coulter particle counter (see Section 2.2.3). Dose-response curves were 
obtained by plotting the ratio of counts in drug treated samples as a 
percentage of that in control as function of drug concentrations.
Results: The responses of the leukaemic cell line SA2  to Ara-C alone 
and in combination w ith mitoxantrone (1 .2 ng /m l determined using 
both pigeon red cell (DISC) and coulter (CC) methods are shown in 
Figure 2. According to both methods, the cell line was not sensitive to 
Ara-C w ithin the concentration range 0 .1 2 -1 2 n g /m l as only slight
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increase in cytotoxicity was observed with increasing dose within that 
range. However, a marked cytotoxic effect was seen with 120ng/ml in 
the D isc assay. There was a close agreement between the two methods 
although the electronic particle count method seemed to underestimate
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Fig.l : Percentage of live cells observed after staining known 
proportions of live and dead cells with fast green.
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Fig.2: The response of SA2 leukaemic cell line to arac alone or in 
combination with mitoxantrone assesed using the DISC assag 
and coulter count method.
cytotoxicity produced using the highest concentration employed 
(120ng/m l). W hilst a slight additive effect was observed when 
mitoxantrone ( l,2ng/m l) was added to Ara-C (in the concentration range 
1.2-12ng/ml) in the DiSC assay, no such effect was observed using the 
coulter method. In the latter case where mitoxantrone was added to Ara- 
C, there was no difference from the response with Ara-C alone. Figure 3 
shows the effect of mitoxantrone alone or in combination with Ara-C  
(1.2ng/m l) on the same (SA2) leukaemic cell line using both methods. 
Again there was close agreement between the dose response curves 
obtained using the two methods. As was observed w ith Ara-C, 
mitoxantrone within the concentration range 0 .1 2 -1 2 ng/m l had virtually 
no effect on cytotoxicity. However, increased cytotoxicity was observed 
when higher concentration of mitoxantrone was used (1 2 0 ng /m l). 
Mitoxantrone alone was no better than Ara-C alone in the extent of cell 
kill produced. Addition of Ara-C to mitoxantrone resulted in either no
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effect (cell count) or antagonism at low concentrations of mitoxantrone 
(DISC).
The responses of the SA7 cell line to Ara-C alone and in combination 
with mitoxantrone are shown in Figure 4. This cell line seemed slightly 
more sensitive to Ara-C alone as compared to the SA2  cell line using the 
cell number assessment method. There was a close agreement between 
the two methods in determining the response of the cell line to Ara-C  
alone. Addition of mitoxantrone (1 .2 ng/m l) to Ara-C resulted in either 
no increased effect (DISC) or an additive effect (CC). This cell line 
seemed more sensitive than SA2 to mitoxantrone alone and in 
combination with Ara-C (Figure 5) as assessed by both DISC and cell 
number assessment methods. Addition of Ara-C to mitoxantrone 
resulted in antagonism at the lowest mitoxantrone concentration 
(0.12ng/ml)(DiSC) or slight additive effect (CC). Figure 6  shows the dose- 
response curve of the SA8  cell line to Ara-C alone and in combination 
w ith mitoxantrone. A t low to intermediate concentrations (0.12- 
12ng/m l), Ara-C had little effect on cytotoxicity as assessed by both 
methods. When the dose of Ara-C was increased to 120ng/ml there was 
about an 80% increase in cytotoxicity relative to control. Both methods 
gave almost identical dose-response curves. Addition of mitoxantrone 
to Ara-C, resulted in additive cytotoxic effects as determined using both 
methods. The SA8  cell line is as sensitive as the SA7 cell line to 
mitoxantrone (CC) (Figure 7). Unlike what was observed with Ara-C, 
increasing the concentration of mitoxantrone w ithin the range 0 .1 2 - 
12ng/m l was associated with increased cytotoxicity.
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However, only the DiSC assay showed an additive effect when Ara-C 
(1.2ng/m l) was added to mitoxantrone. W ith the cell number 
assessment method, addition of Ara-C did not result in increased 
cytotoxicity as compared to mitoxantrone alone.
There was no difference in potency between mitoxantrone and Ara-C on 
their effect on SA2 cell line. However, mitoxantrone seem more potent 
than Ara-C at the 12ng/m l concentration against both SA7HD and 
SA8 H D  cell lines.
3.2 Tritiated Thymidine Uptake Assay: Using this assay, the effects of 
Ara-C, mitoxantrone or their combinations on leukaemic cell lines 
81287; 10.12; 10.13; SA2; SA7 low cell dose passage (SA7LD); SA7 high cell 
dose passage (SA7HD); SA8  low cell dose passage (SA8 LD); SA8  high cell 
dose passage (SA8 HD) and normal bone marrow (NBM) cells were 
determined. Prior to setting up drug experiments, the amount of growth 
factor required for optimum in vitro cell proliferation stimulation was 
determined (section 3.2.1). An experiment was also set up to determine 
the effect of foetal calf serum on in vitro mitoxantrone cytotoxicity 
(section 3.2.2).
Drug effects were monitored either following continuous incubation 
(section 3.2.3) or a one hour pulse (section 3.2.4). In  the continuous 
incubation method, the drugs were left in culture for the duration of the 
assay. In contrast, with the one hour pulse method, the cells were pulsed 
with drug(s) for one hour, followed by washing twice and a second drug 
was then added either immediately or hours later. In both methods, the 
assays were terminated on day 4 by addition of [3H]TdR followed by 
determination of the amount of radioactivity incorporated by drug 
treated and control samples.
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3.2.1 Growth Factor Dose-Response Curve: Microtitre plates were set up 
as described under section 2.2.2. Graded concentrations of W EHi- 
conditioned medium (lOOpl) was added to give final concentration of 5, 
10 or 20% in each well. After 4 days incubation, cells were labelled with 
[3H]TdR and harvested. The amount of radioactivity incorporated was 
determined using a scintillation counter.
Results: Figure 8  shows a typical growth factor dose-response curve 
obtained by incubating normal bone marrow cells w ith various 
concentrations of W EHi conditioned medium. It  is apparent from the 
curve that 10% W EHi produced optimum effect on cell proliferation. 
Therefore, this concentration of growth factor was routinely used to 
stimulate cell proliferation in all in vitro assays reported here except 
those involving the SA2 leukaemic cell line.
3.2.2 Effect of Foetal Calf Serum on Mitoxantrone Cytotoxicity In V itro: 
The aim of this experiment was to determine whether the presence of 
serum affects mitoxantrone-induced cell lethality in vitro. 7 x 10"^  
normal bone marrow cells were plated per well in a microtitre plate and 
W EHi conditioned medium was added to give a final concentration of 
10%. lOOpl of mitoxantrone dissolved in either serum free medium or in 
medium containing 1 0 % foetal calf serum was added to give final 
concentrations in the range of 0.12-120ng/ml. After 4 days incubation 
the wells were labelled, harvested, and the amount of radioactivity 
incorporated by control and drug treated cells determined. Two dose- 
response curves were plotted : one each for mitoxantrone dissolved in 
either serum free medium or in serum containing medium.
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R esults: The presence of serum had no effect on mitoxantrone
cytotoxicity in vitro (Figure 9). In contrast, there was a slightly increased 
inhibition of [3H]TdR uptake when mitoxantrone was dissolved in  
medium containing serum as compared to serum-free medium.
3.2.3 Continuous Incubation: In  these experiments, leukaemic cells 
from the cell lines 81287, 10.12, 10.13, SA2, SA7HD, SA7LD; SA8 LD, 
SA8 H D  and normal (murine) bone marrow cells were incubated with  
Ara-C, mitoxantrone or combinations of the two drugs. The drugs were 
left in culture for the duration of the experiment (four days). For the 
primary (81287) and low cell dose transplant cell lines, spleen cells were 
set up in addition to bone marrow cells.
A  single cell suspension was prepared from the following leukaemic cell 
lines (81287, 10.12, 10.13, SA2, SA7, SA8 ) and NBM cells and plated at 
7 X 10'^  cells per well. lOOpl W EHi conditioned medium was then added 
(except experiments with SA2 cell line) followed by lOOpl of drug (Ara-C 
or mitoxantrone) to give final concentration per well in the range 0 .1 2 - 
120ng/ml. In the combination experiments, the concentration of one of 
the two drugs was varied (0 .1 2 - 1 2 0 ng /m l) while maintaining the 
concentration of the second drug at 1 .2 ng/m l (unless otherwise stated). 
Dose-response curves were obtained by plotting counts per minute in the 
drug treated sample as a percentage of control uptake as a function of 
dose.
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Fig.10: Response of spleen cells from the leukaemic cell line 81287 to 
arac determined using coulter counts and (3H)-thymidine uptake assay.
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Results:
Primary (81287) and Pseudoprimaries (10.12 and 10.13) Leukaemic Cell 
Lines: Figure 10 shows the response of spleen cells from a Primary 
leukaemic cell line 81287 to Ara-C determined using [3H]TdR uptake 
assay. Similar dose-response curve was obtained by the cell number 
assessment method although cytotoxicity seem less pronounced 
according to the latter method. The response of the same spleen cells to 
mitoxantrone is shown in Figure 11. Again, there was qualitative 
similarity between the two dose-response curves although cytotoxicity 
was less pronounced using the electronic cell number assessment 
method even at the highest mitoxantrone concentration used 
(120ng/m l). Spleen cells seem more sensitive to mitoxantrone as 
compared to Ara-C according to the [3H]TdR uptake inhibition results. 
After the leukaemic cells were passaged in syngeneic mice (81287TI), 
spleen cells showed a slight decrease in sensitivity to Ara-C (Figure 12) 
and mitoxantrone (Figure 13). A  comparison of sensitivity of spleen 
cells and bone marrow cells (Figure 14) to Ara-C suggests that spleen cells 
were slightly more sensitive at low concentrations. Similarly, spleen 
cells (Figure 13) were more sensitive to mitoxantrone as compared to 
bone marrow cells (Figure 15) at low concentrations. By the sixth 
passage sensitivity to Ara-C was decreased particularly at 1 2 ng /m l 
(Figure 16). Below this concentration of Ara-C, virtually no effect was 
produced. Addition of mitoxantrone (0.12ng/ml) resulted in a slight 
additive effect at low concentrations which was to be expected since 
mitoxantrone alone at that concentration produced virtually little effect 
(Figure 17).
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Fig.11: Response of spleen cells from primary leukaemic cell line 
81287 to mitoxantrone monitored using coulter counter 
and (3H)-thymldine uptake assay.
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Fig.14: Response of bone marrow cells from 81287T1 cell line to arac.
Cytotoxicity was monitored using(3H)- thymidine uptake assay.
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Mitoxantrone sensitivity was essentially unchanged up to the sixth 
passage. An antagonistic effect was seen at low  mitoxantrone 
concentrations (1.2ng/ml) when Ara-C (1.2ng/ml) was added (Figure 17). 
A comparison of sensitivity of spleen (Figure 18) and bone marrow cells 
(Figure 16) of the 81287T6 cell line to Ara-C indicates that spleen cells 
were more sensitive than bone marrow cells to the same concentrations 
of Ara-C in vitro. Slightly antagonistic to slightly additive effects were 
observed when mitoxantrone (0 .12ng/m l) was added to Ara-C depending 
on the Ara-C concentration (Figure 18). Similarly, spleen cells (Figure 
19) were more sensitive to mitoxantrone at the lowest concentration 
used as compared to bone marrow cells (Figure 17) of the 81287T6 cell 
line. By the tenth passage (81287T10), sensitivity of the bone marrow 
cells to Ara-C was further decreased (Figure 20). Paradoxically however, 
addition of mitoxantrone (0.27ng/m l) resulted in a synergistic effect. 
This was so because the extent of [3H]TdR uptake inhibition produced by 
the combination was greater than the sum of radioactive precursor 
inhibition produced by the individual drugs. There was little change in 
response to mitoxantrone even after the tenth passage (Figure 2 2 ). 
Addition of Ara-C (220ng/ml) resulted in an enhanced cytotoxic effect. 
This was to be expected since Ara-C alone at that concentration 
(220ng/m l) would inhibit [3H]TdR uptake by 90% relative to control 
(Figure 21).
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Figure 22 shows the effect of Ara-C alone or in combination w ith  
mitoxantrone (0 .1 2 ng /m l) on the in vitro  proliferation of a pseudo­
primary leukaemic cell line 10.12. Although there was a lot of variation 
in its response to Ara-C, it appears that this cell line was less sensitive 
than the prim ary leukaemic cell line 81287 to Ara-C. When 
mitoxantrone (0 .1 2ng/m l) was added to Ara-C, antagonistic effect was 
manifested at the lowest Ara-C concentration (1 .2 ng/m l) while additive 
effect was observed with intermediate concentration of Ara-C (12ng/ml). 
The sensitivity of this cell line to mitoxantrone (Figure 23) was similar to 
that of Ara-C although additive effect was observed using low  
mitoxantrone concentrations (below 1 2 ng/m l) when Ara-C (0 .1 2ng/m l) 
was added (Figure 23). Another pseudo-primary cell line (10.13) was not 
as responsive to Ara-C as 81287 or even the 10.12 cell line. 
Concentrations of Ara-C below 12ng/m l had little effect on [3H]TdR  
uptake (Figure 24). When mitoxantrone (0.12ng/ml) was added to Ara-C 
(0.12-120ng/ml) there was a slightly increased inhibition of [3H]TdR  
uptake. However, this cell line was more sensitive than 10.12 cell line to 
mitoxantrone (Figure 25). Mitoxantrone in concentration as low as 
0.12ng/m l inhibited [3H]TdR uptake by up to 30% relative to control. 
When Ara-C (0.12ng/ml) was added to mitoxantrone (0.12-120ng/ml), 
there was a slight additive effect at the lowest mitoxantrone 
concentration (0 .1 2 ng/m l) and a slight antagonistic effect at 1 2 ng/m l 
(Figure 25). Thus, the 10.12 cell line was more sensitive to Ara-C than 
10.13 cell line while the converse was true for mitoxantrone sensitivity.
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Fig.21: Response of bone marrov cells from 81287T10 cell line 
to mitoxantrone alone or in combination with arac 
monitored using (3H)-thymidine uptake assay.
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Fig.22: Response of pseudoprimary cell line 10.12
to arac alone or in combination v ith  mitoxantrone
monitored using(3H)-thymidine uptake assay.
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Fig.23: Response of pseudo primary cell line 10.12
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monitored using the (3H)-thymidine uptake assay
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Fig.25: Response of pseudoprimary cell line 10.13
to mitoxantrone alone or in combination v ith  arac 
monitored using the (3H)-thymidine uptake assay.
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Low Cell Dose Transplant Cell Lines (SA7FT5; SA8FT14): The responses 
of the low cell dose transplant cell line SA7FT5 (SA7LD) to Ara-C alone 
or in combination with mitoxantrone (Figure 26) were similar to those 
of the pseudoprimary cell line 1 0 ,1 2  (Figure 2 2 ). Concentrations of Ara-C 
below 12ng/m l produced little inhibition of D N A  synthesis. When 
mitoxantrone (0 .1 2 ng /m l) was added to Ara-C (1.2-120ng/m l), an 
antagonistic effect was observed at lowest Ara-C concentration 
(1 .2 ng /m l) while slightly additive effect was seen at intermediate 
concentration (1 2 ng/m l). This low cell dose transplant cell line was 
more sensitive to mitoxantrone as compared to the pseudoprimary cell 
line 10.12. A relatively low concentration of mitoxantrone (1.2ng/m l) 
inhibited D N A  synthesis by up to 40% relative to control value (Figure 
27). No difference in [3H]TdR uptake inhibition was observed when 
Ara-C (0.12ng/ml) was added to mitoxantrone. This was to be expected 
since Ara-C alone at that concentration would produce no effect. The
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responses of spleen cells from the SA8FT14 cell line (SA8 LD) to Ara-C 
alone or in combination with mitoxantrone (0.12ng/ml) (Figure 28) and 
mitoxantrone alone or in combination w ith Ara-C (Figure 29) were 
similar to those of the SA7FT5 cell line. Thus, when mitoxantrone 
(0.12ng/ml) was added to Ara-C, an antagonistic effect was produced 
using low Ara-C concentration. However, a slightly additive effect was 
seen when Ara-C concentrations were above 12ng/m l (Figure 28). In  
contrast when Ara-C (0.12ng/ml) was added to mitoxantrone (0.12ng/ml) 
an additive effect was manifested at low concentration of mitoxantrone 
(0 .1 2 n g /m l) w hile no additive cytotoxic effect was seen using 
intermediate to high concentrations of mitoxantrone (1 .2 -1 2 0 ng /m l) 
(Figure 29).
High Cell Dose Transplant Cell Lines (SA2, SA7 and SA8 ) : Figure 30 
shows the dose-response curve of the leukaemic cell line SA2  to Ara-C 
alone or in combination with mitoxantrone (1.2ng/m l). Dose-response 
curves reported were the mean of four separate experiments. The SA2  
cell line was not sensitive to concentrations of Ara-C below 12ng/ml. 
An increase in cytotoxicity was manifested when mitoxantrone 
(1.2ng/m l) was added to Ara-C. However, this was at best an additive 
effect as mitoxantrone alone at that concentration (1 .2 ng/m l) would 
inhibit [3H]TdR uptake to the same extent (Figure 31). The cell line was 
very sensitive to mitoxantrone (Figure 31) although only slight additive 
effect was observed when Ara-C (1 .2 ng/m l) was added to mitoxantrone.
75
100  1
arac
(î.2 n g /m l)
mitox
mîtox+arac(1.2ng/m1)
 I—I I I I 11 * i ■■■■! I—I I I II!
10 100 1000Concentration of mitoxantrone
Fig.27: Respon3e of SA7FT5 cell line to mitoxantrone
alone or in combination with arac monitored
using (3H)-thymidine uptake assay.
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Fig.28: Response of spleen cells from SA8FT1 4 cell line
to arac alone or in combination with mitoxantrone 
monitored using the (3H)-thymidine uptake assay.
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The dose response curves obtained using DiSC (Figure 3) and [3H]TdR 
uptake assays were not in close agreement except when high 
concentration (120ng/m l) of mitoxantrone was used. W ith the DiSC 
assay and cell number assessment method, shoulders were observed in 
the dose-response curves of mitoxantrone, whereas in the [3H]TdR  
uptake assay, the dose-response curve showed simple exponential 
decline with no apparent shoulder. It may be that the DiSC assay and the 
cell number assessment method underestimated the extent of 
cytotoxicity produced by mitoxantrone against SA2 cell line. The SA2 
cell line was more sensitive to mitoxantrone alone as compared to Ara-C 
alone (compare Figures 30 and 31).
The dose-response curves of SA7 high cell dose transplant cell line 
(SA7HD) fo llow ing in vitro treatment w ith Ara-C  alone and 
mitoxantrone alone were plotted from data pooled from 1 2  separate 
experiments. The SA7 cell line seem slightly more sensitive to Ara-C  
alone than SÀ2  cell line particularly at low Ara-C concentration (0.12- 
1.2ng/m l). However, it was less sensitive at 12ng/m l. There was a 
similarity between the dose-response curve of Ara-C determined using 
the Disc assay and the [3H]TdR uptake assay. However, whereas an 
additive effect was observed w ith the combination of Ara-C and
■I'mitoxantrone (1 .2 ng/m l) in the latter assay, no such effect was seen in t
the Disc assay (Figure 4). However, an additive effect was observed for 
the combination using cell number assessment method. Mitoxantrone 
seem more potent than Ara-C on the SA7 cell line (Figure 33) and an 
additive effect was observed when Ara-C (1 .2 ng /m l) was added to 
mitoxantrone (Figure 33).
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F1g.29: Response of spleen cells from SA8FTI4 cell line 
to mitoxantrone alone or In combination v ith  arac 
monitored using the (3H )-thgm idine uptake assay.
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Fig.30: Response of SA2 cell line to arac alone or in combination v ith  
mitoxantrone monitored using the (3H)-thymidine uptake assay.
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Fig.31 [Response of SA2 cell line to mitox alone or in combination v ith
arac monitored using the (3H)-thymidine uptake assay.
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Fig.32: Response of SA7 cell line to orac
alone or In combination v ith  mitoxantrone 
monitored using the (3H)-thymidine uptake assay.
Again, mitoxantrone dose-response curve determined using DiSC assay 
(Figure 5) was in agreement w ith the one determined using [3H]TdR 
uptake assay except w ith a very low concentration of mitoxantrone 
(0 .1 2 ng /m l). No agreement was seen between the result of the 
combination experiments using the two methods.
The SA8  high cell dose transplant cell line (Figure 34) was as responsive 
to Ara-C as SA7HD cell line, although it was more sensitive to the 
combination of Ara-C w ith mitoxantrone (1.2ng/m l) as compared to 
SA7HD. There were similarities in the dose-response curves determined 
using the cell number assessment method, DiSC assay, (Figure 6 ) and 
[3H]-thymidine uptake (Figure 34) assay for both Ara-C alone and in 
combination with mitoxantrone (Figure 34). The SA8  cell line was more 
sensitive to mitoxantrone (Figure 35) as compared to SA7 cell line 
(Figure 33) and when Ara-C (1 .2 ng/m l) was added, there was only a 
slight increase in the extent of [3H]TdR uptake inhibition.
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Normal murine bone marrow cells (NBM) seem slightly more sensitive 
than murine leukaemic cell lines SA2, SA7HD and SA8 H D  to Ara-C 
particularly in the concentration range 0,12-1.2ng/ml (Figure 36). Dose- 
response curves of normal bone marrow cells were constructed using 
pooled data from at least 5 separate experiments. NBM cells seem more 
sensitive than leukaemic cell lines SA2, SA7HD and SA8H D  to the 
combination of Ara-C with mitoxantrone (1.2ng/m l) (Figure 36). In  
addition, they were as sensitive to mitoxantrone as SA7HD and SA8 HD.
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rig .33: Response of SA7 cell line to mitoxantrone 
alone or In combination v ith  arac 
monitored using the (3H)-thymidine uptake assay.
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Fig.34: Response of SA8 cell line to arac alone or in combination v ith  
mitoxantrone monitored using the (3H )-thgm idine uptake assag.
«-N 100 - arac
(1.2ng/m1)£
C  8 0  -oo
O  6 0  -
mitox
milox+arac( 1.2ng/m1)
?  40 - CL
( J
20  -
1 10 100 1000
Concentration of mitoxantrone(ng/m1) 
Fig.35: Response of SA8 cell line to mitoxantrone 
alone or in combination v ith  arac monitored 
using the (3H)-thymidine uptake assay.
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Fig.36: Response of normal bone marrov cells (NBM)
to arac alone or in combination v ith  mitoxantrone 
monitored using the (3H)-thymidine uptake assay.
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However, they were less sensitive than these cell lines to combination of 
mitoxantrone and Ara-C (1 .2ng/m l) at low mitoxantrone concentration 
(0.12-l,2ng/ml)(Fig.37).
Of the leukaemic cell lines studied, the SA2 was most responsive to 
continuous incubation with mitoxantrone, followed by SA8  and SA7 in 
that order. Similarly the SA2  was more sensitive than SA7 (but not SA8 ) 
to combination of Ara-C with mitoxantrone. As compared to NBM cells, 
both SA2 and SA7 were more sensitive to combination of mitoxantrone 
and Ara-C (1.2ng/ml).
3.2.4 Scheduling Studies: In  these in vitro experiments, either normal 
bone marrow cells or leukaemic bone marrow cells from SA2, SA7HD 
and SA8H D  were pulsed with a drug for one hour, washed twice and a 
second drug was added either immediately after washing or 24, 48 or 72 
hours later. The results of one hour pulse with Ara-C followed by 
addition of mitoxantrone (section 3.2.4.1) are reported first, followed by 
those of one hour pulse with mitoxantrone followed by addition of Ara- 
C (section 3.2.5.2).
3.2.4.1 One Hour Pulse w ith Ara-C Followed bv Addition of 
Mitoxantrone:
Normal bone marrow cells or leukaemic bone marrow from the cell 
lines SA2, SA7HD and SA8 HD were either pulsed with Ara-C in the 
concentration range 0 .1 2 -1 2 0 ng/m l or Ara-C (same concentration range) 
together w ith mitoxantrone (1.2ng/m l) for one hour. The cells were 
then washed twice, counted and plated at 7 x lO'^  cells per well in a 
microtitre plate. Mitoxantrone (1.2ng/m l) was added (to those wells 
containing cells that were pulsed with Ara-C only) either immediately 
following cell wash or 24, 48 or 72 hours later (Figure 38). W EHi
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conditioned medium was added (to give a final concentration of 1 0 % per 
well) and the plates were incubated for four days. Control cells were 
pulsed with medium only. Plates were then labelled w ith [3H]TdR, 
harvested and the amount of radioactivity incorporated by the cells was 
determined (Figure 38).
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Fig.37: Response of normal bone marrov cells to mitoxantrone 
or in combination v ith  arac monitored using the [3H] thymidine 
uptake assay.
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Fig.39: Response of SA2 cell line to 1 hr. pulse v ith  arac alone; 
1 hr.pulse v ith  both arac and mitox; or 1 hr. pulse v ith  
arac v ith  mitoxantrone added 24hrs.later.
Results: Figure 39 shows the responses of SA2 cell line to one hour 
pulse w ith  Ara-C alone or in combination w ith  mitoxantrone 
(0.12ng/m l) as compared to one hour pulse w ith  Ara-C w ith  
mitoxantrone added to the cells 24 hours later. A one hour pulse with 
both Ara-C (0.12-120ng/ml) and mitoxantrone (0 .1 2ng/m l) produced an 
additive effect as compared to a one hour pulse w ith Ara-C alone. 
However, there was no difference between one hour pulse with both 
drugs and one hour pulse w ith Ara-C followed by addition of 
mitoxantrone 24 hours later (Figure 39). The latter schedule was still 
more effective at inhibiting [3H]TdR uptake as compared to one hour 
pulse w ith Ara-C alone. There was no difference between one hour 
pulse with Ara-C followed immediately by addition of mitoxantrone and 
one hour pulse w ith Ara-C with mitoxantrone added 48 hours later 
(Figure 40). Both schedules were not as effective as pulsing the cells with
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the two drugs for one hour. As expected, there was more pronounced 
inhibition of [3H]TdR uptake when mitoxantrone was added 24 hours 
rather than 48 or 72 hours following one hour pulse with Ara-C (Figure 
41). Thus, the longer mitoxantrone remained in culture, the more 
pronounced was its effect on [3H]TdR uptake.
Unlike what was observed with SA2 cell line, scheduling had a marked 
effect on inhibition of [3H]TdR uptake produced by Ara-C and 
mitoxantrone on the SA7 high cell dose transplant cell line. Thus, there 
was a synergistic effect on D N A  synthesis inhibition when mitoxantrone 
was added 24 hours rather than immediately following one hour pulse 
with Ara-C (Figure 42). Virtually no additive effect was observed when 
both Ara-C (0.12-120ng/ml) and mitoxantrone (1.2ng/m l) were pulsed 
for one hour. Adding mitoxantrone as late as 72 hours following one 
hour pulse with Ara-C exerted a greater effect on [3H]TdR uptake as 
compared to when cells were pulsed with both drugs for one hour 
(Figure 43). Maximal inhibition was seen when mitoxantrone was added 
24 hours following one hour pulse with Ara-C and decreasing effect if 
mitoxantrone was added 48 or 72 hours later (Figure 43). The least 
effective schedule was when cells were pulsed with both drugs for one 
hour.
Scheduling had no effect on one hour pulse with Ara-C followed by 
mitoxantrone using the SA8  cell line. There was no difference between 
one hour pulse w ith Ara-C alone and one hour pulse w ith Ara-C  
followed by addition of mitoxantrone (1.2ng/m l) 24 hours later (Figure 
44). One hour pulse w ith Ara-C followed by the addition of 
mitoxantrone immediately was only slightly more effective as compared 
to when mitoxantrone was added 24 hours later. One hour pulse with 
both drugs was not more effective than 1 hour pulse w ith Ara-C alone
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(Figure 45), and when mitoxantrone was added 24, 48 or 72 hours later, 
there was increased [3H]TdR uptake (Figure 46).
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Fig.40: Response of SA2 cell line to Ih r . pulse with arac alone;
Ih r . pulse with arac folloved by immediate additon of mitoxantrone, 
or 1 hr. pulse v lth  both arac and mitoxantrone.
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Fig.42: The effect of Ih r . pulse with arac a1one;1hr. pulse with arac followed immeditely by the addition of mitox; 1 hr. pulse with arac, 
followed by the addition of mitox after 24hrs. on the SA7 cell line.
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Fig.45: The response of SA8 cell line to Ih r . pulse
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monitored using the (3H)~thymidine uptake assay.
As was observed with SA7 cell line, scheduling had a marked effect on 
the cytotoxicity produced by one hour pulse with Ara-C followed by 
addition of mitoxantrone in normal bone marrow cells. One hour pulse 
with Ara-C (0.12-120ng/ml) followed by addition of mitoxantrone 24 
hours later was more effective at inhibiting [3H]TdR uptake as compared 
to when mitoxantrone was added immediately after pulsing with Ara-C 
(Figure 47). One hour pulse with both drugs was no more effective than 
one hour pulse with Ara-C alone. When mitoxantrone (0.12ng/ml) was 
added immediately after one hour pulse with Ara-C (Figure 47), there 
was an increase in [3H]TdR uptake which was more pronounced at an 
Ara-C concentration of 1.2ng/ml. As expected, mitoxantrone was more 
effective at inhibiting [3H]TdR uptake if it was added 24 hours rather 
than 48 or 72 hours following one hour pulse with Ara-C (Figure 48). 
An increased inhibition of [3H]TdR uptake was seen when Ara-C was left
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in culture (continuous incubation) and mitoxantrone (1 .2 ng /m l) was 
added 24,48 or 72 hours later (Figure 49).
3.2.4.2 One hour Pulse with Mitoxantrone Followed by Addition of AraC:
In  these experiments normal bone marrow cells or leukaemic bone 
marrow cells (SA2, SA7 and SA8 ) were pulsed with mitoxantrone (0.12- 
1 2 0 ng/m l) for one hour, followed either immediately after washing the 
cells or 24, 48 or 72 hours later by the addition of Ara-C (1.2ng/m l)
(Figure 50).
Results: A one hour pulse with mitoxantrone (Figure 51) resulted in 
greater inhibition of D N A  synthesis as compared to one hour pulse with 
Ara-C (Figure 39) on the SA2 cell line. An additive affect which was 
more pronounced at low mitoxantrone concentration (0 .1 2 ng/m l) was 
seen when SA2 leukaemic cells were pulsed with both drugs for one 
hour (Figure 51). A one hour pulse with both drugs was more effective 
at inhibiting [3H]TdR uptake as compared to when Ara-C was added 
either im mediately or 24 hours following one hour pulse w ith  
mitoxantrone (Figure 52). Greater [3H]TdR uptake inhibition was seen 
when Ara-C was added 24 hours rather than immediately following one 
hour pulse with mitoxantrone (Figure 52). Whether Ara-C was added |
24, 48 or 72 hours following one hour pulse with mitoxantrone made no 
difference except at low mitoxantrone concentration (0 .1 2 ng/m l) when 
the extent of [3H]TdR uptake inhibition depended on the time Ara-C was . 
added (Figure 53).
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Cytotoxicity monitored using the (3H)-thymidine uptake assay
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Figure 54 shows the effect of one hour pulse with mitoxantrone on SA7 
cell line. As was observed with SA2  cell line, one hour pulse with 
mitoxantrone (Figure 54) resulted in greater inhibition of D N À  synthesis 
as compared to one hour pulse with Ara-C (Figure 42). In addition, there 
was not much difference between the effects of one hour pulse and 
continuous incubation w ith mitoxantrone on this cell line (compare 
Figures 33 and 54). When cells of the SA7 cell line were pulsed with 
mitoxantrone (0.12-120ng/ml) and Ara-C (1.2ng/m l), an antagonistic 
effect was seen at mitoxantrone concentrations below 120ng/ml (Figure 
54). A  similar effect was seen when Ara-C was added after 24 hours 
(Figure 55). Similarly, adding Ara-C 24, 48 or 72 hours following a one 
hour pulse with mitoxantrone resulted in an increased [3H]TdR uptakes 
(Figure 58). Thus, whereas inhibition of [3H]TdR uptake following a one 
hour pulse with Ara-C in the SA7 cell line was schedule dependent, no 
such effect was observed when the cells were first pulsed w ith  
mitoxantrone.
A  one hour pulse with mitoxantrone produced less inhibition of D N A  
synthesis on leukaemic cells from SA8  cell line (Figure 57) as compared 
to SA7 cell line (Figure 54) particularly using mitoxantrone 
concentrations below 12ng/ml. Whereas a one hour pulse with both 
drugs resulted in additive effects using low mitoxantrone concentrations 
(0 .1 2 -1 .2 ng/m l), a slightly antagonistic effect was seen with 1 2 ng/m l of 
mitoxantrone (Figure 57). There was no pronounced time-related 
inhibition of D N A  synthesis when Ara-C was added 24, 48 or 72 hours 
following one hour pulse with mitoxantrone (Figure 58). However, an 
additive effect was observed when Ara-C was added 72 hours rather than 
48 hours after one hour pulse w ith mitoxantrone. W ith the 48-hour 
schedule, increased [3H]TdR uptake above that seen with one hour pulse 
with mitoxantrone alone was observed. In addition, greater inhibition
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Fig.51: The effect of Ih r . pulse v ith  mitoxantrone alone 
or in combination v ith  arac on SA2 cell line. 
Cgtotoxicity vas determined using the (3H)-thgmidine uptake assag
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Fig.5 2 : The response o f SA2  ce ll line to Ih r .  pulse v ith  both m itox and arac; 
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C yto toxic ity  v a s  determined using ( 3 H )-thym idine uptake assay.
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Fly.53: The response of SA2 cell line to 1 hr. pulse v ith  mitoxantrone 
alone or v ith  arac(1.2ng/m1> added after 24 ,48,or 72hrs.
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Fig.54: The effect of I hr. pulse v ith  mitoxantrone alone 
or in combination v ith  arac on SA7 cell line.
Cytotoxicity vas determined using the (3H)-thymidine uptake assay
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Fig.55: The response of SA7 cell line to 1 hr. pulse v ith  mitoxantrone either alone or folloved immediately or after 24hrs v ith  aracC 1.2ng/m1) 
Cytotoxicty vas determined using the (3H)-thymidine uptake assay.
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Fig.56: The response of SA7 cell line to I hr pulse v ith  mitoxantrone
alone or folloved by arac ( 1.2ng/m1) 24,48 or72 hrs later.
Cytotoxicity vas determined using the (3H)-thymidine uptake assay.
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of DN A  synthesis was observed if Ara-C was added immediately after 
pulsing the cells w ith mitoxantrone as compared to when Ara-C was 
added 24 hours later (Figure 59).
This effect was more pronounced using a low  mitoxantrone 
concentration (0.12-1.2ng/ml). The SA8  cell line therefore showed no 
schedule dependent effects following a one hour pulse with either Ara-C 
or mitoxantrone.
As was observed with leukaemic cell lines SA2, SA7HD and SA8H D , a 
one hour pulse with mitoxantrone resulted in greater inhibition of DNA  
synthesis in normal bone marrow cells (Figure 60) as compared to 
similar treatment w ith Ara-C (Figure 47). No additive effect was 
observed when Ara-C was added 24, 48 or 72 hours following one hour 
pulse of normal bone marrow cells w ith mitoxantrone. Similarly, 
pulsing the cells w ith both drugs for one hour did not make any 
difference as compared to when mitoxantrone alone was used (Figure 
61). Increased [3H]TdR uptake was observed if Ara-C was added either 
immediately following one hour pulse with mitoxantrone or 24 hours 
later (Figure 62). The effect was more pronounced with the latter (24 
hours) schedule.
3.3 Autoradiography: this technique was employed to determine the in 
vitro labelling indices of the leukaemic cell lines SA2 , SA7 and SA8  and 
also the effect of continous incubation w ith mitoxantrone on the 
labelling indices.
3.3.1 Experimental Procedure: A single cell suspension was prepared 
from the following leukaemic cell lines (SA2, SA7HD and SA8 H D ) and 
plated at 7 X 10"^  cells per well in a microtitre plate. W EHi conditioned 
medium was added to give final concentration of 10% (except SA2 
leukaemic cell line). Mitoxantrone (0.12-120ng/ml) was then added and
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Fig.57: The response of SA8 cell line to Ih r . pulse vith  mitoxantrone alone or In eombination v ith  arac.
Cytotoxicity vas determined using the (3H)-thymidine uptake assay.
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Fig.58: The response of SA8 cell line to 1 hr. pulse v ith  mitoxantrone alone; or v ith  aracCi.2ng/m1), added either 24 , 48 , or 72 hrs later.
Cytotoxicity vas determined using the (3H>-thymidine uptake assay.
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Fig.5 9 : The response o f SA8 cell line to Ih r .  pulse w ith  m itoxantrone alone 
or followed by a ra c (1 .2 ng/m 1)  e ither immediately or 2 4 hrs la te r .  
C ytotoxic ity  was determined using the ( 3 H )-thym id ine uptake assay
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Fig.60: The response of NBM cells to 1 hr. pulse v ith  mitoxantrone 
alone; or v ith  arac( 1 2ng/ml) added after 24 , 48, or 72hrs . 
Cytotoxicity vas determined using the (3H)-thymidine uptake assay.
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Fig.61 : The response of NBM cells to Ih r . pulse v ith  mitoxantrone alone or in combination v ith  arac.
Cytotoxicity vas determined using the (3H)-thymidine uptake assay
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Fig.6 2 : The response o f NBM cells to Ih r .  pulse w ith  m itox alone or followed  
by the addition o f a ra c (1 .2ng /m 1)  e ither Immediately or 24  hrs la te r .
the plates incubated. W ith the SA7 cell line, cells were pulsed with 
[3H]TdR for one hour from days 1 - 4  and washed and then 
cytocentrifuged onto ethanol-washed slides. W ith SA2 and SA8 HD, the 
plates were incubated for four days. On the fourth day, the cells were 
pulsed with [3H]TdR for one hour and slides prepared as described for 
SA7 cell line. A ll slides were processed and developed (section 2.2.4.2) 
and the labelling indices were obtained by counting the number of cells 
that incorporate the label and expressing this as a percentage of the 
whole cell population.
Results: Figure 63 shows the change in labelling index of both untreated 
and mitoxantrone treated cells of the SA7 leukaemic cell line w ith  
duration of culture. The labelling index began to rise ( in untreated cells) 
from day one almost exponentially and reaches its peak on day three and 
fell a little  on day four. W ith the cells continuously exposed to 
mitoxantrone (120ng/m l) the labelling index was depressed to 3% of
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control on day one and by days two through to four, it was virtually zero. 
This is in complete agreement with the result of other cytotoxicity assays 
using this concentration of mitoxantrone. Virtually 100% inhibition of 
[3H]TdR uptake was seen at this concentration (Figure 54) and similar 
effects were seen using DiSC assay and cell number assessment methods 
(Figure 5). The SA7 had a labelling index of 29%, while the SA2(plate 2) 
and SA8 (plate 3) had labelling indices of 37 and 28% respectively after 
four days in culture. Qualitatively similar dose-response curves were 
obtained on the effect of mitoxantrone on SA2 (Figure 64) and SA8  cell 
lines (Figure 65) using autoradiography or [3H]TdR uptake assay. 
Q uantitatively however, the labelling index method seemed to 
underestimate cytotoxicity produced by low concentrations of 
mitoxantrone (0 .1 2 -1 .2 ng/m l).
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Plate 1: A mixture of live and dead SA7HD leukaemic bone 
marrow cells. Dead cells(DC) were stained dark-green by 
fastgreen-nigrosin while live cells(LC) assume normal Jenner- 
Giemsa counterstain(Magnification x 1300).
UNI
Plate 2: An autoradiograph of leukaemic bone marrow cells 
from SA2 leukaemic cell line. The cells were pulsed with (3H)- 
thymidine following 4-days incubation. Cells synthesizing DNA  
incorporated the label while those cells that were not in S- 
phase remained unlabelled .
LC= Labelled cells; U N L =unlabelled cells(magnification X I300)
lCm
UNL %»
Plate 3: An autoradiograph of SA 8 high cell dose
passage(SASHD) leukaemic bone marrow cells. The cells were 
pulsed with (3H)-thym idine following 4- days incubation in 
culture. Cells undergoing DN A  synthesis were labelled(LC) 
whereas those cells that were not in S- phase remained 
unlabelled(UNL)(Magnification X  1300).
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Plate 4: Spleen cells of a mouse bearing SA7HD leukaemia 
that was treated in vivo with 2 doses of mitoxantrone(3mg/Kg). 
No apparent evidence of leukaemic infiltration of spleen is 
seen. Most of the cells are normal lymphocytes(NL) with the 
occasional blast c e ll(B L ). Compare this w ith plate 6  
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5 0  - mitoxantrone (120ng/ml) treated leukaemic cells
XCD“O  4 0  -  c
0>  3 0  -c
20 -
10 -
•^ imiHiinyHMHnm^ niiimiiiyiiiiiiiiiii^
2  3  4 510
Days in culture 
Flg.63: The labelling index of untreated and mitoxantrone 
treated leukaemic cells from the SA7 cell line 
determined using autoradiography.
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.64: The effect of mitoxantrone on in vitro iabeiling
index of SA8 cell line monitored using autoradiography.
3.4 Granulocyte-Macrophage Colony Forming Cell Assay: the effects of 
Ara-C and mitoxantrone alone or in combination on normal bone
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m arrow progenitor cells were determined using granulocyte- 
macrophage colony forming cell (GM-CFC) assay.
Experimental Procedure: Various incubation schedules including one 
hour pulse and continuous incubation methods were employed. In the 
one hour pulse method, normal bone marrow cells were pulsed with  
Ara-C (0.12-120ng/ml) for one hour and plated in agar with the cells (5 x 
1 0 ^) suspended in either plain medium or medium containing 
mitoxantrone (0.27ng/m l). Alternatively the NBM  cells were pulsed 
with mitoxantrone (0 .0 1 2 -1 2 0 ng /m l) for one hour and plated in agar 
with the cells suspended in either plain medium or medium containing 
Ara-C (22ng/ml). In contrast, in the continuous incubation method, 5 x 
10^ NBM  cells were plated out in agar while suspended in medium  
containing Ara-C or mitoxantrone (0,012-120ng/ml). Colonies were 
scored on day 7 blindly or by an independent observer. Dose-response 
curves were obtained by plotting the number of colonies in drug treated 
samples expressed as a percentage of control colonies as a function of 
drug concentration.
Results: Figure 6 6  shows the dose-response curve of normal (murine) 
bone marrow myeloid progenitor cells to Ara-C and mitoxantrone 
treatment In  vitro using the continuous incubation method. It is 
apparent that mitoxantrone seems dose for dose more toxic than Ara-C 
on progenitor cells in vitro. When bone marrow cells were pulsed with 
Ara-C (1 2 0 ng /m l) for one hour, no cytotoxic effect was observed. 
However, if mitoxantrone (36ng/m l) was added and the cells pulsed 
with both drugs for one hour, an additive cytotoxic effect was observed 
(Figure 67). Similar additive effects were observed when the cells were 
pulsed with Ara-C for one hour and then continuously exposed to 
mitoxantrone (0.27ng/m l) for the duration of the assay (Figure 6 8 ). 
Furtherm ore, one hour pulse w ith  m itoxantrone follow ed by
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continuous incubation w ith Ara-C (2 2 ng /m l) resulted in additive 
cytotoxic effect (Figure 6 8 ) as compared to one hour pulse w ith  
mitoxantrone alone (Figure 69). Using the latter schedule, one hour 
pulse with 1 2 0 ng/m l of mitoxantrone resulted in inhibition of all colony 
growth. This is in complete agreement with the result obtained using 
[3H]TdR uptake assay (Figure 62) showing that [3H]TdR uptake was 
inhibited by nearly 1 0 0 % using similar schedule and concentration of 
mitoxantrone.
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Fig. 65:The effect of mitoxantrone on the in vitro labelling
index of the SA8 leukaemic cell line monitored using autoradiography.
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Fig. 66: The response of normal myeloid progenitor cells to mitoxantrone or 
arac treatment in vitro monitored using the GM-CFC assay.
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Fig.67: The effect of 1 hr. pulse v ith  arac alone or in combincita  ^
v ith  mitoxantrone on normal bone marrow myeloid progenitor) 
in v itro , monitored using the GM-CFC assay.
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Fig.6 0 : The response o f GM-CFCS to Ih r .  pulse w ith  arac or mitoxantrone 
followed by contin. incub. w ith  m itox(0 .27ng /m 1) or arac(22ng/m 1) respectw ^
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Fig.69: The effect of Ihr. pulse with mitoxantrone on myeloid progenitor 
ceils monitored using GM-CFC assay.
110
4. RESULTS
CHAPTER FOUR
4. Growth Factor Responses of Leukaemic Cell Lines 
In  this chapter, the growth factor-induced proliferative responses of a 
prim ary leukaemic cell line (81287) and its passaged progeny 
(81287T1,81287T6 and 81287T10) as well as those of SA2 , SA7 low cell 
dose (SA7FT5), SA8  low cell dose transplant (SA8FT14) and SA8  high cell 
dose transplant (SA8 HD) cell lines were monitored using the [3H]TdR 
uptake assay,
4.1 Experimental Procedure: A single bone marrow or spleen cell 
suspension was prepared from the following leukaemic cell lines (81287, 
SA7FT5 and SA8 HD) and plated at 7 x 10"^  cells per well in a microtitre 
plate. lOOpl each of W EHi conditioned medium, L929 conditioned 
medium or combinations of the two to give final concentrations of 5, 10 
or 2 0 % in each well was added. Control wells received only cells and 
medium i.e no growth factors were added. After 4 days incubation, the 
cells were labelled w ith [3H]TdR, harvested and the amount of 
radioactive precursor incorporated by the cells was determined (section
2.2.2). Growth factor dose-response curves were prepared by plotting the 
amount of radioactivity incorporated by the cells (as counts per minute,
c.p.m.) as a function of growth factor concentration.
Results: The responses of spleen cells (Figure 70) and bone marrow cells 
(Figure 71) of the primary leukaemic cell line 81287 to W EHi alone or in 
combination with L929 conditioned medium are shown. This cell line 
was not very responsive to both W EHi, L929 and their combination. 
Whereas additive effects were seen with combination of 10% W EHi and 
10% L929 with spleen cells, there was no difference in the response of 
bone marrow cells to the same concentrations. W ith first passage in
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syngeneic mice (81287TI), bone marrow response to the growth factors 
improved slightly (Figure 72). Additive effects were seen with 5% W EHi 
and 5% L929 and also with 20% W EHi and 20% L929.
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Fig. 70: The response of spleen ceils from leukaemic ceii line 81287 
to WEHi, L929, or combinations of the two conditoned media 
monitored using (3H)-thymidine uptake assay.
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Fig.71 :The response of bone marrow cells from the 81287
cell line to WEHi alone or In combination with L929 
monitored using (3H)-thymidlne uptake assay.
Even after the tenth passage, there was only a modest improvement in 
growth factor responsiveness and an additive effect was observed with 
10% W EHi and 10% L929 (Figure 73).
The responses of spleen cells (Figure 74) and bone marrow cells (Figure 
75) of the low cell dose transplant cell line SA7FT5 to W EHi alone, L929 
alone or their combinations are shown. Both spleen and bone marrow 
cells seem equally sensitive to W EHi although spleen cells were a little 
bit more responsive. However, both spleen and bone marrow cells were 
particularly insensitive to L929 conditioned medium. A ll combinations 
of W EHi and L929 studied resulted in an additive proliferative effect in 
spleen cells but in bone marrow cells only 10% W EHi and 10% L929 
resulted in a slight additive effect. Thus both 81287 (even after 10 
passages) and low cell dose transplant leukaemic cell lines were not very 
responsive to growth factors in vitro. In contrast, the SAB high cell dose 
transplant cell line was very responsive to W EHi conditioned medium
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alone, L929 conditioned medium alone and increased proliferative 
response was observed with combinations of the two conditioned media 
(Fig.76).
4.2 Effects of Foetal Calf Serum and Transferrin on the In Vitro  
Proliferative Response of SA2 Leukaemic Cell Line: The SA2 leukaemic 
cell line is unique in the sense that it was capable of in vitro growth even 
if no growth factor(s) was added to the cells in culture. The effects of 
foetal calf serum and transferrin on the proliferative response of the 
leukaemic cell line were investigated.
4.2.1 Experimental Procedure: A  single cell suspension was prepared 
from the femora of mice bearing the SA2 leukaemic cell line (section
2.1.3). The cells were suspended in medium with or without foetal calf 
serum (10%) and 7 x 10^ cells were plated per well in a microtitre plate. 
Graded concentrations of W EHi conditioned medium, L929 conditioned 
medium or combinations of the two conditioned media were added to 
give final concentrations of 5, 10 or 20% in each well. In  a separate 
experiment, the cells were suspended in serum free medium and 
transferrin with or without growth factors were added. The transferrin 
was either saturated w ith iron or else used unsaturated at the 
concentration of lOpg/m l. Since there may well be up to 1% serum in 
the growth factor conditioned media used, an equivalent amount of 
foetal calf serum (1 %) was added to the control wells that received no 
growth factors.
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Fig.72: The response of bone marrow ceils from 81287T1 cell line to growth factors monitored In vitro 
using the (3H}-thymldine uptake assay.
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Flg.73: The response B.M cells of 81287T10 cell line to growth 
factors monitored In vitro using the (3H)-thymldlne uptake assay.
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Fig.74: The response of spieen ceüs from SA7FT5 ceii iine to 
growth factors monitored in vitro using (3H)-thymidine uptake assay.
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Fig.75:The response of B.M cells from the iow ceil dose tranplant 
cell line (SA7FT6) to growth factors monitored in vitro using 
(SH)-thymidine uptake assay.
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Fig.76: The response of bone marrow ceils from the SA8 high 
cell dose transplant cell line to growth factors monitored In vitro 
uslng(3H)>thym!dlne uptake assay.
Results: Figure 77 shows that leukaemic bone marrow cells from the 
SA2 cell line were capable of proliferating in medium containing serum 
in absence of any exogenously added grow factors (0%). When W EHi 
conditioned medium was added, proliferation (manifested by increased 
[3H]TdR uptake) increased in a concentration dependent manner and 
reaches a peak when 10% W EHi was added. Increasing the W EHi 
concentration to 2 0 % decreased proliferation to below when no growth 
factor(s) was added. In  contrast, addition of L929 conditioned medium 
resulted in inhibition of proliferation (decreased [3H]TdR uptake) in a 
concentration dependent manner. Interestingly however, the 
combination of W EHi and L929 resulted in a synergistic proliferative 
response. In serum free medium, no proliferation was observed in vitro 
unless growth factors were added (Figure 78). 10% horse serum was as
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effective as 1 0 % foetal calf serum in providing proliferative stimulus in  
vitro. In the absence of serum, single growth factor responses were not 
as marked as compared to SA8  leukaemic cell line, probably because 
serum was supplying other nutrients as well. Howeyer, synergistic 
effects were still manifested w ith combinations of W EHi and L929 
conditioned media. W ith 10% W EHi and 10% L929; 20% W EHi + 20% 
L929, in serum free medium, the proliferative responses were greater 
than that observed in the presence of 10% serum . Transferrin (with or 
without iron) was no substitute for serum or growth factors in  
stimulating in vitro proliferation (Figure 79). When transferrin (with or 
without iron) was added to W EHi (Figure 79) or L929 (Figure 80) in 
serum free medium, no increased proliferative responses were 
manifested as compared to when no transferrin was added. Similarly, 
when the cells were suspended in medium containing transferrin 
(saturated w ith iron) w ith  growth factors added, no increased 
proliferative response was observed (Figure 81). In  addition, the 
synergism observed when the two growth factors were combined in the 
presence of transferrin (Figure 81) was less pronounced as compared to 
when no transferrin was present (Figure 78).
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Fig.77:The response of SA2 cell line to growth factors monitored using 
(3H)«thymidine uptake assay.
(The leukaemic cells were suspended in medium with serum.)
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The response of SA2 leukaemic cell line to growth factors in vitro.
(The leukaemic cells were suspended in serum free medium.
1% serum was added to control cells that received no growth factors.)
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Flg.79: The response of SA2 cell line to WEHI and transferrin
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Fig. 80: The response of SA2 cell line to L929 and transferrin
(with or without Iron) In serum free medium monitored 
using (3H)-thymidlne uptake assay.
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Fig.81 : The response of SA2 leukaemic cell line to growth factors in vitro.
The cells were suspended in serum -free medium containing 
transferrin with iron.
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. RESULTS
CHAPTER FIVE
In Vivo Chemotherapeutic Studies 
In this chapter, the results of the following investigations are reported : 
-The responses of low cell dose transplant and high cell dose transplant 
of SA7 cell line to mitoxantrone administered in vivo were monitored 
(section 5.1).
-The in vitro growth factor responses of untreated and relapsed 
leukaemic bone marrow cells of the SA7 high cell dose transplant cell 
line were studied (section 5.2).
-The responses of bone marrow cells of cured mice to growth factors and 
drug treatment in vitro were investigated.
-Normal mice received a similar dose and schedule of mitoxantrone as 
was employed in treating leukaemia bearing mice. The toxicity of the 
drug on the haematopoietic system was assessed using parameters such 
as fem ur cellu larity, spleen weight, haemoglobin (Hb) count, 
haematocrit (packed cell volume, PCV) and in vitro granulocyte- 
macrophage colony forming cell numbers per 5 x 10^ bone marrow cells 
(section 5.3).
5.1 Responses of Low Cell Dose and High Cell Dose Transplants of SA7 
Cell Line to Mitoxantrone Treatment In  Vivo: Mice bearing the low cell 
dose transplant and high cell dose transplant sublines of the SA7 
leukaemic cell line were treated w ith mitoxantrone in vivo. The 
increase in life span of treated mice was used as a therapeutic end point. 
Experimental procedure:
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High Cell Dose Transplant: Groups of five female C B A /H  mice
weighing 20-25g were inoculated w ith 10^ leukaemic cells either 
intravenously (I.V ) or intraperitoneally (LP). On days one and five 
following tumour inoculation, mice were administered the following 
doses of mitoxantrone (freshly diluted in normal saline) I.P : 0.75, 1.5, 2 
and 3m g/Kg. Control mice were administered leukaemic cells and 
saline only. The experiment was repeated.
Low Cell Pose Transplant: Similar number of mice (5 /  group) and 
schedule as described above was followed, except that the leukaemic cells 
were only injected I.V . The following doses of mitoxantrone were 
injected I  P : 0.4, 0.75 and 1.5mg/Kg.
The survival of treated mice relative to control mice from day of tumour 
inoculation was determined and the percent increase in life-span was 
calculated (section 2.6.1). Mice were observed daily and were autopsied 
when sick in order to determine cause of death. Mice that survived for 
60 days (high cell dose transplant) or 90 days (low cell dose transplant) 
were deemed cured if no evidence of leukaemia was found on autopsy. 
In  addition, bone marrow cytology, cellularity and peripheral blood 
picture must all be normal. The drug responses (in vitro) of bone 
marrow cells from cured mice and those dying from drug toxicity were 
investigated.
Results:
Chemotherapeutic Responses of Low Cell Dose and High Cell Dose 
Transplants:
Table 1 shows the response of SA7 high cell dose transplant cell line to 
mitoxantrone when both leukaemic cells and drug were administered 
intraperitoneally (IP-IP). W ithin the dose range 0.75-1.5m g/Kg, there
123
TABLE 1: The response of SA7 high cell dose transplant cell line to 
mitoxantrone treatment in vivo.
Mice were innoculated with 10  ^ leukaemic cells (I.P), and on days 1 and 
5 following tumour innoculation they recieved mitoxantrone (I.P) in 
the doses indicated. (IP-IP)
Dose(mglkg) % ILS “ Number of 60-day surviviors
0.75 62.5 (13c)^ 1/5
1.5 81.5 (146) 1/5
2 60 (128)*= 1/5
3 id 0/5
a. Mean survival of saline-treated control was 12 days.
b. Increase in life span calculated to include 60-day survivors.
c. Only one of the mice from this group died from leukaemia, the rest 
died from drug-related toxicity.
d. A ll animals in this group died from drug toxicity.
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was an increase in life-span w ith increasing dose although not 
proportionately. This is seen from the observation that doubling the 
dose from 0.75mg/Kg to 1.5mg/Kg was only accompanied by a 20% 
increase in life-span or even 1 0 % increase if 60 day survivors were taken 
into account (Table 1). Similarly, no dose-response relationship was 
observed in the number of long term survivors following in vivo 
treatment. Thus, whether 0.75mg/kg or 2m g/kg was administered, only 
one long-term survivor resulted in each case. Doses above 2m g/kg were 
toxic. A ll leukaemia bearing mice that received two doses of 3m g/kg  
mitoxantrone died from drug-related toxicity as no evidence of 
leukaemic infiltration (particularly of the spleen) was seen on autopsy 
(Plate 4). In contrast, there was a decrease in femur cellularity and spleen 
weight in these mice. Identical results were obtained when the 
experiment was repeated.
The route of administration of leukaemic cells had a profound bearing 
on therapeutic outcome. For example, when the leukaemic cells were 
administered I.V  and the drug I.P (IV-IP), there was a sharp decrease in 
life span of mice as compared to when both leukaemia and drug were 
administered I P (Table 2 ). More than 50% decrease in life-span was 
observed within the dose range 0.75-1.5mg/Kg with the IV-IP  regime as 
compared to the IP-IP regime. W ith the latter, most of the mice that 
received 2m g/Kg mitoxantrone died of drug toxicity as no evidence of 
leukaemia was seen on autopsy. In contrast, all mice that received 
mitoxantrone 2m g/kg using the IV -IP  regime died as a result of 
leukaemia. This strongly suggests that survival of the leukaemia 
bearing mice not only depended on the dose of mitoxantrone 
administered, but also the mode of leukaemic inoculation.
In  the light of the effect of route of administration of leukaemia on 
therapeutic outcome, any comparison of the therapeutic response of low
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Table 2 : The Response of SA7 high cell dose transplant cell line to 
mitoxantrone treatment in vivo.
Mice were injected with 10  ^ leukaemic cells intravenously (I. V). On days 
1 and 5 following tumour innoculation, they received mitoxantrone 
(IP ) in the doses indicated(IV-IP).
Dosemglkg % ILSf^ Number of 60-day surviviors
0.75 1 2 .2 0/5
1.5 37.5 0/5
2 .0 50.0 0/5b
a. Mean survival of saline treated controls was 8  days.
b. None of the mice in this group died from drug-related toxicity (ie all 
died from leukaemia).
124a
cell dose transplant and high cell dose transplant cell lines w ill have to 
take this into consideration. The low cell dose transplant cell line (IV-IP) 
seemed more sensitive to mitoxantrone (Table 3) as compared to the 
high cell dose transplant (IV-IP) (Table 2). This is despite the observation 
that the low cell dose transplant grows slower than the high cell dose 
transplant (compare Tables 2(a) and 3(a)). In addition to the observation 
that overall increase in life-span produced by identical doses of 
mitoxantrone were higher in the low cell dose transplant as compared to 
the high cell dose transplant, there was also one long term survivor 
observed. No long term survivors were seen from the high cell dose 
transplant cell line (Table 2) using the IV -IP  regime. There was an 
unexpected incidence of leukaemia relapse which occurred 90 days 
following therapy in the low cell dose transplant cell line. No such 
observation was made with the high cell dose transplant cell line.
A ll other autopsied long term survivors had normal spleen weight (65 ± 
3mg) haemoglobin count (15g/L) and haematocrit (45%). This is in  
contrast to the massively enlarged (leukaemia infiltrated) spleen, 
reduced haemoglobin and haematocrit values (Tables 4 and 5) seen in 
terminally leukaemic mice from both the high cell dose passage (Plate 6 ) 
and the low cell dose transplant cell lines . During the terminal stage, 
the low cell dose transplant cell line produced greater effect on 
haemoglobin (2,8±0.5 vs. 1110.7) and haematocrit (510.9 vs. 3112.5) 
values as compared to the high cell dose transplant cell line (Tables 4 and 
5).
Responses of Bone Marrow Cells from Cured Mice to In Vitro Treatment 
with Ara-C. Mitoxantrone or their Combinations: A common feature of 
bone marrow cells of cured mice is that they become less sensitive to 
subsequent in vitro treatment w ith  mitoxantrone alone or in
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Table 3 : The Response of SA7 low cell dose transplant cell line to 
mitoxantrone treatment in vivo.
Mice were injected with mitoxantrone 10  ^ cells intravenously. They 
received mitoxantrone intraperitoneally on days 1 and 5 following 
tumour innoculation (IV-IP).
Dose % ILS^ Number of(mglkg) 90-day survivors
0.4 10 0/5
0.75 40 0/5
1.5 128(146)13 2/5C
a. Mean survival of saline-treated controls was 29 days.
b. Increase in life-span calculated to include 90-day survivors.
c. One of the two 90-day survivors was discovered upon autopsy to 
have an enlarged spleen.
I
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Table 4 : The effect of SA7 high cell dose transplant cell line on 
normal haematopoiesis at presentation and at relapse fo llo w in g  
treatment with mitoxantroneCin vivo).
SA7 SpleenHigh dose weight Haemoglobin PC VTransplant (mg) (glD (%)
Control (untreated) 402.6± 20.7a ll±0.7a 31±2.5“
Recurrent leukaemia
following treatment with:
0.75mg/Kg mitoxantrone 434.5±26d 11.95+0.7“ 32±1.9“
1.5mg/Kg mitoxantrone 44.2±12b
405.0±15d
II
2m g/Kg mitoxantrone 59.3±15b
27i , 7d
II
60-day survivors 60.5C 14.0 45.0
a. Mean ± SE of five separate determinations.
b. Mice died from drug toxicity (i.e no evidence of leukaemia was seen 
on autopsy)
c. Mice survived for 60 days and were deemed cured.
d. Mice died from leukaemia.
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Table 5 : The effect of SA7 low cell dose transplant leukaemic cell line 
on normal haematopoiesis at presentation and at relapse following 
treatment with mitoxantronedn vivo).
SA7 low dose transplant cell line
Spleenweight(mg) HaemoglobinW L ) PCV
Control(untreated) 255.4±23.2a 2.8±0.5a 5.0±0.9a
0.4mg/Kg mitox 350.2±33.6 5.2+0.9 16.8±0.8
0.75mg/Kg mitox 280.4+20.3 2.6+0.2 8.4±0.7
1.5mg/Kg mitox 337.4+25.6 3.0+0.8 10.7+2.0
357.7 5.8b 16b
90 day survivor 71.6 15.6 45.0
a. Mean ± SE of five separate determinations.
b. Leukaemic relapse occuring 90 days following treatment.
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combination with Ara-C. Figures 82 and 83 show the response (mean of 
two separate experiments) of bone marrow cells from cured mice 
following treatment of SA7 high cell dose passage with mitoxantrone 
(0.75mg/Kg). These bone marrow cells were less sensitive than normal 
(untreated) bone marrow cells to low concentrations of Ara-C (Figure 82). 
When mitoxantrone (1.2ng/m l) was added to Ara-C, no additive effect 
was observed unlike what was observed with bone marrow cells from 
normal (untreated) mice (Figure 82). Similarly, bone marrow cells from 
cured mice were less sensitive to mitoxantrone (Figure 83) as compared 
to bone marrow cells from normal mice. Although there was some 
variab ility in degree of insensitivity to high concentration of 
mitoxantrone (120ng/ml) between different mice, bone marrow cells 
from all cured mice exhibited this decreased sensitivity. For example, 
the I.C 5 0  of mitoxantrone against normal bone marrow cells was 
6ng/ml(Figure 83). In contrast, the I.C 5 0  of mitoxantrone against bone 
marrow cells of cured mice was 105ng/ml (Figure 83). No additive effect 
was seen when Ara-C (1.2ng/ml) was added to mitoxantrone (Figure 83), 
although this was not as pronounced as for bone marrow cells from  
normal (untreated) mice (Figure 83). An essentially identical result was 
obtained on testing bone marrow cells from cured mice following 
treatment with mitoxantrone (2mg/Kg). The only difference was that in 
this case there was no difference in sensitivity to Ara-C between bone 
marrow cells from cured mice and untreated normal mice (Figure 84). 
However, when mitoxantrone (1.2ng/m l) was added to Ara-C (0.12- 
120ng/ml), the cells became markedly insensitive to the combination as 
compared to untreated NBM  cells (Figure 85). The usual decreased 
sensitivity to mitoxantrone was observed even using the highest 
concentration (120ng/ml)(Figures 86 and 87). When a combination of 
W EHi (20%) and L929 (20%) was used to stimulate the in vitro
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proliferation of bone marrow from cured mice, there was slightly 
increased sensitivity to Ara-C (Figure 88), w hile the effect of 
mitoxantrone sensitivity depended on the concentration(Figure 89).
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Fig.82: The response of B.M.cells from cured mice(SA7HD;0.75mg/Kg.) to arac treatment in vitro monitored using the (3H)-thymidine  
uptake assay.
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Fig. 83:The response of B.M. cells from cured mice(SA7HD;0.75mg/Kg) 
to mitoxantrone treatment in vitro. Mitoxantrone I.C. 50 against untreated 
B.M cells vas 6ng/m1, and 1 05ng/m1 for B.M. cells of cured mice.
A t low to intermediate concentrations of mitoxantrone (0.12-12ng/ml), 
there was a slight decrease in sensitivity, while at the highest 
concentration of mitoxantrone used (120ng/ml) there was slight increase 
in sensitivity to mitoxantrone (Figure 89). The decreased sensitivity 
developed by bone marrow cells of cured mice apparently did not depend 
on the mitoxantrone dose used in the treatment since it was observed 
following treatments with both 0.75mg/kg and 2m g/kg mitoxantrone. It 
also did not depend on the type of leukaemia cell line treated, since it
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was also observed in bone marrow cells of cured mice following 
treatment of low cell dose transplant with mitoxantrone (1.5m g/kg). 
Figure 90 shows the response of these bone marrow cells to Ara-C alone 
(0.12-120ng/ml) or in combination with mitoxantrone (1.2ng/m l), while 
Figure 91 shows the response to mitoxantrone (0.12-120ng/m l) in 
combination with Ara-C (1.2ng/ml) and Figure 92 shows response of the 
cells to mitoxantrone alone. Responses similar to those described for 
bone marrow cells of mice cured following treatment of the high cell 
dose transplant w ith mitoxantrone were observed. Even myeloid 
progenitor cells of bone marrow cells from cured mice apparently exhibit 
decreased sensitivity against subsequent mitoxantrone exposure in vitro 
(Figure 93). Thus there was an agreement between the colony assay and 
[3H]TdR uptake assay results.
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Flg.84: The response of BM cells from cured mice(SA7HD; 2mg/Kg) 
to arac treatment In vitro monitored using (3H)-thymldlne uptake assay.
129
24-*coo
o
M
C
CL
Ü
160
140
120
100
80
60
40
20
0
Fig
arac +  m îiox(1 .2ng /m 1)(untreated  NBM cells ) 
arac +mMox(# .2ng/m 1)(BM cells from  cured m ice)
m itox  
( 1 .2ng/m 1)
   r  I 'l i'  i i f ' i ■ i i n  : # y   i « n r" r |
.1 1 10 100Concentration of arac(ng/m1)
.85: The response of BM cells from cured mice(SA7HD; 2mg/Kg) 
to combination of arac v ith  mitoxantrone monitored using 
the (3H)-thymidine uptake assay.
130
120 untreated NBM cells 
BM cells from cured mice
100
S
coo
80
1 10 1001 1000
Concentration of mitoxantrone(ng/ml)
Fig.86: The response of BM cells from cured mice(SA7HD;2mg/Kg) 
to mitoxantrone treatment in vitro monitored using 
(3H)-thymidine uptake assay.
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Flg.87: The response of BM cells from cured mice(SA7HD; 2mg/Kg) 
to mitox treatment in vitro monitored using (3H)-thymidine uptake assay.
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Fig.88: The response to arac treatment in vitro of BM cells 
from cured mice(SA7HD; 0.75mg/Kg).The cells were stimulated 
with either WEHi alone or WEHi +L929 in vitro.
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Fig.89: The response to mitox of BM cells from cured mlce(SA7HD;0.75mg/Kg) 
The cells were stimulated with either WEHi alone or WEHI+L929 In vitro.
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Fig.90: The response of BM cells from cured mice(SA7LD;1.5mg/lcg) 
to arac alone or in combination v ith  mitoxantrone 
monitored using the (3H )-thgm idine uptake assay.
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Fig.91 : The response of BM cells from cured mlce(SA7LD;t .5mg/Kg) 
to mitoxantrone alone or in combination with arac 
monitored using the C3H)-thymidine uptake assay.
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Fig.92: A comparison of the response to mitoxantrone of BM cells from 
cured mice formally bearing high cell dose and low ceii dose passages of 
SA7 leukaemic ceil line monitored using(3H)-thymidine uptake assay.
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Fig.93: The response to in vitro treatment with mitoxantrone
of BM cells from cured(SA7HD) and mitoxantrone treated normal mice. 
Cytotoxicity was determined using GM-CFC assay.
Response of Bone Marrow Cells of a Mouse Dying from Drug Toxicity 
due to Drug Treatment In Vivo: Some mice died 30 days following in
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v iv o  treatment of SA7 high cell dose transplant leukaemia w ith  
mitoxantrone. On autopsy, no evidence of leukaemic infiltration was 
seen in bone marrow (Plate 5), spleen and blood. Compare Plate 5 with 
Plates 6 and 7. The in vitro drug sensitivity of bone marrow cells from 
one of these mice was tested. No difference in sensitivity to in vitro 
mitoxantrone treatment was found between such bone marrow cells and 
bone marrow cells from normal (untreated) mice (Figure 94)(plate 5).
Differential Cell Count of Bone Marrow Cells from Cured Mice: A  
differential count of bone marrow cells from long term survivors of both 
low cell dose passage (Tables 6a and 6b), high cell dose passage (Tables 7a 
and 7b) ( Plate 8) and untreated normal mice (Tables 8a and 8b) (Plate 9) 
shows that the cytology is identical for all three. For example, in all 
three, the generalised blast count was less than 5%. A  blast count of less 
than 5% is one of the criteria for both successful remission induction and 
cure in human acute myeloid leukaemia. In  addition, the percentages 
of mature cells (band and segmented cells) were identical in all three. 
Furthermore, there was no difference in in vitro progenitor numbers per 
5 X 10^ bone marrow cells between cured and normal mice.
137
l^ate 5: Bone marrow cells from a mouse dying of drug toxicity 
while in apparent remission . Mice bearing SA7HD leukaemia 
were treated with mitoxantrone (2m g/Kg).This mouse was 
autopsied 30 days after drug treatment. No evidence of 
leukaemic infiltration of the bone marrow is apparent. Spleen 
was also normal. M M = metamyelocytes; EBL= erythroblast 
GB= Generalised blast (Magnification x 1300).
I
Plate 6: Spleen cells of a mouse bearing SA7HD leukaemia in 
the terminal stage. The spleen was heavily infiltrated with 
leukaemic(generalised) blast cells(GB)(Magnification X  1300).
Plate 7: Bone marrow cells of a mouse bearing SA7HD
leukaemia in the terminal stage. Most of the cells populating 
the bone marrow are generalised blasts(GB) with a few mature 
Lrophils(N)(Magnification x 1300).
•B#
MM]
Plate 8: Bone marrow cells from a cured mouse following 
treatm ent o f S A 7H D  leukaem ia w ith  2 doses of 
m itoxantrone(0.75m g/Kg). A normal d ifferential count was 
obtained. EBL= erythroblast; GB= generalised blast; M M =  
metamyelocyte (M agnification. x 1300).
Table 6a : Differential count of bone marrow cells of a long-term 
survivor fo llow ing in vivo treatm ent of SA7 low  cell dose 
passage(SA7LD) leukaemia with 2 doses of mitoxantrone (1.5mg/kg),
a. See Table 6b for further classification of the myeloid cells.
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Cell Type % Total % Haematopoietic cells ■a
Generalised blasts 3.41 4.76
1:
1
Myeloid cells 29.55^ 4 1 .2 7 a
Monocytes 2.27 3.17 1
Erythroid 32.39 45.24
1
■1Lymphocytes 1.42 1.98
Damaged cells 0.57 0.79 -i-
Unclassified 0.57 0.79
Other cells 
Tissue cells
1.42
28.41
1.98
Table 6b : Further classification of the myeloid cells from  
longterm survivor form erly bearing SA7 low cell dose 
transplant leukaemia that was treated w ith mitoxantrone 
1.5mg/kg(see table 6a)
Cell type %Myeloid
Myeloblasts 10.34
Promyelocytes 7.76
Myelocytes 9.48
Metamyelocytes 31.90
Band cells 31.90
Segmented cells 8.62
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Table 7a : Differential count of bone marrow cells of a cured mouse 
following in vivo treatment of SA7 high cell dose transplant 
leukaemia(SA7HD) with 2 doses of mitoxantrone (0.75mg/kg).
% %Cell type Total Haematopoietic cells
Generalized blasts 1.98 2.08
Myeloid cells 39.68a 41.67a
Monocytes 1.98 2.08
Erythroid cells 31.35 32.92
Lymphocytes 10.71 11.25
Damaged cells 5.16 5.42
Unclassified cells 0,79 0.83
Other cells 3,57 3.75
Tissue cells 4.76
a. See Table 7b for further classification of myeloid cells.
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Table 7b:Further classification of myeloid cells from bone
marrow cells described in Table 7a.
CellType % Myeloid
Myeloblasts 5.15
Promyelocytes 5.15
Myelocytes 9.28
Metamyelocytes 42.27
Band cells 35.05
Segmented cells 3,09
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Table 8 a : A  differential count of normal bone marrow cells 
from C B A /H  mice
Cell type % Total % Haem
Generalised blasts 1.5 1.7
Myeloid cells 5.4 41.0a
Monocytes 0.8 1.9
Erythroid blasts 1.8 22.0
Lymphocytes 1.8 16.0
Damaged cells 2.5 2.2
Unclassified cells 0.9 0.4
Other cells 0.8 1.2
Stromal cells 3.8 1.3
a. See Table 8b for further classification of myeloid cells.
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Table 8b : Further classification of myeloid cells from bone
marrow cells described in Table 8a.
Cell type % Total % Haem
Generalised blasts 3 5.2
Promyelocytes 2.6 5.2
Myelocytes 11 9.4
Metamyelocyte 46 44
Band cells 32 30
Segmented cells 6 6.5
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Fig.94: The response of BM cells from untreated normal mice and mouse
dying from drug toxicity in remission to mitoxantrone treatment in vitro. 
Cytotoxicity was monitored using (3H)-thymidine uptake assay.
5.2 Responses of Recurrent Leukaemic Cells to Growth Factors: The 
growth factor sensitivity of SA7 high cell dose transplant leukaemic bone 
marrow cells before treatment, and at relapse following in v iv o  
treatment with mitoxantrone, were monitored (Section 5.2.2). Relapsed 
(recurrent) leukaemic cells were then passaged in (a) normal (untreated) 
mice and (b) mitoxantrone pretreated normal mice. The in vitro growth 
factor sensitivity of the leukaemic cells after every passage was 
determined.
5.2.1 Experimental Procedure: Models of recurrent (rec) leukaemic 
(leuk) disease following chemotherapy with mitoxantrone were obtained 
as follows: Groups of 5-6 normal mice of similar age, weight and sex as 
described under Section 5.1 were injected (I.P) with 10  ^ leukaemic cells of 
the SA7 high cell dose passage cell line and mitoxantrone was 
administered (I.P) on days 1 and 5 following tumour inoculation in the
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following doses: 0.4, 0.7 and 1.5mg/Kg. Alternatively, the leukaemic 
cells (10^) were injected I.V  and the drug in the following doses was 
injected I.P: 0.7, 1.5 and 2m g/kg. The leukaemias that recur despite 
treatment (called recurrent leukaemias) were tested for growth factor 
(W EHi, L929, WEHi+L929) sensitivity in vitro using procedures already 
described (section 4.1), In  addition, the number of in vitro colony 
forming cells in recurrent leukaemic bone marrow cells were also 
determined (section 5.2.8). This was done using the granulocyte- 
macrophage colony forming cell assay (section 3.4). Briefly, a single cell 
suspension of recurrent leukaemic bone marrow cells was prepared and 
5 X 10  ^ cells were plated in agar and the colonies that developed after 7 
days incubation were scored using an inverted microscope. 
Additionally, the following were carried out:
-Mice bearing the SA7 high cell dose leukaemia were treated by a single 
dose of mitoxantrone (0.75mg/Kg) either 24 hours or 48 hours before 
they became moribund with leukaemia. The growth factor sensitivity of 
the leukaemic bone marrow cells was then determined at autopsy 
(Section 5.2.3).
- Normal mice were administered mitoxantrone (0.75m g/kg) and 
autopsied 48 hours later. Similarly, normal mice were administered the 
following doses of mitoxantrone: 0.4, 0.75, 2 and 3mg/kg. The mice were 
autopsied and the growth factor sensitivity of bone marrow cells 
determined (section 5.2.4.).
- The bone marrow cells of leukaemic mice dying (while in remission) 
of drug toxicity (30 days after drug administration) were tested for growth 
factor sensitivity in vitro (section 5.2.5.).
- Bone marrow cells of cured mice and mice with relapsed low cell dose 
leukaemia (SA7LD ) (which occurred after 90 days) were tested for their 
growth factor sensitivity in vitro (section 5.2.6). In addition, normal
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mice received 2 doses of mitoxantrone (0.75mg/kg) on days 1 and 5. 
They were autopsied 60 days later and the sensitivity of the bone marrow 
cells to growth factors was monitored (section 5.2.6.).
- Recurrent SA7 high cell dose (SA7HD) leukaemic bone marrow cells 
were co-cultured with normal bone marrow cells. The growth factor 
sensitivity of the mixed population was determined (section 5.2.7).
- Recurrent leukaemic bone marrow cells were plated in agar and colony 
growth was evaluated after seven days incubation (Section 5.2.8).
- Recurrent (SA7HD) leukaemic cells were passaged into (a) normal mice 
(b) mice that received single dose of mitoxantrone (0.75mg/kg) 2 days 
previously (given the code PASS M IT  2d) or 2 doses of mitoxantrone 
(0.75mg/kg) 50 days previously (given the code PASS M IT  50d) (see 
Figure 95). The leukaemias from (a) and (b) (called 2nd recurrent 
leukaemias) were tested for growth factor sensitivity in vitro and then 
further passaged two times (in normal untreated mice), testing for in  
vitro growth factor response and myeloid progenitor numbers after each 
passage (Figure 95). After the second passage, the response of the 
leukaemic cells to mitoxantrone treatment in vitro was also investigated 
(Figure 95) (sections 5.2.9 - 5.2.20).
- The spleens of mitoxantrone pretreated mice with (2nd) recurrent 
leukaemia were weighed and compared to those of untreated mice with 
(2nd) recurrent leukaemia (5.2.21).
- The in vitro mitoxantrone sensitivity of recurrent leukaemic cells after 
passage in normal mice was determined (section 5.2.22). Similarly, the 
sensitivity of the (2nd) recurrent leukaemic cells following passage of 
recurrent leukaemia in mitoxantrone pretreated mice was monitored 
(section 5.2.23).
- A  differential count of recurrent leukaemic and untreated leukaemic 
bone marrow cells was performed (section 5.2.24).
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Results:
5.2.2 Growth Factor Sensitivity of Recurrent Leukaemic Cells: When 
mice bearing SA7 high cell dose(SATHD) leukaemia were treated with 
mitoxantrone, there was a dose-dependent increase in life-span of the 
treated mice within the dose range 0.75-1.5mg/Kg. Although some mice 
were even cured by these doses, in many mice the disease recurred. 
Leukaemic bone marrow cells from mice with recurrent leukaemia were 
not responsive to growth factors in vitro. Figure 96 shows the response 
of both untreated SA7HD leukaemic bone marrow cells and recurrent 
(SA7HD) leukaemic bone marrow cells to W EHi (mean of 3-6 separate 
experiments with 2-3 mice per experiment). While untreated leukaemic 
cells were responsive to W EHi, recurrent leukaemic cells (as a result of 
treatment with mitoxantrone 0.4, 0.75, and 1.5mg/Kg) did not respond. 
Sim ilarly, Figures 97 and 98 show (respectively) the responses of 
untreated and recurrent leukaemic cells to L929 alone and combinations 
of W EHi and L929. Again while untreated leukaemic cells were 
responsive to L929 alone and showed synergistic proliferative response 
to combinations of W EHi and L929, the recurrent leukaemic cells were 
insensitive to L929 alone or even combinations of L929 and W EHi 
conditioned media. The growth factor responses of recurrent leukaemic 
cells were significantly (F=0.04) different from those of untreated 
leukaemic cells using the Mann-Whitney test. As was observed with  
drug treatment, there was a difference in growth factor sensitivity when 
the leukaemic cells were injected intravenously w ith mitoxantrone 
administered intraperitoneally. In  this case the recurrent leukaemic cells 
retained minimal response to W EHi (Figure 99), L929 (Figure 100) and 
combinations of W EHi and L929 (Figure 101).
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5.2.3 Growth Factor Responses of Bone Marrow Cells from Leukaemic 
Mice Treated w ith Mitoxantrone 24 or 48 hours before they became 
M oribund w ith Leukaemia: When mitoxantrone(0.75mg/Kg) was
administered to leukaemic mice 24 or 48 hours before they became 
moribund with the disease, the leukaemic cells retained sensitivity to 
growth factors in vitro.
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Fig.96: The response of untreated and recurrent 
SA7HD leukaemic cell line to WEHi. Growth factor 
response was monitored using (3H)-thymidine uptake assay.
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Fig.97: The response of untreated and recurrent(SA7HD) leuk cells to L929. 
Growth factor response was monitored using(3H)-thymldlne uptake assay.
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Fig.98: The response of untreated and recurrent(SA7HD) leukaemic cells 
to WEHi +L929 monitored in vitro using (SH)-thymidine uptake assay.
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Fig.99: The response of untreated and recurrent leukaemic cells to WEHi. 
SA7HD Leuk. cells were Injected i.V. while mitox. was admin i.p.
Growth factor response was monitored using(3H)-thymldine uptake assay.
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Fig.lOO: The response of untreated and recurrent leuk cells to L929. 
SA7HD Leuk ceils were injected l.v while mitox was admin i.p. 
Growth factor response was monitored using (3H)-TdR uptake assay.
30000 -1 ■H  untreated(SA7HD) iekaemic ceils
♦ ........ recurrent(SA7, i.v)ieukaemic ceiis(mitox 0.75mg/Kg,i.p)
-0 - - -  recurrent(SA7, i.v) leukaemic celis(mitox1.5mg/Kg,i.p)
-♦—  recurrent(SA7,i.v) leukaemic ceils( mitox,2mg/Kg,i.p)
25000
20000
OQ. 15000
10000
- ..........................
0 10 20 30
Concentration of WEHi +L929{%)
Fig.101: The resp of untreated and rec.(SA7HD) leuk ceils to growth factors. 
SA7H0 Leuk. ceils were inj( i.v.) and mitox was admin (i.p.). Growth factor 
response was moPitored following 4days incub using (3H)TdR uptake assay.
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The responses of leukaemic cells from mice that received mitoxantrone 
24 hours (Figure 102) or 48 hours (Figure 103) are shown. In  both cases, 
the cells were responsive to W EHi alone, L929 alone and synergistic 
proliferative response was observed with combination of W EHi and 
L929.
5.2.4 Growth Factor Responses of Bone Marrow Cells from Treated and 
Untreated Normal Mice: Bone marrow cells of both mitoxantrone (48 
hours) treated (Figure 104) and untreated (Figure 105) normal mice 
responded to growth factors in vitro in a concentration dependent 
manner with combinations of the growth factors producing synergistic 
effects. Similarly, bone marrow cells of normal mice treated with 
mitoxantrone in the doses 0.4mg/Kg (Figure 106); 2m g/Kg (Figure 107) or 
even 3m g/kg (Figure 108) responded to W EHi, L929 and combinations of 
WEHi+L929 in the expected manner. Each figure is the mean of three 
experiments. These doses range from the lowest to the highest that were 
used in the treatment of SA7 high cell dose transplant leukaemic cells in  
v iv o . Thus, normal bone marrow cells retain their sensitivities to 
growth factors following treatment of normal mice with mitoxantrone.
5.2.5 Growth Factor Responses of Bone Marrow Cells of a Mouse Dying 
from Drug Toxicitv: In one of the drug treated leukaemia bearing mice, 
no evidence of leukaemia was found on autopsy 30 days after the 
initiation of drug treatment, although the mouse was sickly . Death was 
therefore ascribed to drug-related toxicity. The growth factor response of 
bone marrow cells of the mouse was monitored. The bone marrow cells 
were responsive to growth factors in the usual manner (Figure 109) 
except that sensitivity to 5% L929 and 10% L929 was increased probably as 
a result of compensatory mechanisms.
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Fig.102:The Response of In vivo mitox treated leuk cells to growth factors. 
SA7HD Leuk. mice received mltox(0.75mg/Kg) 24hrs before they were morlbouno 
Growth factor response was monitored using (3H)-thymldlne uptake assay.
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Flg.103:The response of mitoxantrone treated leuk cells to growth factors. 
SA7HDLeuk mice received mitox (0.75mg/Kg) 48hrs before they were morlbound 
Growth factor response was determined uslng(3H)-thymldlne uptake assay.
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Fig.104: The response of (In vlvo)mitox treated NBM cells to growth factors. 
Normal mice were treated with mitox(0.75mg/Kg) In vivo for 48hrs.
Growth factor response was monitored using (3H)-thymldlne uptake assay.
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Flg.105: The response of untreated NBM cells to growth factors. 
Growth factor response was monitored uslng(3H)-TdR uptake assay.
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Flg.106:The response of (In vivo) mitox treated NBM ceils to growth factors. 
Normal mice were treated with mltox(0.4mg/kg) 2days before autopsy. 
Growth factor response was monitored using (SH)-thymldlne uptake assay.
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Fig.107: The responses of (in vivo )mltox treated NBM cells to growth factors. 
Normal mice were treated with mitoxantrone(2mg/Kg) , 9days before autopsy. 
Growth factor responses were monitored using (3H)-thymidlne uptake assay.
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Fig.108: The responses of In vivo mitox treated NBM cells to growth factors. 
Normal mice were treated with mitox(3mg/Kg) and autopsied 9 days later. 
Growth factor responses were monitored using (3H)-thymldlne uptake assay.
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Fig.109: The resp of BM ceils of mice dying of drug toxicity to growth factoB/ 
Mice were autopsied SOdays after the initiation of treatment with mitox.
No evidence of ieukaemic Infiltration of the spleen was observed.
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Fig.110: The response of BM ceils from cured mice to growth factors.
Mice bearing SA7HD leukaemia were treated with mitox(0.75mg/Kg) . 
Srowth factor response was monitored using (3H)-thymidine uptake assay.
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5.2.6 Growth Factor Response of Bone Marrow Cells of Cured Mice: 
Bone marrow cells of cured mice from both high cell dose transplant 
(Figures JIO  and 111) and low cell dose transplant (Figure 112) including 
90 day relapse (Figure 113) were responsive to growth factors. Similar 
results were obtained using bone marrow cells of normal mice treated 
with two doses of mitoxantrone 60 days previously (Figure 114). Thus, 
in all the doses and schedules studied, bone marrow cells of 
mitoxantrone treated normal mice always responded to growth factors. 
These data strongly suggests that only leukaemic cells became growth 
factor insensitive as a result of chemotherapeutic intervention with  
mitoxantrone.
5.2.7 Effect of Co-Culturing Recurrent Leukaemic Cells with NBM Cells: 
Recurrent leukaemic cells did not apparently produce factor(s) inhibitory 
to the growth of normal bone marrow cells in vitro. This is deduced 
from the observation that coculturing recurrent leukaemic cells with 
normal bone marrow cells did not inhibit the proliferative response of 
normal bone marrow cells to W EHi (Figure 115), L929 (Figure 116) and 
combinations of W EHi and L929 (Figure 117).
5.2.8 Colony Growth of Recurrent (SA7HD) Leukaemic Bone Marrow  
Cells: Very few colonies (6-7) were formed by recurrent leukaemic cells 
in agar culture. This is in contrast to high colony numbers (71±2) that 
were formed by untreated leukaemic cells (Table 9).
5.2.9 Recovery of Growth Factor Sensitivity and Colony Growth: 
Recovery of growth factor sensitivity was observed when recurrent 
leukaemic cells were passaged in normal mice. Recovery of growth factor
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Table 9 : Number of colonies formed by 5x10"^  recurrent leukaemic 
bone marrow cells. Recurrent leukaemic cells were either passaged 
in normal (untreated) mice or in mice pretreated with single or two 
doses of mitoxantrone (2 or 5 days prior to the transplant respectively)
Dose ofMitoxantrone(mglkg)
Recurrentleukaemiccells
Number of Colonies
Firstpassage(TRl)
Secondpassage(TR2)
0.75 6 .0±0 a 23+3^ 30.0+5&
1.5mg/kg 7±2 22.0+5 68.0+14
PASS M IT  2db 2 .0± 1 47.0+0 423.0+3
PASS M IT  50dc 3.0±0 50.0+1. 33.0+6
29.0±2d NOe N D
Untreated leukaemic bone marrow cells gave 71+2 colonies/5xl0^ cells.
a. Mean ± SE of three separate experiments.
b. Recurrent leukaemic cells passaged in mice that received one dose 
(0.75mg/kg~I.P) of mitoxantrone two days previously.
c. Recurrent leukaemic cells were passaged in mice that received two 
doses (0.75mg/kg-IP) of mitoxantrone 50 days previously.
d. Leukaemic cells from one mouse responded to growth factors.
e. N D  = not determined.
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sensitivity was more pronounced (higher C.P.M ) for recurrent 
leukaemia following treatment w ith mitox 0.4m g/Kg followed by 
1.5mg/Kg and then 0.75mg/Kg which suggests that recovery was not 
dependent on initial mitoxantrone dose. Figures 118, 119 and 120 show 
the recovery of sensitivity to growth factors by recurrent leukaemic cells 
as a result of treating SA7 high cell dose transplant cell line (I.P) with 0.4, 
0.75 and 1.5mg/Kg mitoxantrone (I.P)(given the code 0.4m g/KgTRl, 
0.75mg/KgTRl , 1.5mg/KgTRl) respectively. Each figure was the mean 
of 2-3 experiments. It was apparent that there was considerable variation 
(between experiments) in the recovery of growth factor sensitivity.
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F ig . I l l :  The response of BM cells from cured mice to growth factors.
Mice bearing SA7HD leukaemia were treated with mltoxantrone(2mg/kg). 
Growth factor response was monitored using (3H)-thymldlne uptake assay.
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Fig.112: The response of BM cells of cured mice to growth factors.
Mice bearing SA7LD leukaemia were treated with mltoxantrone(1.5mg/Kg). 
Growth factor response was monitored using (3H)-thymldlne uptake assay.
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Fig.113: The resp of BM cells of mice with relapsed leuk to growth factors. 
Mice bearing the SA7LD leukaemia relapsed QOdays following treatment. 
Growth factor response was monitored using (3H)-TdR uptake assay.
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Fig.114: The response of (In vivo)mitox treated NBM cells to growth factors. 
Normal mice recieved mltox(0.75mg/Kg) and were autopsied 60 days later. 
Growth factor response was monitored using (3H)-thymldlne uptake assay.
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Flg.115: The resp of a mixture of NBM cells and rec leuk cells to WEHi. 
Growth factor response was monitored using (3H)-TdR uptake assay.
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Fig116: The response of a mixture of NBM cells and rec leuk cells to L929. 
Growth factor response was monitored using (3H)-thymldine uptake assay.
Similarly, in an experiment monitoring the recovery of recurrent 
leukaemia as a result of treating 1 0  ^ leukaemic cells with mitoxantrone 
l,5m g/kg , the cells did not regain their sensitivity to growth factors to 
pretreatment levels even after one passage in normal mice (Figure 1 2 1 ). 
In the latter case, the leukaemic cells were not very responsive even to 
combinations of W EHi and L929. This suggests that the in itial 
leukaemic load may also be important. Similar to what was observed in 
the [3H]TdR uptake assay, there was increased colony numbers in 
response to W EHi after recurrent leukaemic cells were passaged once in 
normal mice (Table 9).
5.2.10 Growth Factor Sensitivity and Colony Growth of Recurrent 
Leukaemia After Two Passages in Mice: After the 2nd passage of 
recurrent leukaemic cells in normal mice, there was increased 
proliferative response to single and combinations of growth factors. In  
this case too, recurrent leukaemic cells as a result of treatment with
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mitoxantrone 1.5m g/Kg (given the code 1.5mg/KgTR2) were more 
sensitive to W E H i, L929 but not combinations of the two (Figure 122) as 
compared to recurrent leukaem ia fo llow ing treatm ent w ith  
mitoxantrone 0.75m g/Kg (Figure 123). Sim ilarly, colony numbers 
following a second transplant were higher than those seen after the first 
transplant (Table 9). Interestingly, colony numbers after the second 
transplant were higher for 1.5mg/Kg TR2 as compared to 0.75mg/KgTR2 
(Table 9) which suggest further agreement between colony assay and 
[3H]-thymidine uptake assay.
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Fig.117: The resp of a mixture of NBM and recurrent leukaemia to WEHi +L929. 
Growth factor response was monitored using (3H) -TdR uptake assay.
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Fig.118: The response of rec. leuk. cells (0.4mg/KgTR1)to growth factors. 
The recurrent leukaemia was passaged once In norm mice.
Growth factor response was monitored using (3H)-thymldlne uptake assay.
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Fig.119: The response of rec.leuk.(0.75mg/KgTR1)to growth factors. 
The recurrent leukaemia was passaged once in norm. mice.
Growth factor response was monitored using (3H)-TdR uptake assay.
158
30000 -, WEHi alone 
L929 alone 
WEHI + L92925000 -
20000 -
15000 -
10000 -
5000
2 0 301 00
Concentration of WEHi, L929, or WEHi + L929(%)
Flg.120:The response of rec.leuk. (1.5mg/KgTR1)to growth factors.
The recurrent leukaemia was passaged once in normal mice 
Growth factor response was monitored using (3H)-thymldlne uptake assay.
159
5000 1
WEHi alone 
L929 alone 
WEHI + L929
® 4000 -
3
C
E 3000 -
Q)Q.
0)  2000 -HH-*c3Oo 1000
0 f
0 1 0 20 30
Concentration of WEHI, L929, or WEHI + L929{%)
Fig.121: The response of recurrent leukaemia to growth factors.
The recurrent leukaemia (10 cells,l.p) was passaged once in norm mice. 
Growth factor response was monitored using (3H)-thymldlne uptake assay.
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Fig.122: The response of rec.leuk.(1.5mg/KgTR2) to growth factors.
The recurrent leukaemia was passaged twice in normal mice
Growth factor response was monitored using (3H)-thymidlne uptake assay.
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Flg.123:The response of rec leukaemic cells(0.75mg/Kg TR2) to growth 
factors.Growth factor response monitored using (3H)-thymldlne uptake assay. 
The recurrent leukaemia was passaged twice in normal mice.
5.2.11 Effect of Passaging Recurrent Leukaemic Cells in Mice Pretreated 
with Mitoxantrone Two Days Previously: When recurrent leukaemic 
cells were passaged in mice that were pretreated w ith one dose of 
mitoxantrone (0.75mg/kg) two days previously (given the code PASS 
M IT  2d) (Figure 95) the leukaemia that subsequently developed 
(hereafter called second recurrent leukaemia) was insensitive to growth 
factors (W EHi, L929, W EHI+L929) in vitro. Figure 124 shows the 
response of such leukaemic cells to W EHi, L929 and combinations of the 
two (mean of two experiments). The leukaemia was insensitive to 
single or combinations of growth factors.
5.2.12 Effect of Passaging Second Recurrent Leukaemia(PASS M IT  2d) in 
Normal (untreated) Mice: When second recurrent leukaemia (PASS 
M IT  2d) was passaged in normal (untreated) mice (Figure 95) the 
resulting leukaemia (given the code PASS M IT  2dTRl) was responsive
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to growth factors. Figure 125 shows the recovery of sensitivity to W EHi, 
L929 and combinations of W EHi and L929 by PASS M IT  2dTRl cells. 
Each curve in the figure is the mean of three experiments.
5.2.13 Effect of Passaging PASS M IT  2d on In  Vitro Colony Num bers: 
Only 2±1.0 colonies were formed when 5 x 10^ PASS M IT  2d bone 
marrow(BM) cells were plated in agar (Table 9). However, when the 
leukaemic cells were passaged in normal (untreated) mice, there was a 
corresponding increase in colony numbers (47±4) thus agreeing with 
recovery of growth factor sensitivity monitored using (SH)-thymidine 
uptake assay reported above.
5.2.14 Effect of Passaging PASS M IT 2dTRl in Normal (untreated) Mice: 
The sensitivity of leukaemic bone marrow cells to W EHi, L929 and 
combinations of WEHi-*-L929 after passaging PASS M IT  2dTRl in 
normal (untreated) mice was monitored. The leukaemic cells (now 
given the code PASS M IT  2d TR2) were as responsive to growth factors 
as PASS M IT  2dTRl (Figure 126).
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FIg. 124: The response of recurrent leukaennla(PASS MIT 2d) to growth 
factors. Growth factor responses monitored uslng(3H)-thymldlne uptake assay.
The recurrent leukaemia was passaged In mitox. pretreated mice.
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Flg.125: The response of PASS MIT 2dTR1 to growth factors.
Growth factor response was monitored using (3H)-thymldlne uptake assay. 
The recurrent leukaemia was passaged once in normal mice.
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5.2.15 Effect of Passaging PASS M IT  2 dTRl on Colony Numbers: PASS 
M IT  2dTRl was further passaged in normal mice, and the resulting 
leukaemia (PASS M IT  2d TR2) was plated in agar. A  decrease in colony 
numbers was observed as compared to PASS M IT  2dTRl (Table 9). This 
contrasts with the no difference in growth factor sensitivity observed 
between PASS M IT  2dTRl and PASS M IT  2d TR2 when response was 
monitored using (3H)-thymidine uptake assay.
5.2.16 Effect of Passaging Recurrent leukaemia in Mice Pretreated w ith  
Two Doses of Mitoxantrone (Q.75mg/kg) 50 days previously: Recurrent 
leukaemic cells were passaged in three mice (M i, M 2  and M 3 ) that were 
pretreated 50 days previously w ith two doses of mitoxantrone 
(0.75mg/Kg). The growth factor sensitivity of leukaemic bone marrow 
cells of these mice was monitored in vitro. The leukaemic cells (given 
the code PASS M IT  50d) were insensitive to growth factors in 2 of 3 mice. 
Figure 127 shows the response of PASS M IT  50d to W EHi, L929 and 
combinations of the two. Whereas, bone marrow cells of M% and M 2  did 
not respond to these growth factors, those of M 3  did respond.
5.2.17 Colony Assav of PASS M IT  50d: Whereas leukaemic bone marrow 
cells of M l and M 2  formed 3.6±0,2 colonies when plated in agar, those of 
M 3  formed 29±2 colonies (Table 9). This indicates further agreement 
between colony assay result and [3H]TdR uptake results.
5.2.18 Effect of Passaging PASS M IT  50d in Normal (untreated) Mice:
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When growth factor insensitive PASS M IT  50d was passaged into 
normal (untreated) mice, (now given the code PASS M IT  50d TR l), its 
growth factor sensitivity was restored. The leukaemic cells became 
extremely sensitive to W EHi, L929 and combinations of the two (Figure 
128). The figures were mean of three experiments.
5.2.19 Effect of Passaging PASS M IT  50d on In vitro Colonv Growth: 
Similar to what was observed with [3H]TdR uptake assay, passaging 
PASS M IT  50d in normal mice resulted in an increased colony formation 
by the leukaemic bone marrow cells (Table 9) (50±1 vs 3.610.2).
5.2.20 Effect of Passaging PASS M IT  50d TR l on Growth Factor 
Sensitivitv
and Colonv Growth: When PASS M IT  50d TRl was further passaged in 
normal (untreated) mice, the resulting leukaemia (given the code PASS 
M IT  50d TR2) was less responsive to W EHi, L929 or their combinations 
as compared to PASS M IT  50d TR l. Figure 131 shows the response of 
PASS M IT  50d TR2 to W EHi, L929 and combinations of the two. Each 
figure was the mean of three experiments.
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Fig. 126; The response of PASS MIT 2d TR2 to growth factors.
Growth factor response was monitored using(3H)-thymidine uptake assay. 
The recurrent ieukaemia was passaged twice in normal mice.
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Fig.127: The response of PASS MIT SOd to WEHi.
M1,M2^nd M3 represent three different mice.
Growth Motor response was monitored using (3H)-TdR uptake assay.
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The decrease in response to growth factors between PASS M IT  50d TRl 
and PASS M IT  50d TR2 was also reflected by a fall in colony numbers 
between the two passages (Table 9). Although, sensitivity to growth 
factors was restored after a single passage of the recurrent leukaemic cells 
in normal (untreated) mice (according to [3H]TdR uptake assay results), 
colony numbers (except probably for 1.5m g/KgTRl) did not return to 
pretreatment levels even after the second passage (Table 9).
5-2.21 Comparison of Recurrent Leukaemic Spleen Weights in  
Mitoxantrone Pretreated or Untreated Mice: Pooled spleen weights from 
mitoxantrone pretreated mice bearing recurrent leukaemia were up to 
80mg heavier than comparable spleens from untreated normal mice. It 
is likely that the presence of mitoxantrone in the pretreated mice 
triggered the leukaemic cells to divide hence the increased spleen 
weight.
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Fig.128; The response of PASS MIT 50d to L929.
M l, M2, and M3 represent three different mice.
Growth factor response was monitored using(3H)- TdR uptake assay.
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Flg.129: The response of PASS MIT 50d to WEHI + L929.
M l,M2, and M3 represent three different mice.
Growth factor response was monitored using (3H)>TdR uptake assay.
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Comparison of In  V itro Colony Numbers Produced by Recurrent 
Leukaemic Bone M arrow Cells from Pretreated or Untreated Mice: 
Colony numbers formed by bone marrow cells of PASS M IT  2dTRl and 
PASS M IT  50d TRl were higher than those formed after the first passage 
of recurrent leukaemia in untreated normal mice (Table 9).
5.2.22 In Vitro Mitoxantrone Sensitivity of Recurrent Leukaemic Cells 
After
Passage in Normal (untreated) Mice: Even after two passages in normal 
mice, the sensitivity of recurrent leukaemic cells to subsequent 
mitoxantrone treatment in vitro did not revert to pretreatment levels. 
This resistance was dependent on the initial mitoxantrone dose the 
leukaemic cells were exposed to in vivo. Figure 132 shows the 
mitoxantrone dose-response curve of recurrent leukaemia following 
treatment of SA7 high cell dose leukaemic cells w ith  0.4m g/Kg  
mitoxantrone in vivo (0.4m g/Kg mitox) after it was passaged once in 
normal (untreated) mice (given the code 0.4mg/Kg TR l). The cells were 
even slightly more sensitive than untreated leukaemic cells to 
mitoxantrone (Figure 132). This is further shown by the following 
example: 0.4m g/Kg TR l was as sensitive to Ara-C as untreated
leukaemic cells (Figure 133). However, when mitoxantrone (1.2ng/m l) 
was added, the cells became more sensitive to the combination as 
compared to untreated leukaemic cells (Figure 133). 0.4mg/Kg TRl cells 
became more sensitive to Ara-C treatment in vitro if a combination of 
W EHi (5%) and L929 (5%) was used to stimulate their proliferation in  
vitro (Figure 134). Similarly, combinations of Ara-C (0.12-120ng/ml) 
w ith mitoxantrone (1 .2 n g /m l) produced greater effects when a 
combination of growth factors rather than single growth factor (WEHi) 
was used to stimulate the in vitro proliferation of the cells (Figure 134).
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Apparently mitoxantrone alone or in combination w ith Ara-C  
(1.2ng/m l) also seems more effective when combination of W EHi (5%) 
and L929 (5%) was used to stimulate the cells in vitro as compared to 
when W EHi alone was used (Figure 135).
When mitoxantrone 0.75mg/Kg was used in the treatment of SA7 high 
cell dose transplant leukaemia, the recurrent leukaemic cells (after two 
passages in normal untreated mice (0,75mg/Kg TR2) were less sensitive 
to low concentrations (0 .1 2 -1 .2 ng/m l) of mitoxantrone and stimulation 
of [3H]TdR uptake rather than inhibition of DNA synthesis was observed 
with these concentrations (Figure 136).
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Fig.130: The response of PASS MH" 50dTR1 to growth factors.
Growth factor response was monitored using (3H)-TdR uptake assay.
The recurrent leukaemia was passaged once In normal mice.
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Flg.131: The response of PASS MIT 50d TR2 to growth factors.
Growth factor responses were monitored using (3H)-TdR uptake assay.
The recurrent leukaemia was passaged twice In normal mice.
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Flg.132: The response of rec leuk cells(0.4mg/Kg TRl) to mitoxantrone. 
Cytotoxicity was determined uslng(3H)-thymldlne uptake assay.
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Fig.133:The response of rec. leuk. cells (0.4mg/KgTR1) to arac 
alone or In combination v lth  mitoxantrone monitored In vitro. 
Cytotoxicity vas determined using the (3H)-thymidine uptake assay
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A t higher mitoxantrone concentrations (12-120ng/m l) there was no 
difference in sensitivity between recurrent leukaemic cells (0.75mg/kg 
TR2) and untreated leukaemic cells. This is shown clearly in Figure 136, 
which is mean of 3 separate experiments.
Recurrent leukaemia following treatment of SA7HD with mitoxantrone 
(1.5m g/Kg) was markedly insensitive to subsequent mitoxantrone 
treatment in vitro even after the recurrent leukaemic cells were passaged 
twice in normal (untreated) mice (1.5mg/Kg TR2). Figure 137 shows the 
response (mean of 3 experiments) of 1.5mg/Kg TR2 to mitoxantrone 
treatment in vitro. A resistant factor (I.C5 0  of mitoxantrone against 
1.5mg/Kg TR2 divided by I.C 5 0  of the drug against untreated SA7HD 
leukaemic cells) of 17 was found. Whereas 12ng/m l of mitoxantrone 
inhibited [3H]TdR uptake by 80% (relative to control) in untreated 
SA7HD leukaemic cells (Figure 33), the same concentration stimulated 
[3H]TdR uptake (and hence proliferation?) of the recurrent leukaemic 
cells (1.5mg/kg TR2) to well above control values (138±22%)(Figure 137). 
If  such stimulation of the recurrent leukaemic cells by mitoxantrone 
occurs in vivo, it could explain the increased spleen weights in mice 
pretreated with mitoxantrone.
These data strongly suggests that the degree of mitoxantrone resistance 
in vitro depended on the dose of mitoxantrone administered to the 
leukaemic cells in vivo. This is shown clearly in Figure 138 where there 
was increasing insensitivity to in vitro m itoxantrone (in the 
concentration range 0.12-12ng/m l) w ith increasing dose of in vivo 
administered mitoxantrone. The resistance developed by 1.5mg/Kg TR2 
to in vitro treatment with mitoxantrone (within the concentration range 
1.2-12ng/m l) was significantly different (P=0.012) from untreated 
leukaemic cells using the Mann-Whitney test.
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Fig. 1 3 4 : The response o f 0 .4m g/K gTR I to arac alone or in combination v ith  m itox  
The recu rren t leukaemic cells w ere stim ulated by a combination o f  
VEHi(59S) and L 9 2 9 (5 % ). The (3H )-thym id ine  uptake assay v a s  used.
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Fig. 135; The response of 0.4mg/KgTR1 to mitoxantrone alone or in 
combination v ith  arac monitored using the (3H)-thymidine uptake assay 
The rec. leuk cells were stimulated by a combination of WEHi and L929.
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Fig.136: The response of rec ieuk(0.75mg/Kg TR2) to mitoxantrone. 
Cytotoxicity was determined using(3H)-thymidine uptake assay in vitro. 
The rec. leuk. was passaged twice in normal mice.
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Fig.137: The response of rec.ieuk.(1.5mg/KgTR2) to mitoxantrone. 
Cytotoxicity was determined using (3H)-thymidine uptake assay in vitro. 
The rec. iekaemia was passaged twice in normal mice.
5.2.23 In Vitro Mitoxantrone Sensitivity of Recurrent Leukaemic Cells 
After Passage in Mitoxantrone Pretreated M ice: Surprisingly, no
increased resistance to mitoxantrone treatment in vitro was observed 
when recurrent leukaemic cells were first passaged in mitoxantrone 
pretreated mice before passaging again in untreated normal mice. This 
supports the view that it was the initial dose the leukaemic cells were 
first exposed to (in vivo ), that determined the degree of any subsequent 
resistance they develop. Subsequent exposures after the first apparently 
had no effect. Figure 139 shows the response of PASS M IT  2dTRl to 
mitoxantrone treatment in vitro (mean of 3 experiments). The recurrent 
leukaemic cells were less sensitive to mitoxantrone as compared to 
untreated leukaemic cells only at low concentration within the range 
0.12-12ng/ml. However, w ith further passage in normal (untreated) 
mice (PASS M IT  2d TR2) there was no difference in sensitivity as
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compared to untreated leukaemic cells (Figure 140) (mean of 3 
experiments).
Figure 141 shows the response of PASS M IT  50d TR l to in vitro  
treatment with mitoxantrone (mean of 2 experiments). No difference in 
sensitivity to mitoxantrone was observed. However, w ith further 
passage in normal (untreated) mice, PASS M IT  50d TR2 became less 
sensitive to low concentrations of mitoxantrone (0.12-1.2ng/ml) where 
stimulation rather than inhibition of [3H]TdR uptake was observed 
(Figure 142) (mean of 3 experiments). Thus, whereas PASS M IT 2dTRl 
became more sensitive to mitoxantrone with passaging , PASS M IT  
50TR1 on the other hand, became less sensitive to low concentrations of 
mitoxantrone after passaging. However, none of these recurrent 
leukaemias was as insensitive to mitoxantrone as 1.5mg/Kg TR2 thus, 
lending support to the observation that no increase in mitoxantrone 
insensitivity was seen when recurrent leukaemic cells were passaged in 
mitoxantrone pretreated mice.
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Flg.138:A comparison of mitoxantrone sensitivities of the various rec. ieuks. 
Cytotoxicity was determined using (3H)-thymidine uptake assay in vitro.
120  -1
SA7HD (untreated) 
PASS MIT 2dTR1
—  100 -o
coo 80 -
«#—o 60 -
. 40 - Ql
Ü
20 -
.1 1 1 0 100 1000
Concentration of mitoxantrone(ng/ml)
Fig.139: The response of rec. leukaemia(PASS MIT 2dTR1) to mitox. 
Cytotoxicity was determined using (3H)-TdR uptake assay in vitro.
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Fig.140: The response of PASS MIT 2dTR2 to mitoxantrone.
The rec. leukaemia was passaged twice 
Cytotoxicity was determined using (3H)-thymidine uptake assay.
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Flg.141: The response of PASS MIT SOdTRI to mitoxantrone In vitro. 
Cytotoxicity was determined using (3H)-thymidlne uptake assay.
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Fig.142: The response of PASS MIT 50dTR2 to mitoxantrone.
The recurrent leukaemia was passaged twice.
Cytotoxicity was determined using (3H)-TdR uptake assay in vitro.
5.2.24 Differential Count of Recurrent Leukaemic Bone Marrow Cells 
and
Untreated Leukaemic Bone M arrow Cells. Tables 10 and 11 show 
(respectively) the differential count of untreated and recurrent 
leukaemic bone marrow cells following treatment of SA7HD w ith  
0.4m g/kg mitoxantrone. Both leukaemias had nearly identical 
generalised blast count (23.68 vs 28.94%) and percentage of myeloid cells. 
Thus, recurrent leukaemic cells were not morphologically different from 
untreated leukaemic cells (Plate 10). (Compare with Plate 7).
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Plate 9: Bone marrow cells of a normal CBA/H mouse. Very few 
immature cells are evident. EB= erythroblast; GB = 
generalised blast; M M = metamyelocyte (m agnification x 
1300).
#
Plate 10. Leukaemic bone marrow cells of a recurrent 
leukaemia following treatment of SA7HD with 2 doses of 
mitoxantrone (0.4m g/Kg). The differential count of these bone 
m arrow cells is identical to that o f untreated 
(SA7HD)leukaemic bone marrow. BL= blast cells. (Magnification 
X 13(X)).
Table 10 : Differential count of bone marrow cells from untreated 
SA7 high cell dose transplant cell line.
% Total % Haem
Generalised blasts 23.68 26.67
Myeloid cells 49.01 55.19
Monocytes 2.96 3.33
Erythroid cells 2.30 2.59
Lymphocytes 6.58 7.41
Damaged cells 0.99 1.11
Unclassified cells 0.99 1.11
Other cells 2.30 2.59
Tissue cells 11.18
% Myeloid
Myeloblasts 34.45
Promyelocytes 12.92
Myelocytes 21.05
Metamyelocytes 27.27
Band cells 3.83
Segmented cells 0.48
%
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Table 11 : Differential counts of bone marrow cells from 
recurrent leukaemia following treatment of SA7HD cell 
line with 2 doses of mitoxantrone (0.4mg/Kg (TP)).
cells
% Total % Haem.
Generalised blasts 28.94 35.0
Myeloid cells 47.27a 57.0
Monocytes 1.29 1.0
Erythroid cells 0.00 0.0
Lymphocytes 1.29 1.1
Damaged cells 0.96 1.1
Unclassified cells 0.96 1.1
Other cells 1.93 2.3
Tissue cells 17.36 -
% Myeloid cells from (a ) above
Myeloblasts 37.97
Promyelocytes 29.11
Myelocytes 27.43
Metamyelocytes 5.49
Band cells 0.00
Segmented cells 0.00
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5.3 The Effect of Mitoxantrone on Normal Mice:
The aim of the following investigation is to investigate the toxic effect of 
mitoxantrone on the haematopoietic system of normal mice. In  
addition, bone marrow cells of in vivo treated normal mice were 
monitored for their response to treatment with mitoxantrone in vitro.
5.3.1 Experimental procedure: Normal C B A /H  female mice weighing 20- 
25g were injected (I.P) with the following doses of mitoxantrone on days 
1 and 5: 0.4,0.75,1.5,2 and 3mg/kg. Groups of 5 mice per dose were used. 
The following haematological parameters were determined on days 4, 8, 
16, 30 and 60 fo llow ing the last m itoxantrone injection: 
haematocrit(PCV), femur cellularity, spleen weight, haemoglobin(Hb) 
and number of GM-CFC’s per 5 x 10^ treated bone marrow cells. In  
addition, the response of the bone marrow cells to subsequent 
mitoxantrone treatment in vitro was investigated, using the tritiated 
thymidine uptake assay (section 3.2). Similarly, the response of normal 
bone marrow myeloid progenitors of the (in vivo) treated mice to 
mitoxantrone treatment in vitro was determined using GM-CFC assay.
Results
5.3.2 Effect of Mitoxantrone on Haematopoietic System of Normal Mice: 
Mitoxantrone in the doses studied had no marked effects on spleen 
weight, Hb, PCV, femur cellularity and myeloid progenitor number in 
normal mice (Tables 12 a and b). Even with the highest dose used 
(3mg/kg), the most noticeable effect was a depression of spleen weight to 
about 60% of untreated values (Table 12a). However, none of the mice 
died from any drug-related toxicity in an observation period of nine days.
This contrasts sharply with the toxicity observed with the same dose of 
mitoxantrone (3mg/kg) in leukaemia bearing mice whereby all the mice 
died from drug toxicity.
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Table 12b : The effect of mitoxantrone on femur cellularity and 
myeloid progenitor cell numbers in normal C B A /H  mice.
Mice received two doses of mitoxantrone on days 1 and 5.
Femur cellularity (xlO^) GM-CFC
Days 4 8 16 60 4 8 16 60
Dose (mg/kg)
Control 14.0 13 12 - 39±2a 45+3 45+2 ( -P
0.4 9.0 13 13 - 65±4 65±3 49+3 -
0.75 - - - 13 - - - 40
1.5 9.0 10 13 - 51+2 44±2 49+3
3 - 12 - - - - - -
a. Mean ± SE of five determinations.
b. (-) = not determined.
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5.3.3 Response of In Vivo treated Bone Marrow Cells to Mitoxantrone 
Treatment In  V itro: Bone marrow cells of normal mice that received 
mitoxantrone (0.75m g/Kg) in vivo 48 hours previously, developed 
protective effect towards subsequent mitoxantrone exposure in vitro 
(Figure 143). However, no such protective effect was developed by bone 
marrow cells of leukaemic mice that received mitoxantrone (0.75mg/Kg) 
24 hours before the mice became moribund with leukaemia (Figure 143). 
The I.C50 of the treated normal bone marrow cells was 60ng/m l (Figure 
143) as compared to 6ng/m l for untreated NBM cells.
Figure 144 (mean of 3 experiments) shows a comparison of responses of 
bone marrow cells of mitoxantrone treated (0.4m g/kg) and untreated 
normal mice to Ara-C alone or in combination w ith mitoxantrone 
(1.2ng/m l) in vitro. Bone marrow cells from treated mice were less 
sensitive to Ara-C alone as compared to untreated NBM cells. Similarly, 
they were markedly less sensitive to the combination of Ara-C and 
mitoxantrone. Similar insensitivity to mitoxantrone alone or in 
combination w ith Ara-C was observed (Figure 145)(mean of 3 
experiments).
The decreased sensitivity to mitoxantrone persists for 30 days after 
mitoxantrone administration. The responses of bone marrow cells to 
Ara-C alone or in combination with mitoxantrone from mice treated 30 
days previously with 2 doses of mitoxantrone (0.75mg/Kg) are shown in 
Figure 146. Response to Ara-C alone was unchanged, however, when 
mitoxantrone (1.2ng/m l) was added, the cells became markedly less 
sensitive to the combination as compared to untreated cells (Figure 146).
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140 1 SA7HD( treated with mitox0.75mg/Kg,ln vivo for 24hrs.) 
Norm mice treated with mitox0.75mg/Kg for 48hrs.120 -
o  100 -
80 -
40 -
20 -
10.1 1 100 1000
Concentration of mltoxantrone(ng/ml)
Fig. 143: A comparison of in vitro mitoxantrone sensitivity 
of in vivo pretreated normal and leukaemic bone marrow cells.
Cytotoxicity was determined using (3H)-TdR uptake assay in vitro.
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Fig .14 4 : A comparison o f in v itro  m itoxantrone sen s itiv ity  
o f in v ivo  m itox (0  4mg /k g ) pretreated  and untreated NBMcells. 
C yto to xic ity  was determined using the (3H )-thym id ine  uptake assay %
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The treated cells were also less sensitive to mitoxantrone alone and in 
combination w ith Ara-C (1.2ng/m l) (Figure 147). The I.C 50 of 
mitoxantrone, against treated cells was still unchanged at 60ng/m l, while 
that of untreated cells was 6ng/m l (Figure 147).
When mice were treated with a higher dose of mitoxantrone (2mg/kg), 
the bone marrow cells of such mice were as sensitive as bone marrow 
cells from untreated mice to Ara-C alone or in combination w ith  
mitoxantrone (1.2ng/m l) (Figure 148), S im ilarly, sensitivity to 
mitoxantrone alone or in combination with Ara-C (1.2ng/m l) was 
unchanged in the treated bone marrow cells (Figure 149). Similar 
responses as described for 2 m g/Kg were observed in bone marrow cells 
of mice treated w ith 3m g/K g mitoxantrone. Thus, no change in 
sensitivity was observed in response to Ara-C w ith or w ithout 
mitoxantrone (Figure 150) and mitoxantrone with or without Ara-C  
(Figure 151). In  addition, there was no difference in IC 50 of 
mitoxantrone against treated and untreated normal bone marrow cells. 
The protective effect developed by bone marrow cells following 
treatment of normal mice with mitoxantrone (0.75mg/Kg) lasts up to 60 
days after the last mitoxantrone injection.
Figure 152 shows the response of such bone marrow cells to Ara-C 
alone or in combination with mitoxantrone (1.2ng/m l) indicating that 
they were less sensitive as compared to untreated(NBM) cells. Similarly, 
Figure 153 shows response of the treated cells to mitoxantrone as 
compared to untreated cells. Again the IC 50 of mitoxantrone against 
treated cells was 60ng/m l white IC50 against untreated cells was 6ng/m l. 
Thus, the protective effect begins from as early as 48 hours following 
administration of mitoxantrone ( 0.75mg/Kg) and lasts for as long as 60 
days.
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m ito x + ara c d  .2ng/m 1)(untreated NBM)
mitoxCin v ivo  m ito x(0 .4m g /K g ) trea ted  NBM) 
lto x + ara c (1 .2 n g /m l)(tre a te d  NBM)C 150-
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Fig. 145: The response of in vivo treated and untreated NBM cells to In vitro treatment v ith  mitox alone or in combination v ith  arac. Cytotoxicity vas determined using the (3H)-thymidine uptake assay.
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Fig. 1 4 6 : A comparison o f the response o f in v ivo  m itox trea ted  and untreated NBi
cells to  in v itro  treatm ent v ith  combination o f arac and m itoxantrone. 
The pretreated  mice received 2  doses o f m ito x (0 .75m g /K g ) 3 0  days previously.
5.3.4 Response of Myeloid Progenitors from In Vivo Treated Bone 
Marrow Cells to Mitoxantrone Treatment In V itro: Bone marrow cells 
of mice treated with mitoxantrone (0.4, 0.75 and 2m g/Kg ) in vivo were 
tested for the response of myeloid progenitors to subsequent
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mitoxC In v ivo  treated  NBM cells ) 
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Fig. 1 4 7 : The response o f in v ivo trea ted  and untreated NBM cells  
to In v itro  treatm ent v lth  m ltox alone or in combination v ith  arac.
The pretreated  mice received 2 doses o f m lto x(0 .75m g /K g ) 3 0  dags previously.
120 aracCin v ivo  m ltox(2m g /K g ) trea ted  NBM cells ) 
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Fig.148:The response of in vivo mltox(2 mg/Kg) treated NBM 
cells to in vitro treatment v ith  arac alone or in combination v ith  mltox 
Cgtotoxicitg vas monitored using the <3H)-thymidine uptake assay.
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Fig.149: The response of in vivo mltox (2mg/Kg) treated NBM cells 
to In vitro treatment with mitox alone or In combination v ith  arac. 
Cytotoxicity was determined using the (3H)-thymidine uptake assay.
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Fig.150:The response of In vivo mitoxC3mg/Kg) treated NBM cells
to In vitro treatment v ith  arac alone or in combination v ith  mitox. 
Cytotoxicity vas determined using the (3H)-thymidine uptake assay
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Fig.151: The response of in vivo mitox(3mg/Kg) treated NBM cells 
to in vitro treatment v ith  mitox alone or in combination v ith  arac. 
Cytotoxicity vas determined using the (3H)-thymidine uptake assay
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Fig.15 2 :  The response o f in v ivo  m itoxantrone trea ted  and untreated NBM 
cells to in v it ro  treatm ent v ith  arac alone or in combination v ith  m itoxantrone. 
Norm mice v e re  pretreated  v ith  2  doses o f m ito x (0 .75m g /K g ) 6 0  days previously.
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Flg.153: A comparison of the response of In vivo mitoxantrone treated 
and untreated NBM cells to in vitro treatment with mitoxantrone.
Norm mice received 2 doses of mltox(0.75mg/Kg) 60 days previously.
mitoxantrone treatment in vitro. Figure 154 shows that in mice treated 
w ith m itoxantrone(0.4mg/Kg or 0.75m g/Kg), myeloid progenitors 
apparently exhibit decreased sensitivity to subsequent mitoxantrone 
treatment in vitro . In  bone marrow cells of mice that received two 
doses of mitoxantrone( 0.75mg/Kg) , the protective effect was evident 
even after 60 days following the last mitoxantrone injection.
It is noteworthy that bone marrow cells of mice cured of leukaemia by 
mitoxantrone treatment also exhibit protective effect towards subsequent 
mitoxantrone exposure in vitro. In addition, doses of mitoxantrone (2- 
3mg/kg) that resulted in loss of protective effect by bone marrow cells of 
treated normal mice were also toxic to leukaemia bearing mice (Table 1). 
Moreover, bone marrow cells of a mouse dying in remission from drug 
related toxicity lacked protective effect towards mitoxantrone exposure 
in vitro. However, although 2m g/Kg administered to normal mice 
resulted in loss of protective effect, bone marrow cells of mice cured of
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leukaemia with identical dose of mitoxantrone (2m g/Kg) (Table 1) still 
developed protective effect against subsequent mitoxantrone exposure 
in vitro (Figure 86).
160 -, untreated NBM cells 
mitox(in vivo, 0.4mg/Kg, pretreated NBM 
mitox (0.75mg/Kg, 60 days previously) 
mltox(2mg/Kg)
Ç  1 20 -
1 0 0 -
\
I I  I I I I I■I ■ I l l l
.001 .01 .1 1 10 
Concentration of mltoxantrone(ng/ml)
Fig. l54:The resp of myeloid progenitors of Invlvo treated and untreated 
NBM cells to subsequent treatment with mitoxantrone In vitro.
Norm mice were pretreated with 0.4, 0.75, or,2 mg/Kg mitoxantrone.
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6. DISCUSSION
CHAPTER SIX
6. DISCUSSION
6.1 Choice of In  Vitro Drug Concentrations and Mode of Drug 
Exposure
The choice of drug concentrations for use in in vitro assays is a difficult 
one. How ever, generally either one-tenth the peak plasma 
concentration or the concentration x time ( C x T) is used. The C x T of 
an anticancer drug is one of the most important pharmacokinetic 
parameter in determining drug efficacy and toxicity (Alberts, Chen and 
Salmon, 1980). The peak plasma concentration of Ara-C following I.V  
administration of lOOmg/m^ in humans was lOfxg/ml and the C x T was 
340 - 430ng h r/m l (Alberts, Chen and Salmon, 1980). Similarly, Spiro et 
al 1981 have determined that 38ng/m l Ara-C would inhibit 90% of 
human m yeloid colony form ing cells in vitro. The C x T for 
mitoxantrone was 36ng h r/m l (Alberts et aL 1985) and one-tenth peak 
plasma range concentration lies in the range of 5 - lO ng/m l. The 
concentrations of the two drugs used in this study (0.12 - 120ng/ml) lie 
between one-tenth and peak plasma concentration and C x T values 
reported above.
The next decision following determination of the drug concentrations 
was the mode of drug exposure. Again, it is difficult to determine what 
mode of drug exposure - one hour pulse or continuous incubation - 
mimics the clinical situation. One hour pulse exposure can lead to 
falsely high resistance rates for cycle specific drugs. However, it has been 
stated that one hour treatment approximates serum peak levels after 
bolus administration (Drewinko et al. 1981). On the other hand, 
continuous drug exposure may yield falsely high sensitivity rates. In  
one study, up to 92% correlation with in vivo result was obtained when
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continuous incubation was employed as opposed to 71% correlation 
with one hour pulse (Park et ah 1983). Both types of drug exposure have 
been employed in this study.
After deciding drug concentrations, mode of drug exposure, it was 
necessary to determine next, the type of assay to be employed in 
assessing drug-induced cell kill. As no single assay is perfect it is better 
to use different methods that provide complementary information 
rather than a single method (Rosenblaum et al 1980). In this study both 
clonogenic and nonclonogenic assays have been employed. It has been 
suggested that because the dose-limiting toxicity of cytotoxic drugs is 
toxicity to normal tissues, it is necessary to compare drug effects on both 
leukaemic and normal bone marrow cells (Park et aL 1983). Therefore, 
effects of both cytosine arabinoside (Ara-C) and mitoxantrone (mitox) on 
leukaemic cell lines and normal (murine) bone marrow cells were 
determined. In  clinical practice, combinations of drugs rather than any 
single drug are used in the treatment of leukaemia. In this study, the 
effect of combinations of Ara-C w ith mitoxantrone or mitoxantrone 
with Ara-C were monitored. However, it has been emphasized that it 
was not important whether a particular drug combination was additive, 
synergistic or subadditive. What was important was whether there was 
a differential effect between tumour and normal tissue (Brown and 
Rasey, 1980).
Most in vitro drug effects on tumour cells are investigated using cell 
culture techniques. The latter provide a rapid, and economical method 
of determining the effects of antitumour agents. However, a major 
drawback is extrapolating in vitro effects to the situation in vivo. 
Whereas cells in culture usually grow exponentially, a large fraction of 
tumour cells in vivo are in quiescent (Go) state. The latter are usually 
considered less sensitive than proliferating cells to the lethal activity of
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most antitumour drugs (Drewinko et al. 1981). The difference in cell 
killing efficacy between proliferating and stationary cells is generally 
attributed to the ability of quiescent cells to repair drug-induced damage 
before it became a fixed lethal event at mitosis (Ikebuchi et aL 1988).
6.2 Effect of Serum on Drug Activity In Vitro
Serum is usually added to media for growing cells in vitro. In  this 
study, foetal calf serum was employed. It has been reported that the 
interaction of antitumour drugs and serum albumin could have a major 
influence on drug pharmacology and efficiency (Takahashi et aL 1980). 
Cytotoxic agents were divided into three categories depending on effect 
of serum on their activity : (a) compounds such as adriamycin and 
mitomycin C whose biological activities were decreased in the presence 
of serum albumin; (b) those that were unaffected such as Ara-C, 
actinomycin D, fluorouracil and (c) those whose biological effects were 
increased in the presence of serum eg bleomycin, vincristine and 
vinblastine (Takahashi et al. 1980). In this study, serum did not appear 
to affect mitoxantrone cytotoxicity in vitro (Figure 9).
6.3 Differential Staining Cytotoxicity (DiSC) Assay
Staining of cells w ith vital dyes has been traditionally used as an 
indicator of cell death following cell membrane damage (Roper and 
Drewinko, 1976). However, care must be exercised since the dye could 
be excluded by both living and reproductively dead cells .
The timing suggested by Weisenthal et aL (1983 b) (4 days) was adopted ( 
in this study) in order to allow for drug-induced damaged cells to 
become membrane permeable while at the same time minimising loss 
of control viability.
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One problem of the cell viability (DiSC) assay is that cells that survive 
drug treatment may continue to proliferate during the time it takes 
lethally damaged cells to lose membrane integrity. Thus, by the time 
dead cells exclude the dye, the surviving cells may have proliferated to 
such an extent that the percent cell k ill is grossly underestimated. In  
addition, some lethally damaged cells may undergo early disintegration 
so that they w ill not be available to stain with the dye at the end of the 
assay. The use of an internal standard (of Pigeon red cells in this study) 
has overcome the problem of proliferation of surviving cells and /  or 
disintegration of damaged cells in culture. An elegant example from  
Weisenthal et aL (1983b) serves to illustrate the significance of including 
an internal standard of duck red blood cells (DRBC's).
The criteria for an in vitro response in the dye exclusion assay was 
defined as reduction of the viable tumour cell number to 30% or less of 
the control value (Weisenthal et aL 1983b). Similarly, a cut off point of 
30% tumour cell viability (TCV) was used by Bosanquet et ah (1983) in in 
vitro - in vivo correlations. Using these criteria, none of the leukaemic 
cell lines studied (SA2, SA7 and SA8) was sensitive to Ara-C below 
120ng/ml (Figures 2, 4 and 6). Even when mitoxantrone (1.2ng/ml) was 
added, no increased effect was observed. Similarly, the SA2 line was 
sensitive only to the highest concentration of mitoxantrone used 
(120ng/m l) (Figure 3), while the SA7 and SA8 (Figures 5 and 7 
respectively) seem more sensitive at lower concentrations. It  has been 
suggested that TCV below 25% would predict for partial or complete 
response in vivo (Bosanquet et al. 1983).
Although there was qualitative agreement between cell viability assay 
and cell number assessment using electronic particle counter in this 
study, there were quantitative differences particularly w ith the SA2 cell 
line (Figures 2 and 3). This may be because the electronic particle count
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probably included incompletely lysed dead cells which stain with fast 
green (Weisenthal et al, 1983 b).
Some of the drawbacks of the dye exclusion method include the fact that 
it is difficult to distinguish between tumour and nontumour cells 
particularly in bone marrow preparations. Also, the assay may be 
incapable of detecting cell growth inhibition which is not followed by 
cell death (Weisenthal et aL 1983). This is a potential problem with cell 
cycle specific agents. The vital dye assay based upon the ability of 
"viable" cells to exclude trypan blue was found in one report to indicate 
cytotoxic effect of treatment for only one of four drugs tested. 
Adriamycin, cisplatin and vincristine elicited an insignificant reduction 
(<5%) in the proportion of viable cells, even though these drugs reduced 
survival by more than one log when measured by a clonogenic assay 
(Rupniak and H ill, 1980). However, Weisenthal et aL (1983 b) have 
cautioned against labelling the results of either assay as "correct" or 
"incorrect" and care is needed in comparisons of two different assays. It 
is possible that the more sensitive assay may overestimate cell k ill or 
else the less sensitive assay may underestimate cell kill. Rather than a 
direct comparison of two assays using the same drug concentrations, 
each assay may require different range of drug concentrations.
The advantages of a dye exclusion assay include simplicity, and the fact 
that it can be employed to assess drug induced cytotoxicity in quiescent 
cells (Bosanquet et ah 1983). In  comparison to cloning assays which only 
work with 25% of specimens, the assay can be used to determine drug 
effect in in vitro nongrowing neoplasms such as chronic lymphocytic 
leukaemia and the assay has found wide application in other tumour 
systems as well. There are correlations reported w ith results of both 
clonogenic assay and clinical response (Bosanquet et ahl983: Durkin, 
Ghanta and Hiramoto, 1983). In addition, because results are available
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in a shorter time (as compared to colony assays), it may be used to 
monitor patient's response in the clinic.
6.4 Tritiated Thymidine Uptake Assay
The rate of nucleic acid synthesis has been used as a measure of the 
proliferative activity of a tumour. Therefore, the ^HTdR uptake assay 
can be employed to determine the proliferation dependent cytotoxic 
effect of antitumour drugs (Volm, Maas and Mattern, 1980). It  is 
assumed that the amount of radioactive precursor (eg ^ H T d R )  
incorporated by the cells is proportional to the extent of DNA synthesis. 
And zero incorporation of ^HTdR means zero viability (Freshney, Paul 
and Kane, 1975). It has been suggested that exposure to drug in this assay 
should cover at least two cell cycle times. And conditions must be such 
that control cultures maintain logarithmic growth throughout the assay. 
Finally, sufficient time must be allowed for delayed cytotoxicity to be 
expressed (Freshney, Paul and Kane, 1975). In this study, leukaemic 
bone marrow cells or normal bone marrow cells were pulsed with  
[3H]TdR, four days following either continuous incubation or 1 hour 
pulse with drugs.
The ability of an in vitro assay to predict in vivo activity depends on the 
criteria used to define in vitro sensitivity. In one study, the cut-off level 
of drug sensitivity was arbitrarily defined as the concentration inhibiting 
50% of ]-thymidine uptake (I.C50). It  was claimed that this level
roughly corresponded with 50% colony inhibition with many different 
types of cytotoxic agents. Therefore, if the I.C50 of the test drug is lower 
than the pharmacologically achievable plasma concentration, the drug is 
considered as being active (Nakayama et aL 1989). Applying this criteria 
to the present results, both Ara-C and mitoxantrone would be expected 
to be active in vivo since they inhibited [3H]TdR uptake in the
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leukaemic cell lines in vitro using concentrations that were below peak 
plasma concentrations of the drugs in humans. However, in order for 
the assay to predict for clinical responses in humans, a stricter criteria 
was suggested. Greater than 80% suppression of ^HTdR uptake was 
employed as a criteria in one study (Maddox et aL 1984).
A common finding in this study was that very low concentrations of 
both Ara-C and mitoxantrone stimulated radioactive precursor uptake 
(to above control levels) rather than inhibited ^HTdR uptake following 
both 1 hour pulse or continuous incubation w ith either of the two 
drugs (Figures 15, 20 and 39-43 respectively). This was also observed by 
other workers who found that very low concentrations of daunorubicin 
and 6-thioguanine stimulated precursor uptake in some blast cells using 
both thymidine and leucine uptake assays. (Sanfillipo et al. 1981). A t 
low concentrations (10"^0 - lO '^M ) adriamycin causes stimulation of 
growth. Early work (Wang et aL 1972) demonstrated that adriamycin 
stimulated [^H]-thym idine incorporation into D N A  at low doses. 
Similarly, Roper and Drewinko, 1976 also noted over 50% stimulation of 
DN A  synthesis by low concentrations of adriamycin. In  all these cases, 
higher concentrations resulted in cytotoxicity. Although adriamycin 
causes up regulation of receptors for a growth-stimulating substance 
(Zuckier and Tritton, 1983) this effect occurs only at concentrations 
which cause cytotoxicity and thus w ill probably not explain growth 
stimulation by the drug (Vichi and Tritton, 1989). It has been suggested 
that cytotoxicity is the opposing counterpart to growth stimulation and 
common cellular mechanisms may govern both processes (Vichi and 
Tritton, 1989).
The limitations of the ^HTdR uptake assay include the following facts: 
different batches of animal sera contain different amounts of 
endogenous thym idine which w ill compete w ith  [3H]TdR for
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incorporation into newly synthesized DNA. Many suppliers of serum 
do not provide an estimate of the concentration of thymidine in the 
serum (Larcom and Smith, 1988). Also ^HTdR could be converted to 
thymine during the incubation period. The cells being examined in 
short term culture may not be representative of the whole in vivo cell 
population(Maddox, 1984). Non-tumour cells for example, stromal cells 
that are also proliferating may incorporate radioactive label 
(Twentyman, Walls and Wright, 1984).
Changes in [3H]TdR uptake may be either due to a change in the number 
of cells taking up the label or the amount of thymidine incorporated by 
each cell as the two cannot be distinguished using scintillation counting. 
In  addition, there may be drug-induced alteration in nucleoside 
transport. Thym idine transport through cell membrane seem 
susceptible to attack by agents capable of alkylating sulfhydryl groups 
involved in transport reaction (Maurer, 1981). Non-dividing cells that 
are undergoing D N A  repair could incorporate exogenously added 
[3H]TdR and this w ill obviously not correlate w ith cell division. 
Furthermore, the re-utilisation of ^HTdR following catabolism of DN A  
from dead cells is a significant process in rat bone marrow (Maurer, 
1981). It has been reported that exogenously administered [3H]TdR is 
incorporated exclusively via the salvage pathway (M aurer, 1981). 
However, the salvage pathway of D N A  synthesis is important for 
proliferation of tumour cells (Hirose et ah 1987). The salvage pathway is 
important for the supply of nucleosides for DNA synthesis in some 
tumour cells since nucleosides reverse the toxic effects of some drugs e.g 
methotrexate (Hirose et aL 1987).
The main advantages of the [3H]-thym idine uptake assay include 
simplicity, speed and it is less tedious than comparable assays such as 
autoradiography. The [3H]-thymidine uptake assay has been employed
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to determine the presence of acquired drug resistance in tumours. 
Leukaemic cells from  patients w ith  resistant disease showed 
significantly decreased sensitivity to Ara-C, daunorubicin and 6- 
thioguanine alone or in combination when response was monitored 
using [3H]TdR uptake assay (Viano et aL 1986). It has been suggested that 
if colony size was reduced by drug treatment, it may not be noticeable in 
a clonogenic assay, whereas in an isotope uptake assay it would be 
expected to result in reduced ^HTdR uptake (Twentyman, Walls and 
W right, 1984).
S im ilarly, a ^HTdR uptake assay correlated with GM-CFC assay in 
mouse bone marrow cells (Horak, 1983). An increase in ^ H T d R  
incorporation reflected an increase in both progenitor numbers and 
their proliferative status. However, Twentyman, Walls and W right, 
(1984) have warned that it should not be expected that two assays w ill 
necessarily produce identical dose-response curves.
In this study, the [^HJ-thymidine uptake assay was employed to 
determine the responses of leukaemic cell lines (81287, 10.12, 10.13, SA2, 
SA7 and SA8) and normal bone marrow (NBM) cells to continuous 
incubation with Ara-C, mitoxantrone alone or in combination.
6.4.1 Continuous Incubation with Ara-C
Increasing the concentration of Ara-C caused increased inhibition of 
[^H]-thymidine uptake in all leukaemic cell lines and NBM cells using 
the continuous incubation method. This is in agreement with a report 
by Heinemann et aL (1988) showing that inhibition of DN A  synthesis 
was linearly related to the intracellular concentrations of Ara-C. Even 
very low concentrations lO ng/m l kills NBM  cells w ith prolonged 
exposure (Greenberg, Vernkersen and Mosny, 1976). A t very low Ara-C 
concentrations the rate of Ara-C accumulation w ithin cells was
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dependent on rate of transport of the molecule across cell membrane.
However, at high concentration the phosphorylation capacity of the 
cells determines the net uptake (White, Wrathmel and Capizzi, 1987).
The responses of 81287 leukaemia to both Ara-C and mitoxantrone 
changed with transplantation. Similarly, spleen cells appeared to be 
more sensitive to these drugs as compared to bone marrow cells. This 
may be as a result of different subpopulations of leukaemic cells residing 
in the two haematopoietic tissues. Whether the decreased sensitivity to 
Ara-C with transplantation of the 81287 cell line was due to a change in 
number of cells in S- phase or simply due to variation between 
experiments can only be speculated. It has been reported that sensitivity 
to Ara-C is not simply dependent on the number of cells in S-phase.
This is because it must first be taken up by cells, phosphorylated and 
incorporated into DN A  before any cell killing effect w ill be manifested 
(Rustum and Preisler, 1979). In  addition, the cytotoxic effect of Ara-C 
must be interpreted with caution. This is because where isotopically 
labelled thymidine is used to follow D NA synthesis in the presence of 
Ara-C, erroneous values may arise due to competition between Ara-C 
and thymidine for transport (Mulder and Harrap, 1975). Despite this 
drawback, however, Ara-C sensitivity of cells from patients with  
leukaemia correlated with clinical outcome (Preisler et aL 1984).
The most noteworthy finding regarding continuous incubation w ith  
Ara-C in this study, it its lack of differential cytotoxicity. Ara-C was not 
more toxic to the leukaemic cell lines as compared to normal bone 
marrow cells (compare Figures 30, 32 and 34 with Figure 36). If anything, 
normal bone marrow cells seemed slightly more sensitive as compared 
to leukaemic cell lines (SA2, SA7 and SA8). This is supported by a study 
by Singer and Lynch, (1987). The beneficial effect of Ara-C in the clinic 
may be due to its ability to inhibit self renewal of leukaemic stem cells
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(McCulloch et al. 1988). And the fact that the differential effect of 
chemotherapy is as a result of differences in recovery between normal 
and leukaemic cells (Singer and Lynch, 1987).
6.4.2 Continuous Incubation with Mitoxantrone
Leukaemic bone marrow cells from the cell lines 81287,10.12,10.13, SA2, 
SA7, SA8 and normal bone m arrow cells were treated w ith  
mitoxantrone and the cytotoxicity produced determined using [3H]TdR 
uptake assay. As was observed with Ara-C, the responses of 81287 cell 
line changed with transplantation. Sensitivity apparently decreased 
with passaging although this was not marked with mitoxantrone. In  
addition, spleen cells were slightly more sensitive than bone marrow 
cells. Of the high cell dose transplant leukaemias (SA2, SA7 and SA8), 
the SA2 cell line seem most sensitive to mitoxantrone, followed by SA8 
and lastly the SA7 cell line. No obvious explanation for this difference 
in sensitivity can be offered. As mitoxantrone enters cells by passive 
diffusion, it is unlikely that a difference in drug uptake can account for 
the differences in sensitivity (Haugstad, et aL 1987). The cytotoxic effect 
of mitoxantrone does not depend on the cell type or whether the cells 
are in proliferative or stationary phase, although it is apparently more 
effective during late 'S' Phase (Poirier, 1986). It  binds D N A  by 
intercalation and the degree of D N A  strand breaks correlates w ith  
cytotoxicity (Alberts et al. 1985). In all leukaemic cell lines and normal 
bone marrow cells studied, mitoxantrone was more potent than Ara-C 
in vitro using comparable doses. However, H ill (1987), has cautioned 
against such comparisons without taking into account the doses of the 
drugs used clinically and also the possibility of metabolism or 
inactivation which may occur in vitro. Except on the SA2 cell line,
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mitoxantrone did not exhibit selective toxicity on leukaemic cell lines as 
compared to normal bone marrow cells in this study. This is in 
agreement w ith the study reported by Schozel, Van Putten and 
Lowenberg, (1986), as well as Buick; et aL (1979) and Fountzilas et al; 
(1986). In  one of the leukaemic cell lines (SA7), there was no marked 
difference between one hour pulse with mitoxantrone and continuous 
incubation w ith mitoxantrone. This is in agreement w ith the report 
that there was little or no dependence of cytotoxicity on duration of drug 
exposure (Johnson et a l, 1983).
From these results, it would appear that mitoxantrone may be more 
potent than Ara-C in vivo. However, the efficacy of each drug w ill 
depend on the overall balance between antileukaemic effect and toxicity 
particularly against normal bone marrow cells.
6.4.3 Drug Combinations and One Hour Pulse Treatments 
When mitoxantrone (1.2ng/m l) was added to Ara-C (0.12-120ng/ml), 
there was additive inhibition of [3H]TdR uptake in the vast majority of 
cell lines (81287T6, SA7, SA2, SA8, NBM), slight antagonistic effects in a 
few cell lines (SA7FT5, SA8FT14) and in only one instance was 
synergism observed (81287T10, Figure 20). In  the latter case, the 
sensitivity of the leukaemia was changing with transplantation and 
therefore this observation may or may not be manifested w ith  
subsequent passaging. Similar additive to slightly antagonistic effects 
were observed when Ara-C (1.2ng/ml) was added to mitoxantrone (0.12- 
120ng/m l). It  is possible to suggest explanation for the absence of 
synergy or consistent additivity with these drug combinations. If a drug 
alone completely inhibits D N A  synthesis, there is no possibility of a 
synergistic effect by a second drug. Both mitoxantrone and Ara-C have 
the same molecular target : inhibition of D N A  synthesis via
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intercalation and inhibition of incorporation of nucleotides respectively. 
Viano et aL(1986) have suggested similar mechanism to explain the 
effect of combinations of daunorubicin, Ara-C and 6-thioguanine (6-TG). 
The most prominent observation regarding one hour pulse w ith Ara-C 
followed by addition of mitoxantrone either immediately or 24, 48 or 72 
hours later was that SA7 and NBM were subject to the effects of drug 
scheduling, while SA2 and SA8 were unaffected. Synergistic effects were 
observed with SA7 and NBM cells when mitoxantrone was added 24 
hours rather than immediately following one hour pulse w ith Ara-C. 
This may be because the cytotoxicity of Ara-C is highly schedule 
dependent (Heinemann et al; 1988). For example, two 3-hour exposure 
of HL-60 cells to Ara-C separated by a drug-free interval were more 
cytotoxic than continuous 6-hour exposure (Powell et al. 1988). 
Sim ilarly, Kallman et ah (1989) have suggested that the effects of a 
second drug may depend on the cell cycle status of the cells surviving 
the first treatment. In  addition, it was reported that killing of cells in S- 
phase by Ara-C may be followed by recruitment and syncronisation of 
the surviving cells (Colly, Peters and Willemze, 1986).
The effects of mitoxantrone and Ara-C were evaluated in vitro using the 
HL-60 cell line in one study. The cells were exposed for one hour to each 
drug either simultaneously or sequentially (up to 28 hours interval), 
washed free of the drug and seeded in replicate plates. Colony growth 
was observed on day 7. Simultaneous exposure of the two drugs 
produced additive cell kill. Ara-C followed by mitoxantrone produced 
time-dependent synergism. Up to 99% increase in cell k ill was observed 
when mitoxantrone was added 8 hours or longer following Ara-C. 
Reversal of the order of exposure i.e mitoxantrone followed by Ara-C 
did not produce time-dependent synergism (Fountzilas et aL 1983). 
Similarly, in this study, pulsing NBM and SA7HD leukaemic cells with
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Ara-C for one hour followed by addition of mitoxantrone after 24hrs 
was more cytotoxic as compared to when mitoxantrone was added 
immediately following a one hour pulse w ith Ara-C. A  similar 
schedule-dependent effect was found to follow  combinations of 
vincristine and methotrexate. However, it must be borne in mind that 
clinically active drug combinations do not necessarily produce additivity 
or synergism in vitro nor in vivo. Conversely, synergistic combinations 
in vitro may not always be therapeutically more effective (Kano et al: 
1988).
6.5 Autoradiographv
The labelling indices of the leukaemic cell lines SA2, SA7 and SA8 were 
determined both in the presence and absence of mitoxantrone. In  all 
cases, there was a qualitative correlation between labelling index 
inhibition monitored using autoradiography and [3H]TdR uptake 
inhibition measured using scintillation counting. A similar correlation 
was reported by Lucke et aL (1986). However, at low concentrations of 
mitoxantrone in this study, there was no close correlation between 
inhibition of labelling index and [3H]TdR uptake suppression 
determined using scintillation counting. S im ilarly, Roper and 
Drewinko, (1976) reported that the labelling index method either 
overestimates or underestimates the degree of cell k ill produced by 
adriamycin and BCNU respectively. And the labelling index method 
was found to consistently underestimate cell killing by methotrexate 
(Rupniak and H ill, 1980). In  addition, labelling index determination is a 
tedious procedure. Moreover, a misleadingly high labelling index 
maybe obtained as cells killed by a drug undergo degeneration leaving 
only undamaged cells to be recognised and enumerated (Weisenthal, 
1981). However, unlike scintillation counting, the labelling index
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method gives information on which cells are labelled in a tissue 
composed of different cell types (Aherne, Camplejohn and W right,
1977). In  addition, the labelling index does provide a guide to the 
proliferative activity of a cell population.
6.6 Granulocyte-Macrophage Colony Forming Cell (GM-CFC) Assay 
The responses of normal bone marrow myeloid progenitor cells to one 
hour pulse and continuous incubation treatments w ith Ara-C and 
mitoxantrone were monitored in vitro. In all doses and schedules 
studied, mitoxantrone was much more toxic to normal bone marrow 
cells as compared to Ara-C. One hour pulse w ith mitoxantrone 
produced virtually the same effect as continuous incubation with Ara-C 
using comparable doses in vitro. In  support of this observation is the 
report that mitoxantrone causes greater myelosuppression than even 
doxorubicin (Okunewick, Buffo and Kociban, 1985). In  v itro  drug- 
induced inhibition of GM-CFC has been reported to correlate with in  
vivo myelosuppression (Hug et al: 1984). It  has been established that 
bone marrow represents the dose lim iting tissue for most cytotoxic 
agents. It has been stated that only agents that affect tumour cells more 
profoundly than bone marrow cells can effectively reduce tumour 
burden (Hug et al. 1984). It has been reported that the cytotoxic effects of 
Ara-C on mouse and human GM -CFCs were in general similar 
(Greenberg, Vankersen and Mosney, 1976). Ara-C was not specifically 
more toxic to acute myeloid leukaemia colony forming units (AM L- 
CFU) as compared to GM-CFC ( Greenberg, Vankersen and Mosny, 1976; 
Singer and Lynch, 1987) . However, Ara-C was reported to exhibit 
increased specificity for chronic-myeloid leukaemia colony forming 
units (CML-CFU-C) as compared to GM-CFC. The heightened sensitivity
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of CML-CFU-C to Ara-C was likely to be as a result of either differences 
in drug uptake or phosphorylation but not due to number of cells in S- 
phase. The lack of differential sensitivity to hydroxyurea, a phase- 
specific agent supports this claim (Spiro et aL 1981). The beneficial effect 
of Ara-C in AM L may be due to the ability of the drug to suppress not 
only terminal division but also self-renewal of leukaemic stem cells. 
Self renewal inhibition by Ara-C is determined using suspension 
culture, and correlates better w ith clinical outcome as compared to 
inhibition of terminal division in methylcellulose (McCulloch, 1988). 
Mitoxantrone like Ara-C is myelosuppressive in humans. It also does 
not display differential toxicity towards AML-CFU as compared to GM- 
CFC (Schozel, Van Putten and Lowenberg, 1986; Buick et al, 1987; 
Fountzilas et aL 1986).
Hug et aL 1984, have suggested that the GM-CFC assay could be 
employed to determine appropriate drug concentrations for use in new 
drug screening against tumour cell lines in vitro. Thus, in vitro tests 
meant to predict clinical response should employ dose ranges based 
rationally on bone marrow tolerance. In this way false positive 
predictions from testing too high concentrations and false negative 
predictions from testing at very low concentrations may be avoided 
(H ill, 1987).
A  major problem with the colony assay is that normal cell to cell contact 
may be minimal. And colony growth was found to show marked 
variation even between incubators. In addition, there could be 
significant loss of water from the system during incubation. When a 
colony assay was employed to measure the sensitivity of tumours to 
drugs, clinical correlations have been obtained, making many authors 
suggest that it should be the standard with which other assays are to be 
compared (Salmon 1983; Mattox and Von Hoff, 1980; Chang, 1983; Selby,
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Buick and Tannock, 1983; Von Hoff, 1983A). However, the caution 
advised by Weisenthal and Lippman (1985), must be borne in mind. 
These include poor reproducibility of test results between different 
laboratories and subjectivity of colony counts. In addition, there is a 
possibility that tumour stem cells may be nondividing in vivo while 
cells forming colonies are necessarily dividing cells. Lastly, clonogenic 
assays measure cell k ill over a narrow log range while meaningful 
clinical responses require m ultiple-log cell k ill (Weisenthal and 
Lippman, 1985).
6.7 Responses of Leukaemic Cell Lines to Growth Factors Monitored In 
V itro
W EHi myelomonocytic leukaemia conditioned medium and L-cell 
conditioned medium were used singly and in combination to stimulate 
the in vitro proliferation of leukaemic cell lines in this study. The 
W EH i-3 cell line synthesizes m ulti- colony stim ulating factor 
(Interleukin-3, IL-3) (Metcalf, 1985). Two distinct forms of IL-3 have been 
purified from WEHi-3-conditioned medium. The two have identical 
amino acid sequence but one is shorter by six amino acids at the N - 
terminal. The relation between the two is not fu lly  understood 
although the full length form may be more active (M urthy et aL 1989). 
The L929 fibroblast cell line is a crude source of macrophage colony 
stimulating factor (CSF-I; M-CSF) (Fragnell et aL 1988). When murine 
bone marrow cells were incubated with ^^I-CSF-1 for 6 hours, 50-70% of 
myeloblasts, promyelocytes and small numbers of late granulocytic cells 
were labelled (Shadduck et al. 1983). The primary leukaemic cell line 
81287 (Figures 70 and 71) and low cell dose transplant of SA7 cell line 
(SA7FT5, Figures 74 and 75) were not very responsive to W EHi, L929 or 
their combinations in vitro. In  contrast, the high cell dose transplant
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SA8 cell line was relatively more responsive to single and combinations 
of W EHi and L929 conditioned media (Figure 76). This difference in 
sensitivity between low cell dose and primary leukaemia on one hand 
and high cell dose passage leukaemia on the other, may be due to the 
relatively closer sim ilarity in morphology between low cell dose 
transplant and primary cell lines (Hepburn et aL 1987). As was observed 
in this study, acute myeloid leukaemias respond to growth factors by an 
increase in proliferation. Because of the intrinsic abnormalities in 
leukaemias, CSF-stimulated proliferation results in self- generative 
divisions rather than divisions leading to the production of 
differentiating progeny (Metcalf, 1985). This increase in proliferation is 
usually manifested by an increase in DN A  synthesis (Salem et ah 1989). 
A dose-response relationship exists between CSF concentration and 
magnitude of proliferation (Metcalf, 1985).
Responses of Leukaemic Cell Lines to Combinations of Growth Factors 
Despite their lineage specificities, colony stimulating factors (CSFS) do 
produce synergistic effects when they are combined (Falk and Vogel,
1988). For example, in both normal and 5-fluorouracil treated murine 
bone marrow cells, recombinant granulocyte-macrophage colony 
stimulating factor (rGM-CSF) synergises with CSF-I to produce large 
colonies following 10-12 days incubation (Falk and Vogel, 1988). This is 
as a result of the stimulation of murine macrophage progenitors with a 
high-proliferative potential (HPF-CFC) (Bradley and Hodgson, 1979). A  
similar synergistic effect was observed following combinations of IL-3 
with CSF-I both in vitro and in vivo (Williams et aL 1987). Even in 
serum-free medium, combinations of multi-CSF and M-CSF increased 
the size of colonies. The number of granulocyte-macrophage progenitor 
cells responding to the combination is greater than the number
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responding to the individual growth factors (Mortsyn and Burgess,
1988). The commonest methods for studying the synergistic effects of 
cytokines include colony formation in agar as well as proliferative 
responses measured by [3H]TdR incorporation (Falk and Vogel, 1988). A  
similar synergistic effect was displayed by SA2 leukaemic cell line with 
combinations of W EHi and L929 conditioned media in both serum 
containing and serum free media (Figures 72 and 78 respectively).
Growth factors have also been used to increase the cytotoxic effects of 
Ara-C. Ara-C exposure inhibits the proliferation of a higher proportion 
of AM L clonogenic cells in cultures pretreated with growth factors than 
in controls (that were not growth factor treated) (Lista et aL 1989). The 
increased proliferative effect as a result of combinations of W EHi and 
L929 could explain the slightly enhanced effect observed in this study 
with Ara-C and mitoxantrone against SA7 leukaemic cell line in vitro 
(Figures 134 and 135).
The ^HTdR incorporation assay may be more sensitive for measuring 
CSF responses than methylcellulose colony cultures, since activation of 
D N A  synthesis was more frequently observed than induction of colony 
formation (Delwel et aL 1988). A comparison of the results of ^HTdR  
incorporation and colony cultures showed that growth factor responses 
were less frequently evident in the methylcellulose colony assay. In five 
cases reported, significant amount of [3H]TdR was incorporated whereas 
no colonies formed. These differences were attributed to the fact that 
^HTdR uptake was measured on day-4 (similar to this study), whereas 
with the colony assay only a minority of cells that give rise to progeny 
following several cell divisions during 12-14 days of incubation is 
assayed. In addition, there is evidence to support the idea that AM L cell 
growth may be better maintained in liquid culture systems than in semi­
solid cultures. Moreover, in the cell suspension cultures, the cells settle
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at the bottom of the microtitre plate thus enhancing cell to cell contact 
which may enhance AM L growth (Delwel et aL 1988). The microtitre 
(^HTdR uptake) assay is also faster and easier to evaluate than 
conventional colony counting (Horak et al, 1983).
6.8 Effect of Serum and Transferrin on Proliferative Response of SA2 
Leukaemic Cell Line
The SA2 leukaemic cell line was capable of proliferating in vitro  
without the requirement for an exogenous supply of growth factors 
(Figure 77). The autocrine secretion of growth factor(s) has been 
postulated to result in the continuous proliferation of certain malignant 
cells (Weiss, 1983). It is generally accepted that serum plays an important 
role in ensuring the growth of most cell types in culture. Serum is a 
complex m ixture and many serum components are poorly  
characterized. Moreover, there is usually a marked variation in some 
serum components between batches (Barnes and Sato, 1980). Although 
it may not be applicable to all cell types, certain cells reportedly grow 
better in media supplemented with horse serum as compared to foetal 
calf serum (Yoshimara et aL 1989). An example is THP-1 human 
monocytic leukaemia cell line. In  the absence of serum, the SA2 
leukaemic cell line was unable to proliferate in vitro. This suggests that 
substances present in the serum could be providing the leukaemia with 
growth stimulus. For example, a growth promoting factor in horse 
serum was identified as horse serum transferrin (Yoshimara et aL 1989). 
Similarly, cell lines which were hormone dependent in vivo did not 
show hormone dependent growth in vitro unless serum added to the 
culture medium was first depleted of hormones. The explanation was
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that serum provided a mixture of hormones which was stimulatory for 
cell growth. Thus, hormones present in serum were masking effects of 
any supplementary hormones (Barnes and Sato, 1980). A  similar effect 
could be operating w ith the SA2 leukaemic cell line as serum may 
contain colony stimulating factors. This partly explains the use of 
serum-free media by some investigators (Delwel et ah 1988).
The fact that transferrin did not provide the stimulus for the growth of 
the SA2 leukaemic cell line in vitro suggests that it is not the activity in 
serum that was responsible for the growth of the leukaemic cells. 
Transferrin seems to be essential for the proliferation of many cell types 
in vitro (Forsbeck and Nillsson, 1985). It  has been shown to act as a 
growth factor for lymphocytes and small cell lung cancer cells (Forsbeck 
and Nillsson, 1985). The major function of iron binding proteins 
including transferrin is storage and transport of iron (Taetle and 
Honeysett, 1986). In  addition, transferrin receptor is present on all 
dividing cells and is increased in cycling cells but absent in quiescent 
cells (Spooncer and Whetton, 1985).
It  was suggested by some investigators that serum could be providing 
colony stimulating factors that were required for the growth of a 
megarkaryoblastic cell line in vitro (Yoshida et aL 1986). Inspite of the 
fact that in the presence of serum, the SA2 leukaemic cell line can grow 
in vitro with no exogenous growth factor added, synergistic proliferative 
effect was still observed following combinations of W EHi and L929. 
S im ilarly , two cases of erythroleukaem ia and one case of 
myelomonocytic leukaemia grew in vitro without addition of growth 
factors. Yet, increased colony formation was observed when CSF was 
added (Yoshida et al, 1986). In addition, although colony formation by 
W EHi-3 cells in vitro was not dependent on stimulation by CSF, the
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number and size of colonies were increased by the addition of CSF 
(Metcalf, Moore and Warner,1969).
6.9 Responses of Low Cell Dose Transplant and High Cell Dose 
Transplants
of SA7 Cell Line to Mitoxantrone Treatment In  Vivo 
The SA7 is a myeloid leukaemia cell line and its morphological 
characteristic has been reported (Hepburn et al, 1987). The low cell dose 
transplant variant is slower growing than the high cell dose transplant 
(Tables 2(a) and 3(a)). During the terminal stages, both high cell dose 
transplant and low cell dose transplant leukaemic cell lines present with 
inhibition of normal haemopoiesis which is particularly severe with the 
low cell dose transplant (Tables 3 and 4). It has been reported that 
following injection of leukaemic cells into syngeneic mice, leukaemic 
cells proliferated in the bone marrow, spleen, liver and peripheral blood 
(Nara et aL 1984). Leukaemic cells may have "homing" receptors that 
function not only to provide adherence to bone marrow stroma but also 
support leukaemia cell survival and growth in the bone marrow  
environment . As the leukaemia develops in the bone marrow, the 
number of normal colony forming cells (GM-CFC's) and fibroblastoid 
colony forming units (CFU-F) decreased (Nara et aL 1984). The fact that 
the mice continued to live for a few days more when all the bone 
marrow cells were replaced by leukaemic cells may be due to persistent 
haematopoietic activity in the spleen and other extramedullary sites. 
Normal haemopoiesis is suppressed by physical displacement of stem 
cells by leukaemic cells and/or by production of inhibitory humoral 
factors such as acidic isoferritins (Broxmeyer et aL 1981).
Acute myeloid leukaemia (AM L) and acute lymphocytic leukaemic 
(ALL) are clinically distinct diseases with different presentations and
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prognosis. Yet in the preclinical screening of drugs for use in the 
treatment of AM L, lymphoid murine models (P388 and L1210) are 
usually employed. In  addition, the two leukaemias have different 
patterns of tissue in filtra tio n  and respond d ifferen tly  to 
chemotherapeutic agents. Even the rate at which the two leukaemias 
incorporate 35So4 was found to be significantly different (Theodorakis 
and Goldberg, 1983). In  this study, the response of SA7 myeloid 
leukaemia to mitoxantrone treatment in vivo was studied. This w ill 
then be compared to the responses of both P388 and L I210 leukaemias 
reported in the literature (Baumgart et aL 1988).
There was an increase in life-span and some mice were even cured with 
mitoxantrone in the dose range 0.75-2mg/Kg (IP-IP, Table 1). The 
maximum increase in life-span (%ILS) (including one long term  
survivor) of 146% was observed when mitoxantrone (1.5m g/Kg) was 
administered (I.P) using the SA7 high cell dose transplant. Similar 
response was obtained with identical dose of mitoxantrone (I.P) in the 
treatment of the low cell dose transplant of SA7 cell line (IV-IP, Table 3). 
In contrast, using same range of doses and schedule, a different response 
was observed with the P388 leukaemia . The optimal dose in P388 was 
3m g/Kg which produced an average 175% increase in life-span and was 
curative to an average of 50% of the treated mice (Johnson et a l , 1983). 
In  this study, all tumour bearing mice that received 3 m g/K g  
mitoxantrone died from drug toxicity, with no evidence of leukaemia. 
In addition, no increase in life-span over untreated control was observed 
in these mice (Table 1). When the dose of mitoxantrone in P388 
leukaemia was reduced to 1.5mg/Kg, there was an average of 150% ILS 
with a 30% long term survivors. In a similar study but with the drug 
administered on days 1, 3 and 5, Fujimoto and Ogawa, 1982, observed 
that the optimal dose of mitoxantrone was 1.6mg/kg (IP-IP). W ith that
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dose all five mice treated survived for 60 days. This suggests that this 
acute myeloid leukaemia model is less sensitive to the effect of 
mitoxantrone. The criteria for selecting candidate drug in the preclinical 
screening process has been reported by Venditti, 1981. The lower efficacy 
end point for preclinical screening (IP-IP) is T.C%> 120 and 125 (ILS > 
20%) for P388 and L1210 leukaemias respectively. The higher efficacy 
T.C% is 175 for P388 and 150 for L1210. T is mean or median survival 
time of treated mice x 100 divided by the survival time of controls (C). 
The % increase in the life-span over control (% ILS) is equal to T.C%-100. 
Thus, applying this criteria for the SA7 cell line, mitoxantrone has 
reached the lower efficacy but not the higher efficacy end point. 
However, it is likely that the response of the SA7 cell line actually 
mirrors the clinical experience w ith mitoxantrone. For example, 
mitoxantrone when used singly was capable of inducing remission in 
only 20% of patients (Gale and Foon, 1986) and in one study, none of the 
patients receiving a single bolus infusion of mitoxantrone achieved 
complete remission (Prentice et aL 1984).
In the SA7 cell line there was no proportionality between dose and 
response. That is to say, doubling the dose within the therapeutic range 
was not accompanied by a proportional increase in life-span or cure of 
the treated mice. In a similar study using the rat brown Norway 
myeloid leukaemia model (BNML), Ara-C was shown to exhibit a weak 
dose-response relation. For example, a five fold increase in the dosage of 
Ara-C was only accompanied by a slight prolongation of the survival 
time (Rachel et aL 1988). It  has been suggested that the relationship 
between cell kill and tumour response is extremely complex and varies 
from one drug to another (Twentyman, 1980). For example, in the B16 
melanoma, 90% of the clonogenic cells could be killed by CCNU without 
causing a significant delay in tumour growth. In  contrast, adriamycin
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can produce a very considerable tumour growth delay without causing 
measurable degree of cell k ill (Twentyman, 1980). Furthermore, when 
mitoxantrone was administered to SA7 cell line in vivo at 3m g/Kg body 
weight, all mice died as a result of drug toxicity. This suggests a very 
narrow therapeutic margin (0.75mg/kg to 2m g/kg) above which toxicity 
supersedes any antileukaemic activity and below which, no measurable 
antileukaemic effect was observed (Table 3). Indeed, steep dose-response 
curves are characteristic of many anti tumour drugs. This severely 
restricts the degree of tumour cell kill that can be achieved by a course of 
chemotherapy (Griswold, 1986). In  addition, cell-killing by many drugs 
follow first-order kinetics and therefore it is a constant fraction of and 
not absolute number of cells that is killed by a particular drug dose. 
Thus, a dose that would reduce 10^ sensitive cells to 10  ^ would also 
reduce 10  ^ to 10  ^ (Griswold, 1986). However, although no strict dose- 
response relationship exists there is still a relationship between the 
number of leukaemic cells inoculated and amount of drug necessary to 
obtain curative effect. The dose necessary to achieve complete response 
or cure increases with the number of clonogenic cells (Hug et aL 1984).
In  this study, the route of administration of leukaemic cells (I.V  or I.P) 
had a marked effect on therapeutic outcome. For example, decrease in 
life-span was observed when leukaemic cells were injected I.V  w ith  
mitoxantrone administered I.P  as compared to the IP -IP  regime 
(compare Tables 1 and 2), Similar observation was made by Johnson et 
1979. They reported that mitoxantrone was less effective when (P388 
and L I 210) leukaemic cells were injected I.V  w ith mitoxantrone 
administered I.P. Moreover, as in this study, no long term  
survivors(cures) were seen with the I.V -IP  regime. Similarly, whereas 
4 /6  mice bearing L1210 leukaemia were cured using mitoxantrone in an 
IP-IP regime, no long term survivors (0 /8) were seen with IV -IV  regime.
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One possible explanation for the decreased effect in the IV -IP  regime is 
that mitoxantrone is sequestered in the peritoneal tissue compartment 
and only slowly released (Blochl-Daum, 1988). Thus, the amount of 
drug reaching the leukaemia was not sufficient to prevent leukaemic 
growth. Not all drugs are affected by the schedule of administration. 
Thus, the route of administration of cyclophosphamide (i.e I.V  or I.P) 
did not affect treatment outcome using BNML leukaemia (Hagenbeek 
and Martens, 1982) unlike what was observed w ith mitoxantrone in 
P388 leukaemia (Baguley and Wilson, 1987). Clinically, however, 
mitoxantrone is usually administered intravenously in the treatment of 
acute myeloid leukaemia (Alberts et aL 1988).
There was an incidence of leukaemia relapse in this study, occurring 3 
months following treatment of low cell dose transplant of SA7 cell line 
with mitoxantrone (1.5mg/Kg , Table 3). One of the two mice surviving 
for 90 days was discovered to have enlarged spleen upon autopsy and 
probably would have died from leukaemia a few days later. This 
highlights the importance of autopsying all long term survivors(cures) 
following chemotherapeutic treatment. The central nervous system is 
an important site of leukaemia involvement although this is more 
common in acute lymphocytic leukaemia (ALL). Furthermore, the 
blood-brain barrier may shelter leukaemia cells from  systemic 
chemotherapy. In  humans, involvement of CNS is uncommon at 
diagnosis but it is a frequent site of relapse (Bleyer and Poplack, 1985). 
CNS relapse is often followed by systemic relapse.
A ll other autopsied long term (60 days or 90 days) survivors had normal 
spleen weight, femur cellularity, PCV, Hb and differential bone marrow 
counts. Even clinically, remission documentation is normally by 
morphological examination of the bone marrow and a level of 5-10% 
blasts are thought to indicate remission (Katz et aL 1989). Whether these
218
$
J 'f
i
blasts are normal regenerating precursors or leukaemic 'rebound' 
cannot be ascertained by morphology alone. The use of 60 day-survival 
as a criteria for cure is adopted by many investigators including 
Fujimoto and Ogawa, 1982; Shenkenberg and Von Hoff, 1986. Similarly, 
in this study, no difference in number of colony forming cells per 5x10^ 
bone marrow cells was found between normal and cured mice. And 
recovery of colony numbers has been used as an indicator for 
haematological remission by Spitzer et aL 1977. Remission colonies in 
the report exhibited nonleukaemic karyotype.
A  lot of factors determine drug response in tumour-bearing mice apart 
from the drug dose and route of administration discussed above. For 
example, although all mice used were genetically identical and of the 
same sex and weight, yet there was marked difference in the response of 
individual mice to the drug. Some mice were cured (one per dose) 
while others only had their life-span extended. A ll mice were injected 
with the same single cell suspension and by the same individual, yet it is 
very likely that the leukaemic cell dose received by each mouse was 
different. It was reported that the subpopulation of tumour cells present 
in any two experimental animal hosts inoculated with the same tumour 
w ill inevitably be different (Poste, 1986). In addition, although the 
response of males and female mice to mitoxantrone are similar, females 
seem slightly more sensitive to the per-acute and delayed toxic effects of 
mitoxantrone than males (Johnson et al, 1979).
One obvious advantage of the SA7 leukaemic cell line (and possibly 
other models as well) is the fact that it is non-immunogenic (Hepburn et 
aL 1987). It  has been reported that in most human tumours there is no 
unequivocal evidence that host immunity plays a part in response to 
therapy. This supports the suitability of non-immunogenic models for 
experimental chemotherapy studies (Hewit, 1978). However, because no
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single tumour model is perfect, it has been suggested that more than a 
single tumour system should be employed for preclinical drug screening 
(Kallman et aL 1985). Generally, experimental leukaemia models have 
proved their value in predicting response in humans. For example, 
compounds such as epirubicin and idarubicin that showed activity at 
least equal to doxorubicin in mice were found to be active 
antileukaemic agents in patients. Anthracyclines that were less toxic (eg 
aclarubicin) than doxorubicin in mice were also less toxic in patients. 
And those that were more toxic than doxorubicin (eg carubicin, 
idarubicin) were also more toxic in man (Casazza, 1986). However, 
caution must be exercised as not all findings in the laboratory can be 
directly extrapolated to the clinical situation. For example, humans and 
mice metabolize epirubicin differently (Casazza, 1986). In addition to the 
clinical correlations often observed between laboratory models and 
human patients murine leukaemia models also provide relatively 
economical preclinical screens (Baumgart et aL 1988).
During exponential growth, both P388 and L I 210 lymphoid leukaemias 
showed a growth fraction of unity (Clausen, Bolstad and Mjelva, 1988). 
This suggests that all tumour cells present are stem cells. However, this 
is not the case with human tumours (Mackillop et aL 1983a). Rapidly 
proliferating tumours are usually more susceptible to drugs than slow 
growing tumours. This suggests that these models may not be adequate 
for preclinical screening of phase-specific agents (Aherne, Camplejohn 
and W right, 1977). However, similar to the finding in humans, late 
stage leukaemic disease in LBN-M L model is not curable by even 
massive doses of Ara-C (Vaughan and Burke, 1983).
In  addition to P388 and L I210 leukaemia models, human tumour 
xenografts are also used in preclinical drug screening. They are 
attractive because of their clinical origins and there is evidence that they
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may retain the therapeutic sensitivity of the source human tumour 
(Kallman et a l, 1985).
6.10 Growth Factor Responses of Recurrent Leukaemias 
The SA7 high cell dose transplant leukaemic cell line normally responds 
to growth factors (W EHi, L929, WEHi+L929) in vitro by increased 
proliferation that was growth factor concentration-dependant. 
However, at relapse following (in vivo) treatment w ith mitoxantrone 
the leukaemic cells were not responsive to W EHi, L929 or combinations 
of the two. By the time recurrent disease is diagnosed in humans, the 
tumour cells present at presentation may be phenotypically very 
different from those in the original tumour due to the emergence of 
new subpopulation (Poste, 1986). And in a substantial number of cases, 
there is a change in French-American-British (FAB) subgroup at relapse 
(Vanderweide, VanRhenen and Langenhuijsen, 1985). It  has been 
suggested that because many cytotoxic agents (including mitoxantrone) 
are mutagens, the emergence of new cell variants following treatment is 
facilitated (Kerbel and Davies, 1982).
When mitoxantrone was administered to leukaemic mice either 24 
hours or 48 hours before they became moribund with the disease, the 
leukaemic cells still retained growth factor sensitivity in vitro. This 
suggests that the leukaemic cells probably needed to undergo several cell 
divisions in order to lose growth factor sensitivity. As the leukaemia 
was virtually established when the drug was administered, the growth 
rate was decreased. Alternatively, a metabolite of mitoxantrone could be 
responsible for inducing the leukaemic cells to develop growth factor 
insensitivity in vitro. It  is also unlikely that the observed growth factor 
insensitivity was due to leaching out of mitoxantrone from the
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leukaemic cells which in turn inhibits their growth in vitro. The loss of 
growth factor sensitivity may be due to loss of receptors for growth 
factors on the leukaemic cells. For example, it has been reported that 
adriamycin is capable of regulating the number of epidermal growth 
factor (EGF) receptors in both Hela and 3T3 cells. The effect requires the 
continuous presence of the drug for several days (Zuckier and Tritton, 
1983). This is probably and adaptive response to anthracycline toxicity 
(Vichi and Tritton, 1989). Similarly, it has been suggested by Nowell, 
1986, that some tumours may have altered response to circulating 
hormones through loss of specific receptors. The hyporesponsiveness of 
some autoimmune deficiency syndrome (AIDS) patients to interferon 
alpha (a-IFN ) therapy may be due to decreased numbers of IFN  alpha 
receptors expressed on the cell surface as a consequence of continuous in  
vivo exposure to endogenous IFN  (Lau, Read and Williams, 1988).
Bone marrow cells from normal mice retain their sensitivity to W EHi, 
L929 and combinations of the two follow ing treatment w ith  
mitoxantrone. Similarly, bone marrow cells of mice cured of leukaemia 
by mitoxantrone treatment were fully responsive to growth factors. 
Even bone marrow cells of a leukaemic mouse (with no evidence of 
'clinical' leukaemia) that died in remission as a result of drug related 
toxicity 30 days following treatment, retained growth factor sensitivity. 
Thus only relapsed leukaemic cells showed growth factor insensitivity. 
Untreated (SA7HD) leukaemic bone marrow cells formed colonies in 
culture. In contrast, recurrent leukaemic cells formed very few colonies 
in culture. Even these may be due to "passenger" normal colony 
forming cells, although there is no evidence from this study to support 
such speculation. However, recurrent leukaemic bone marrow cells did 
not inhibit the growth of normal bone marrow cells when the two were 
co-cultured together. This is interpreted to mean that although the
222
recurrent leukaemic cells themselves were insensitive to growth factors 
and would therefore not form colonies in vitro, the few normal 
clonogenic cells present in the cell suspension could form colonies. 
Sim ilarly, it was reported that conditioned medium from human 
leukaemias that formed colonies in vitro had least inhibitory effect on 
the growth of normal bone marrow (Gordon, Douglas and Blackett
1978). A survey of the literature did not provide definite explanation for 
the lack of growth factor sensitivity by relapsed leukaemic cells. In  
addition, no data from this study is available as explanation for the 
observed effect. So one can only speculate as to the possible reason(s) for 
the loss of growth factor sensitivity by recurrent leukaemic bone marrow 
cells.
The colony stimulating factors (CSF) present in the conditioned media 
employed (eg IL-3) are necessary for the proliferation of leukaemic cells 
in vitro. W ithdrawal of CSF from haematopoietic cells in vitro is 
usually followed by rapid cessation of DNA and protein synthesis and 
cell death (Metcalf, 1985). IL-3 regulates the entry of D-glucose into cells 
and its presence is necessary for the maintenance of cytoplasmic 
concentrations of ATP (Dexter, Whetton and Heyworth,1986). This 
suggests that the recurrent leukaemic cells could be dying in culture as a 
result of the absence of the above-mentioned processes. The exact 
mechanisms whereby growth factors trigger cell proliferation is yet 
unknown. However, autophosphorylation of M-CSF receptor has been 
noted following binding of M-CSF and the CSFS have been shown to 
induce changes in the rate of synthesis of a number of cytoplasmic and 
nuclear proteins (Metcalf, 1985). A t the nuclear level, growth factors 
induce changes in the transcriptional programme of the cell. They 
induce the expression of nuclear proto-oncogenes C-fos and C-myc . The
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product of these proto-oncogenes are believed to be part of the genetic 
elements involved in cell proliferation (Farrar et a l, 1988 ).
Before growth factors can exert their effect they must first bind to 
receptors present on the cell membrane. And it has been reported that 
the binding of growth factors to their receptors appears to be potential 
target for disruption by cytotoxic agents (Zuckier and Tritton, 1983). It 
has also been shown that the cell membrane of leukaemic cells could 
undergo phenotypic shift at relapse. This has been attributed to the 
effects of chemotherapy (Borella, Casper and Lauer, 1979). Adriamycin 
could be cytotoxic to L I 210 without even entering the cells, probably due 
to an effect on the cell membrane (Tritton and Yee, 1982).
The most substantial evidence for the possible involvement of receptor 
loss in the development of growth factor insensitivity by recurrent 
leukaemic cells, comes from the study of the effect of mitoxantrone on 
EGF receptors in breast cancer cell line (M CF-7)). After 12-hour 
incubation w ith mitoxantrone, EGF binding was dose-dependently 
decreased. This was due to loss of receptor affinity (Trijssnaar et aL
1989). Similarly, it has been suggested that although the pathways must 
ultimately diverge, cytotoxic drugs and growth factors may have shared 
underlying mechanisms (Vichi and Tritton, 1989).
The relapsed leukaemic cells probably modified their growth factor 
sensitivity in vivo as it enabled the cells to survive the cytotoxic effect of 
mitoxantrone. The in vivo environment is probably necessary, because 
the SA7 leukaemic bone marrow cells did not lose growth factor 
sensitivity, when they were treated with mitoxantrone in vitro. Thus, 
there appears to be a relationship between drug sensitivity and growth 
factor response. Studies have shown that AML clonogenic cells from a 
proportion of patients may be less sensitive as compared to normal 
granulocyte-macrophage progenitor cells to colony stimulating activity.
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The degree of reduction in sensitivity is closely related to the 
proliferative capacity of the AM L colony forming cells in vitro (Francis,
1981). The degree of sensitivity to colony stimulating activity (CSA) at 
presentation was found to be closely correlated to the response to 
induction chemotherapy in 15 patients. A M L cells that were very 
insensitive to CSA were associated w ith a slower response to therapy 
and a reduced remission rate. Such insensitive cells are unlikely to be in 
D N A  synthesis and could thus provide a more difficult target for 
cytotoxic agents (Francis, 1981). An alternative explanation may be that 
all the recurrent leukaemic cells are in Go state and would therefore not 
respond to growth factors by increase in proliferation. However, this is 
unlikely as the leukaemia grows in vivo.
The loss of growth factor sensitivity was also dependent on the route of 
leukaemia administration similar to what was observed with drug 
therapy. Thus, minimal growth factor sensitivity was retained when the 
leukaemic cells were injected I.V  w ith the drug administered I.P.
Because w ith I.P administration, mitoxantrone is sequestered in the 
peritoneal tissue, little of the drug was available to the leukaemic cells to 
pose a "threat" to their existence and so make them lose substantial 
growth factor sensitivity.
Contact inhibition is one of the mechanisms postulated to explain the 
suppression of normal haemopoiesis in leukaemia (Nara et aL 1984). In  
addition, a leukaemia inhibitory activity (L IA ) has also been implicated 
(Broxmeyer et aL 1978). Inhibition of colony formation was found when 
normal marrow was cultured in the presence of leukaemic cells in vitro.
Similarly, colony forming unit- fibroblastoid (CFU-F), was suppressed 
probably to a greater extent (Nara et aL 1984). However, in this study, no
inhibition of normal bone marrow growth was observed in vitro when
recurrent leukaemic cells were co-cultured w ith normal bone marrow j
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ceils. It may be because L IA  is lost at 37°C within 5 hours (Broxmeyer et 
al, 1978) and the experiments were conducted at 37°C. Other workers 
were also unable to detect inhibition of normal bone marrow growth in  
vitro by leukaemic cells. They suggested that the inhibitor may be too 
subtle to be detected in vitro (Nara et aL 1984). Other investigators have 
noted that conditioned medium from human leukaemic cells that form 
colonies in vitro was least inhibitory to growth by normal bone marrow 
cells (Gordon, Douglas and Blackett, 1978).
6.10.1 Passage of Recurrent Leukaemic Cells in Mitoxantrone 
Pretreated Mice
When recurrent leukaemic cells were passaged in mice pretreated with a 
single dose of mitoxantrone, the resulting leukaemia (called second 
recurrent leukaemia or PASS M IT  2d) was not responsive to growth 
factors. In contrast, when the same recurrent leukaemic cells were 
passaged in mice pretreated 50 days previously, the leukaemia in 2 of 3 
mice did not respond to growth factors. The most likely explanation for 
this difference between the latter mice may be found in the 
pharmacokinetics of mitoxantrone. Up to 50% of administered dose of 
mitoxantrone was present in rats 10 days after the drug's administration. 
Similarly, persistently high levels of ^^C-mitoxantrone were found in 
tissues after dosing (James et aL 1983). And mitoxantrone can still be 
detected for up to 73 days following dosing. Thus, it is likely that the 
drug was present in the mice 50 days after it was administered. The 
reason why the leukaemic cells were growth factor sensitive in vitro in 
one case may be due to variation in the mitoxantrone metabolism and 
excretion which occurs even in inbred animals (Hagenbeek and 
Martens, 1982). Thus, there may be a concentration of mitoxantrone 
above which the leukaemias need to m aintain growth factor
226
insensitivity to survive and below which they could revert to normalcy. 
And in the third mouse (M 3) , virtually all the mitoxantrone was 
excreted (within fifty days), so that the net effect of transplantation 
would be similar to passaging the recurrent leukaemic cells in untreated 
normal mice.
6.10.2 Passage of Recurrent Leukaemic Cells in Normal (untreated) Mice 
When recurrent leukaemic cells were passaged in normal (untreated) 
mice they regained their growth factor sensitivity. This was also true for 
recurrent leukaemic cells that were first passaged in mitoxantrone 
pretreated mice. This suggests that the leukaemic cells were responding 
to environmental influence. If  the receptor mechanism proposed is 
correct, the recurrent leukaemia would be synthesizing new receptors 
during its growth in untreated normal mice and would therefore 
respond to growth factors in vitro when tested at presentation. In  
support of this is the finding that B6SutA cells increase their receptor 
number for IL-3 from 10,000 to 100,000 in 18 hours at 37°C (Murthy, et aL
1989). Similarly, it was shown that increase in receptor numbers in Hela 
and 3T3 cells following treatment w ith adriamycin involved synthesis 
of new receptors (Zuckier and Tritton, 1983).
When the recurrent leukaemic cells recovered growth factor sensitivity 
they also formed colonies in agar. There appears to be a clear cut 
relationship between exposure of leukaemic cells in vivo to 
mitoxantrone and loss of growth factor sensitivity monitored using 
[3H]TdR uptake or colony growth. In this study, there was a close 
agreement between growth factor sensitivity monitored using [3H]TdR 
and colony growth of the leukaemia in agar. This suggests that the lack 
of growth factor sensitivity by recurrent leukaemic cells was not due to 
an artifact in, say, [3H]TdR uptake determination (eg inhibition of
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[3H]TdR transport across cell membrane, competition with endogenous 
thymidine etc).
6.11 Drug Sensitivity of Recurrent Leukaemic Cells after Passage in Mice 
It  is well known that tumours that are initially drug sensitive at the 
beginning of treatment often become progressively less responsive and 
may ultimately fail to respond during continuing treatment (Schabel et 
al, 1983). Recurrence in the face of continued treatment usually reflects 
overgrowth of drug-resistant variants (Griswold, 1986). These are 
usually detected in patients who relapse after chemotherapy (White et 
al, 1989). There are relatively few laboratory studies whereby resistance 
mechanisms are investigated following in vivo treatment. Repeated 
treatments in vivo mimic the clinical situation better and may prove 
more applicable to the mechanism of resistance as compared to the 
usual method of inducing resistance by in vitro treatment (Mattern et al, 
1988).
The extent of mitoxantrone resistance developed by recurrent leukaemic 
cells following passage in normal mice depended on the dose of 
mitoxantrone that was used in the treatment in vivo. Thus, with very 
low doses (0.4m g/Kg), the recurrent leukaemic cells were (after one 
passage in mice) equally sensitive or even slightly more sensitive than 
untreated leukaemic cells. When 0.75m g/Kg mitoxantrone was 
administered, the recurrent leukaemic cells were insensitive to low  
concentrations of mitoxantrone (in vitro) when tested after two passages 
in normal mice. When mitoxantrone treatment dose was 1.5mg/Kg the 
degree of resistance increased. The recurrent leukaemic cells (after 2 
passages in normal mice) were about 17 times less sensitive as compared 
to untreated leukaemic cells. W ith concentrations of mitoxantrone that 
would inhibit D N A  synthesis, in untreated leukaemic cells by 80%
228
relative to control, increased D N A  synthesis of the recurrent leukaemic 
cells was observed. An identical effect was observed in L1210 resistant to 
Ara-C after the cells were treated with the drug in vitro (Volm, Mass and 
Mattern, 1980).
Recently, a similar observation was documented clinically. A  patient 
with acute lymphoblastic leukaemia was treated w ith high dose Ara-C. 
Following the attainment of remission, the patient relapsed six weeks 
later. Two cell lines PER-145 and PER-163 were established from bone 
marrow samples obtained before and after chemotherapy respectively. 
Exposure of the two cell lines to Ara-C in vitro showed that the primary 
leukaemia PER -145 was sensitive to Ara-C while PER-163 was resistant. 
Ara-C concentrations from l-33pg /m l rather than inhibiting growth 
(using [3H]TdR uptake assay) actually gave a dose-dependent 
stimulation of the relapsed cell line (similar to the observation reported 
in this study). Following subsequent treatment with Ara-C in vivo, the 
patient's blasts count increased 10 fold, implying that the stimulation 
observed in vitro probably occurred in vivo as well (Kees, 1987). 
Sim ilarly, in this study, recurrent leukaemias passaged in mice 
pretreated with mitoxantrone had bigger spleens as compared to those 
passaged in normal untreated mice. It may well be that the presence of 
low concentrations of mitoxantrone in the pretreated mice actually 
stimulated the leukaemia to divide and hence the increased spleen 
weight.
The recurrent leukaemic cells probably grow at the same rate (in vivo) as 
untreated SA7 leukaemia, since no change was observed in the time it 
takes the recurrent leukaemia to manifest the disease in syngeneic 
recipients. In one study, no difference in growth rate was seen between 
Ara-C resistant and sensitive variants of the L I210 leukaemic cell line.
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Thus development of drug resistance need not be followed by difference 
in growth rate (Volm Maas and Mattern, 1980).
A  surprising observation was the finding that there was no growth delay 
when recurrent leukaemic cells were passaged in mitoxantrone 
pretreated mice. In  contrast, mitoxantrone produced significant 
inhibition of P388 leukaemia growth when administered up to 30 days 
prior to tumour implantation. Similarly, the degree of prophylactic 
activity of mitoxantrone against L1210 varied with treatment route, 
being optimal following I  P administration (White and Durr, 1985). 
Another surprising observation regards the in v itro  mitoxantrone 
sensitivity of recurrent leukaemic cells after they were first passaged in 
mitoxantrone pretreated mice. It  would be expected that the degree of 
mitoxantrone resistance would be increased, but it did not. Recurrent 
leukaemic cells passaged in mitoxantrone pretreated mice were not 
more resistant to subsequent treatment with mitoxantrone in vitro as 
compared to those passaged in untreated mice. Again, it was the dose of 
mitoxantrone the leukaemic cells were initially exposed to (in vivo), 
that determines the degree of insensitivity to subsequent mitoxantrone 
exposure in vitro. The degree of resistance developed by tumour cells 
may either build up through successive changes or be attained in a 
single step. The pattern followed is characteristic of the drug. Two 
patterns have been described: the so-called 'penicillin' pattern in which 
resistance is reached only through multistep changes; and the 
'streptomycin' pattern in which resistance may arise in a single step 
(Mattern et al, 1988). From this data, it would seem that mitoxantrone 
mimics the 'streptomcyin' pattern since passaging recurrent leukaemic 
cells in mitoxantrone pretreated mice did not increase their resistance to 
mitoxantrone treatment in vitro.
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The mechanisms whereby leukaemic cells develop resistance to 
mitoxantrone is presently unknown. However, it does not appear to 
involve decreased uptake of the drug into cells although there is a 
conflicting report. In  one study, the uptake of ^^C-mitoxantrone was 
slower in resistant cells than in sensitive cells (Shenkenberg and Von 
Hoff, 1986). However, Harker et al 1989, reported that mitoxantrone 
resistant variant of HL-60 cells essentially retains ^^C-mitoxantrone to 
the same extent as the sensitive parental line. In addition, unlike cells 
which display the classic m ulti-drug resistant phenotype (M DR-1), 
mitoxantrone resistant HL-60 cells retained sensitivity to vinca 
alkaloids, melphalan and mitomycin C. There was also no over 
expression of p-glycoprotein in resistant HL-60 cells. This suggests that 
resistance to mitoxantrone is unlikely to be mediated by altered 
expression of the p-glycoprotein gene. Thus, Ca2± channel blocking 
drug verapamil does not potentiate the cytotoxicity of mitoxantrone in 
both the sensitive and resistant HL-60 cells. (Harker et aL 1989).
Finally, the differential count of (SA7HD) recurrent leukaemic bone 
marrow cells was identical to that of untreated SA7HD leukaemic cells. 
This suggests that the two leukaemias may not be distinguishable 
morphologically.
6.12 Haematological Toxicity of Mitoxantrone in Normal Mice 
In the doses studied (0.4-3mg/Kg) mitoxantrone had no marked effect on 
blood Hb, PCV and femur cellularity in normal female C B A /H  mice. 
The most noticeable effect was a depression of spleen weight with  
3m g/kg and a rise in GM-CFC numbers in vitro with doses in the range 
0.4-1.5mg/Kg. The latter effect is probably a compensatory mechanism 
because the numbers returned to control levels after 16 days. Similarly, 
increased progenitor numbers were found following treatment of
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normal mice with Ara-C (Gherson et al, 1982). A single nontoxic dose of 
mitoxantrone resulted in extensive destruction of splenic marginal zone 
cells in rats and mice. It was followed by phagocytosis of cell debris. 
Small doses gave cumulative effect (Levine and Gherson, 1986). A  
similar mechanism could be responsible for the decreased spleen weight 
following treatment of normal mice with 3m g/Kg mitoxantrone.
The limitation of peripheral blood differential count as a determinant of 
the haematological toxicity of cytotoxic drugs must be borne in mind. In  
humans, the proliferative ability of bone marrow progenitors measured 
by colony forming cell assays can be depressed for long periods after 
exposure to cytotoxic chemotherapy despite normal counts in peripheral 
blood (Rosenberg et al. 1988). In  addition, significant differences exist 
between mice and humans for direct extrapolation of laboratory to the 
clinical situation. For example, both human and mouse cells have 
similar sensitivities to BCNU. However, human cells seem more 
sensitive to melphalan as compared to murine cells. The converse 
seems to be true for nitrogen mustard and 5-fluorouracil sensitivity 
(Ogawa, Bersagel and McCulloch, 1975; Gordon and Blackett, 1976).
6.13 Comparison of Mitoxantrone Sensitivity of Leukaemia- 
bearing and Normal Mice
In  this study, all leukaemia-bearing mice that received 3m g/K g  
mitoxantrone died from drug toxicity with no evidence of leukaemia 
seen in blood film  and spleen. However, none of the normal mice that 
received that dose (3m g/Kg) of mitoxantrone died as a result of drug 
toxicity in an observation period of 9 days. Most of the leukaemia 
bearing mice died within 9 days of drug administration. In  addition, the 
femur cellularity in leukaemia bearing mice was depressed following 
3m g/K g mitoxantrone. Apart from the early deaths, some mice
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survived for 30 days after treatment only to die from a drug-related 
toxicity with no evidence of leukaemia. It has been reported that there's 
a 30-day period usually associated with haematopoietic failure in mice 
and 75% of deaths occur w ithin that period (Okunewick, Buffo and 
Kociban, 1985). However, this is unlikely to explain these deaths as the 
femur cellularity in these mice were hardly affected. It is unlikely to be 
due to intestinal toxicity either, because these occur w ithin 4-8 days 
(Okunewick, Buffo and Kociban, 1985). These workers suggested that the 
haematopoietic toxicity of mitoxantrone may exceed its antileukaemic 
effect. The myelosuppressive effect of mitoxantrone could be minimized 
by I.P rather than I.V  injection (Alberts et al, 1988).
The parameters that markedly modify the toxicity of antitumour drugs 
in mice are the strain, the drug vehicle and route of administration. It 
has been reported that there was a difference of as much as 71% in the 
LD50 obtained by six different laboratories that administered injection of 
the same drug. Moreover, there was 20% chance with I  P administration 
that part of the drug was not injected into the peritoneal cavity (Guarino 
etaL 1979).
A ll SJL/J normal mice that received mitoxantrone 20mg/Kg were alive 
up to 8 days after injection. And 60% of the mice that received lOmg/Kg 
were alive by 90 days (Okunewick, Buffo and Kociban, 1985). Although 
a different strain of mice (C B A /H ) were used in this study, it is still 
unlikely that 3m g/Kg would be fatal to these mice. Furthermore, doses 
greater than 142mg/Kg (I.V) were required to produce per-acute lethality 
in CD2FI male mice (Johnson et aL 1979).
Tumour bearing mice were more susceptible to the toxic side effects of 
Ara-C than tumour free animals. The tumour itself increased the 
vulnerability of normal cells to the drug (Schafer and Maurer-schultze, 
1987). Similarly, there was a clear cut difference as regards the LD50 for
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cyclophosphamide between normal and leukaemic rats (164 and 
llO m g/kg respectively). In  BNML leukaemic rats, excessive leukaemic 
cell k ill leading to tumour cell embolism in association with impaired 
functions of vital organs by leukaemic cells were additional factors 
contributing to early death (Hagenbeek and Martens, 1982). There is 
evidence that the pharmacokinetics of cytotoxic agents may be 
influenced by the presence of tumour. Drugs affected included 
cyclophosphamide, adriamycin and bleomycin. The factors responsible 
for this effect include reduced metabolic capacity of the liver, impaired 
kidney function, anaemia, leucocytosis, changes in serum protein 
contents or toxic factors produced by the tumour. For example, there 
were significant differences between tumour free mice and mice with  
leukaemic cell load w ith respect to the distribution pattern of 
ambazone (Kuhnel et aL 1988).
In  this study, there was a very marked difference in the sensitivity to 
toxic effects of mitoxantrone between normal mice and leukaemia 
bearing mice. It has been reported that coagulation cascade may be 
activated following treatment of acute promyelocytic leukaemia w ith  
antineoplastic agents. This is as a result of release of proagulant activity 
from the leukaemic promyelocytes and it could lead to disseminated 
intravascular coagulation (DIC) (Gale, 1985). Similar effect could explain 
the death of leukaemia bearing mice that were treated w ith 3m g/Kg  
mitoxantrone.
6.14 Mitoxantrone Sensitivitv of Bone M arrow Cells from Treated 
Normal and Cured Mice
Reduced sensitivity to mitoxantrone in vitro was displayed by bone 
marrow cells from all normal mice that received low doses (0.4-
0.75mg/Kg) of mitoxantrone. Similarly bone marrow cells of cured mice
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exhibited this protective effect. In  this case the effect was present no 
matter what dose of mitoxantrone was used in the treatment of the 
leukaemia. Thus, although 2m g/Kg administered to normal mice 
resulted in the loss of protective effect, the bone marrow cells of mice 
cured of leukaemia w ith that dose still exhibited this effect. Doses of 
mitoxantrone that resulted in loss of protective effect by normal bone 
marrow cells was also toxic to leukaemic mice (eg 2 and 3m g/Kg). No 
protective effect was seen in bone marrow cells of a mouse dying as a 
result of drug toxicity. The protective effect was manifested by 10-fold 
increase in the I.C50 of mitoxantrone. And the effect was detected up to 
60 days following mitoxantrone administration and was also shown by 
myeloid progenitor cells as well. Administration of priming doses of 
antitumour agents can protect animals from subsequent toxic doses of 
drugs. This protective effect is associated w ith  an increase in  
glutathione-S-transferase levels in bone marrow cells (Cowan, 1989). It 
was found that fo llow ing cyclophosphamide adm inistration, 
glutathione (GSH) levels were particularly increased in granulocytes. 
Similar changes were observed following administration of Ara-C in 
vivo in CBA mice. It was proposed that high GSH and GSH-transferase 
represent a general response to cytotoxic insult. This provides at least 
partial explanation for the protection conferred against subsequent toxin 
administration (Adams, Carmichael and W olf, 1985). In  addition, 
mitoxantrone is also metabolized by GSH-transferase. These enzymes 
catalyse the conjugation of thiol containing GSH w ith electrophillic 
substrates. They are therefore well suited to protect cells from toxins. 
GSH levels were elevated for up to 25 months following treatment of 
patients w ith alkylating agents (Britten and Green, 1989). These 
evidences suggest that the protective effect developed by bone marrow 
cells of cured mice and normal mice treated w ith  low does of
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mitoxantrone may be due to the elevation of GSH and or GSH-S- 
transferase (GST) levels* The ability to develop this protective effect 
appears to be associated with long term survival in leukaemic mice.
In  conclusion, these leukaemic models appear to be good models for 
studying the cytotoxic activity of antileukaemic drugs. They could be 
used in the preclinical screening of new drugs or in the re-evaluation 
of drugs already in clinical use. The development of growth factor 
insensitivity by relapsed leukaemic cells clearly needs further 
investigation. It should not only provide clues on the behaviour of 
leukaemic cells, but could shed light on drug resistance mechanisms.
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SUMMARY
1. The SA2, SA7HD and SA8H D  myeloid leukaemic cell lines seem 
equally responsive to cytosine arabinoside (Ara-C) when response was 
monitored using DiSC assay. However, the SA7HD cell line seem more 
sensitive to mitoxantrone as compared to SA2 and SA8H D  cell lines 
using this assay. The DiSC assay appears to be simple and convenient 
although scoring of slides may be subjective.
2. When [3H]-thym idine uptake assay was employed to assess 
cytotoxicity, the SA2 leukaemic cell line seem most sensitive to DNA  
synthesis inhibition by mitoxantrone. W ith the exception of this cell 
line, neither Ara-C nor mitoxantrone showed differential cytotoxicity 
against leukaemic cell lines as compared to normal bone marrow cells. 
In  all the leukaemic cell lines studied, mitoxantrone seem more potent 
than Ara-C, using comparable doses in vitro. However, mitoxantrone 
was also more toxic to normal bone marrow cells. In the 81287 cell line 
and its transplant progeny, spleen cells seem slightly more sensitive to 
Ara-C than bone marrow cells. The primary leukaemic cell line (81287) 
appears to become less sensitive to both Ara-C and mitoxantrone with 
passaging. Generally, combinations of Ara-C and mitoxantrone resulted 
in additive effects. The SA7HD cell line and normal bone marrow cells 
(NBM) seem susceptible to the effect of drug scheduling ( FIGURE SI). 
In  both cases, one hour-pulse with Ara-C followed by the addition of 
mitoxantrone after 24 hours seem more cytotoxic as compared to when 
mitoxantrone was added immediately following one hour pulse with  
Ara-C. The SA2 and SA8 cell lines were unaffected by drug scheduling 
(FIGURE SI).
237
3. The SA7HD cell line appears to grow exponentially in culture as 
indicated by labelling index determination. Mitoxantrone suppressed 
labelling indices of SA2, SA7HD and SA8H D  cell lines in a dose- 
dependent manner. There was a correlation between in vitro labelling 
index suppression using high concentration of mitoxantrone, and 
inhibition of [3H]TdR uptake determined using scintillation counting. 
However, the autoradiograph method probably underestimates 
cytotoxicity produced by low concentrations of mitoxantrone.
4. Mitoxantrone was markedly more toxic to normal myeloid progenitor 
cells as compared to Ara-C when response was monitored using GM- 
CFC assay. Unlike mitoxantrone, one hour pulse w ith Ara-C was non­
toxic to myeloid progenitor cells in the doses studied.
5. The primary (81287) and low cell dose transplant cell lines (SA7FT5 
and SA8FT14) were less responsive to growth factors in vitro as 
compared to high cell dose transplants of SA7 and SA8 cell lines 
(SA7HD; SA8HD). The SA2 leukaemic cell line grows in vitro without 
requirement for exogenous supply of growth factors. However, in 
serum-free medium, no in vitro growth was observed unless growth 
factors were added. This strongly suggests that serum was providing the 
stimulus for the in vitro proliferation of the leukaemic cells. Transferrin 
alone or saturated with iron, did not stimulate the SA2 leukaemic cells 
to proliferate in vitro unless growth factors were added as well. L929 
conditioned medium in concentration between 5-20% decreases the in  
vitro proliferation of SA2 cell line. Similarly, 20% W EHi conditioned 
medium has the same effect. However, when combinations of W EHi 
and L929 (5-20%) were used, synergistic proliferative response was 
observed.
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6. Mitoxantrone possess antileukaemic activity against both low cell 
dose transplant and high cell dose transplant of SA7 leukaemic cell line 
in vivo. A  narrow therapeutic margin was observed. The route of 
administration of leukaemic cells had an effect on therapeutic outcome. 
Mitoxantrone seem more effective in the high cell dose transplant cell 
line when both leukaem ia and drug were adm inistered  
intraperitoneally (I.P). The responses of these myeloid leukaemias were 
distinctly different from those reported in the literature for murine 
lymphoid leukaemias. For example, doubling the dose of mitoxantrone 
within the therapeutic range was not accompanied by an increase in the 
number of long-term survivors (cures). Of the two variants of SA7 cell 
line studied, the low cell dose transplant appears to be more sensitive to 
mitoxantrone in vivo.
7. SA7HD leukaemic bone marrow cells were normally responsive to 
stimulation of proliferation by growth factors(WEHi, L929, WEHi+L929) 
in vitro. However, in mice w ith relapsed leukaemia following in vivo 
treatment w ith mitoxantrone, the recurrent leukaemic bone marrow  
cells became significantly insensitive to growth factors in vitro. No 
growth factor insensitivity was developed by bone marrow cells of 
normal mice treated w ith mitoxantrone in vivo. Similarly, bone 
marrow cells of mice cured of leukaemia by mitoxantrone treatment 
also responded to growth factors. Furthermore, when mitoxantrone was 
administered to leukaemic mice 24 or 48 hours before they became 
moribund w ith leukaemia, the leukaemic cells still retained growth 
factor sensitivity. Even bone marrow cells of a leukaemic mouse dying 
from drug toxicity while in remission, responded to growth factors. 
When mice inoculated w ith leukaemia intravenously, were treated
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1with mitoxantrone intraperitoneally, the resulting recurrent leukaemia 
retained minimal growth factor sensitivity in vitro , thus, showing 
route of administration dependence as was observed w ith drug 
treatment. The recurrent leukaemic cells did not inhibit the growth of 
normal bone marrow cells when the two were co-cultured in vitro ( 
FIGURE S2) .
Recovery of growth factor sensitivity was observed upon passaging the 
recurrent leukaemic cells in normal (untreated) mice. The degree of 
recovery of growth factor sensitivity appears to depend on the number 
of leukaemic cells injected prior to treatment. When recurrent 
leukaemic cells were passaged in mitoxantrone pre-treated mice, no 
recovery of growth factor sensitivity was observed in most cases 
(FIGURE S2).
8. Despite recovery of growth factor responsiveness, the sensitivity of 
recurrent leukaemic cells to subsequent mitoxantrone treatment in vitro  
depended on the dose of mitoxantrone used in treating the leukaemic 
mice (in v iv o ). When a low dose of mitoxantrone (0.4m g/Kg) was 
used, the recurrent leukaemic cells (after a single passage in mice), were 
as sensitive as untreated leukaemic cells to mitoxantrone in vitro. 
However, with a dose within the therapeutic range (1.5m g/Kg), the 
recurrent leukaemic cells were significantly less sensitive to some 
concentrations of mitoxantrone in vitro. Passaging the recurrent 
leukaemic cells in mitoxantrone pre-treated mice did not increase their 
level of resistance to mitoxantrone. This suggests that the initial 
mitoxantrone dose administered during treatment was an important 
determinant of degree of resistance.
No difference in in vivo growth rate was observed between relapsed 
and untreated leukaemic cells when both were injected in syngeneic
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recipients. S im ilarly, passaging recurrent leukaem ic cells in  
mitoxantrone pre-treated mice was not accompanied by delay in 
growth of the leukaemia.
9. Norm al C B A /H  mice seem less sensitive to toxic effects of 
mitoxantrone as compared to leukaemia bearing mice , inspite of the fact 
that mitoxantrone treatment was started a day after tumour inoculation, 
when virtually few or no leukaemic cells were in the bone marrow. 
This suggests that some mechanisms , other than those associated with 
leukaemic infiltration, may be responsible for these deaths.
10. Bone marrow cells of cured mice and normal mice treated with low  
doses of mitoxantrone developed protective effect towards subsequent 
mitoxantrone exposure in vitro. The protective effect was manifested as 
a 10-fold increase in mitoxantrone I.C50 in vitro which was observed
using both [3H]thymidine uptake assay and GM-CFC assay. Bone 
marrow cells of a mouse dying as a result of drug toxicity while still in 
remission, did not exhibit protective effect towards mitoxantrone 
exposure in vitro. Similarly, doses of mitoxantrone that resulted in loss 
of protective effect by bone marrow cells of normal mice, were also toxic 
to leukaemia bearing mice. For example,when mitoxantrone (3mg/Kg) 
was administered to normal mice, the bone marrow cells did not 
develop protective effect . Similarly, all leukaemia bearing mice that 
received 3m g/Kg of mitoxantrone, died from drug toxicity w ith no 
evidence of leukaemia found on autopsy.
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